Kit, device, and method for detecting bladder cancer

Abstract

In one embodiment, the present invention provides a kit or device for detecting bladder cancer and a detection method. In one embodiment, the present invention relates to a kit or device for detecting bladder cancer comprising miRNA in a sample of a subject or a nucleic acid capable of specifically binding to the complementary chain thereof, and a method for detecting bladder cancer comprising measuring the miRNA in vitro.

Description

Technology Field

[0001] The present invention relates to a kit or device for detecting bladder cancer comprising a specific miRNA or a nucleic acid capable of specifically binding to its complementary chain, used for testing the presence or absence of bladder cancer in a subject, and a method for detecting bladder cancer comprising measuring the expression level of the miRNA. Background Technology

[0002] The bladder is an organ located within the pelvis that serves as a temporary reservoir for urine produced in the kidneys after it is transported through the renal pelvis and ureters. When the bladder expands due to accumulated urine, this is felt as an urge to urinate, and the activity of urination occurs through the contraction of muscles. The inner surface of the bladder is covered with transitional epithelial cells and is highly elastic, but bladder cancer is caused by the cancerous transformation of these transitional epithelial cells, and histologically, transitional cell carcinoma is known to account for 90% of all bladder cancers.

[0003] The cancer mortality rate for Japanese people in 2008 was 547.7 per 100,000 people, and the proportion of bladder cancer among causes of death is increasing every year due to the aging population and the influx of Western culture. Urothelial carcinomas, including bladder cancer, are the second most frequent urological tumors after prostate cancer; in Japan, the number of patients was approximately 16,000 in 2002, centered on the elderly, and the incidence rate was about four times higher in men than in women. It is known that smoking plays a significant role in the development of bladder cancer, and occupational exposure to aromatic amines is also an established risk factor. When bladder cancer is classified by the T factor in the TNM classification used to evaluate the degree of invasion, or stage, it is classified into three types in order of least invasion: carcinoma in situ (Tis), superficial bladder cancer (Ta, T1), and invasive bladder cancer (T2 or higher). Carcinoma in situ is known to occur as a complication of superficial or invasive cancer, or as a standalone condition. Because it exists as small dots within the bladder mucosa or progresses in a creeping manner, it is known to be easily overlooked even when performing endoscopic examinations, which are the definitive diagnostic tests. Superficial bladder cancer is a type of cancer where invasion remains confined to the surface of the bladder—specifically the superficial mucosa or the submucosal layer beneath it. While metastasis to other organs is rare, it is known to have a tendency to recur multiple times within the bladder, making follow-up examinations highly important. Invasive bladder cancer develops by extending its roots into the bladder muscles or even outside the bladder, and is known to be prone to metastasis. Furthermore, regarding the histological atypia of bladder cancer, which is classified into High / Low grades, High-grade bladder cancer is considered to have a high degree of malignancy and is prone to early invasion and metastasis, making early detection particularly crucial.

[0004] The treatment of bladder cancer is determined by considering the stage of progression (Course of Management for Renal Pelvis, Ureter, and Bladder Cancer, edited by the Japanese Urological Association, the Japanese Society of Pathology, and the Japanese Society of Medical Radiology, Kanehara Publishing, 2011), metastasis, and the patient's general condition. Standard treatment methods for bladder cancer are outlined in the (Guidelines for the Treatment of Bladder Cancer, edited by the Japanese Urological Association, 2015 edition, Medical Book Publishing). Currently, the most common treatments consist of surgical resection (Transurethral Resection of Bladder Tumors (TUR-BT), total cystectomy), radiation therapy, chemotherapy with anticancer agents, and intravesical instillation of BCG. For invasive bladder cancer classified as T2 or higher according to the TNM classification, total cystectomy is the standard treatment, and early detection is crucial.

[0005] In addition, the most reliable general methods for detecting bladder cancer currently are cystoscopy and urine cytology, but cystoscopy is highly invasive, so urine cytology, which detects dissected cancer cells microscopically, is a more desirable method in terms of invasiveness, but its specificity is reported to be about 94% and its sensitivity 35% (Non-patent Literature 1).

[0006] Bladder cancer has a high recurrence rate, often recurring within two years. The recurrence rate after treatment is high at 50–80%, and 10–25% of these cases are found to be advanced cancer that has invaded the muscle layer; therefore, it is important to detect recurrence early and treat it early to extend the patient's survival time.

[0007] Currently, several urinary protein markers are available as clinical test markers for non-invasive bladder cancer. These marker tests have higher sensitivity than urine cytology. For example, the NMP22 test, which detects the specific nuclear matrix protein NuMA, has a sensitivity of 47-100% and a specificity of 55-98% (Non-patent Literature 1). In addition, the BTAtrak test, which detects specific basement membrane fragment complexes, has a sensitivity of 60-83% and a specificity of 60-79% (Non-patent Literature 1).

[0008] In addition, markers based on gene expression have been reported, including miR-92a-2-5p, miR-150-3p, miR-1207-5p, miR-1202, miR-135a-3p, miR-1914-3p, miR-1469, miR-149-3p, miR-663a as shown in Patent Document 1, miR-1254, miR-1246, miR-92a-3p as shown in Patent Document 2, miR-191-5p, miR-940 as shown in Non-Patent Document 2, and miR-423-5p as shown in Non-Patent Document 3. Prior art literature

[0009] Japanese Patent Publication No. 2013-000067 and U.S. Patent Application No. US2013 / 0084241 Specification

[0010] Bas WG van Rhijin et al., 2005, European Urology 47, pp. 736-748 Long JD et al., 2015, Am J Transl Res 7(11) pp. 2500-2509 Du L et al., 2017, Oncotarget 8(25) pp. 40832-40842 The problem to be solved

[0011] Among currently widely used diagnostic methods for bladder cancer, urine cytology has a low sensitivity of 35%. This presents challenges, as it is not a universal test; sensitivity can be low depending on the type of specimen—such as the difficulty in distinguishing low-grade histological atypia classified as High / Low—and it exhibits high inter-observer variability. While cystoscopy is said to have a high sensitivity of 90%, in reality, it relies on the operator's subjectivity. Furthermore, differentiation from mucosal inflammation is often subtle, and there is a risk of oversight, as the follow-up period is shortened in unclear cases to delay the conclusion until the next cystoscopy, which may result in a confirmed cancer diagnosis. Additionally, since cystoscopy is performed transurethrally without anesthesia, it causes pain to the patient. This pain is particularly severe for men due to the presence of the penis, posing a challenge by making it an unnecessary examination that places a burden on the patient. The aforementioned existing protein and gene expression indicators have drawbacks, such as a lack of specificity and / or sensitivity, which results in significant fluctuations in measurement results depending on the timing of the test.

[0012] Therefore, there is a possibility of unnecessary additional testing due to misdiagnosing non-bladder cancer patients as bladder cancer patients, or the loss of treatment opportunities due to overlooking bladder cancer patients, and thus there is a need for a high-precision marker that can immediately identify bladder cancer without relying on stage, degree of invasion, histological atypia, or initial / recurrence. In addition, a method for detecting bladder cancer from urine specimens is described in Patent Document 1, which states that the precision was 86% for a verification group of 36 cases (of which 27 were bladder cancer cases), but the number of verification samples is insufficient, and because the amount of nucleic acids in urine is very small, a large amount of processing is required, making the detection process cumbersome and thus it has not reached practical application.

[0013] The present invention aims to provide a disease diagnostic kit or device useful for the diagnosis and treatment of bladder cancer in a non-invasive and small sample volume, and a method for determining (or detecting) bladder cancer. means of solving the problem

[0014] As a result of careful consideration to solve the above problem, the inventors identified a gene usable as a bladder cancer detection marker from blood that can be collected minimally, and discovered that bladder cancer can be significantly detected using this gene, thereby completing the present invention.

[0015] <Summary of the Invention>

[0016] That is, the present invention includes the following forms.

[0017] (1) miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195, miR-3197, miR-320a, miR-320b, miR-328-5p miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298, miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459, miR-4462,miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p, miR-4687-5p miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771, miR-4783-3p miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p, miR-6515-5p, miR-663b miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p, miR-6743-5p,miR-6746-5p,miR-6749-5p,miR-6760-5p,miR-6762-5p,miR-6765-3p,miR-6765-5p,miR-6766-3p,miR-6766-5p,mimi6771-5p,mimi6774-5p,mimi6777-5p miR-6778-5p,miR-6780b-5p,miR-6781-5p,miR-6782-5p,miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p,miR-6794-5p,miR-6800-5p, miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p,miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p,miR-6840-3p,miR-6842-5p miR-6850-5p,miR-6861-5p,miR-6869-5p,miR-6870-5p,miR-6877-5p,miR-6879-5p,miR-6880-3p,miR-6880-5p,miR-6885-5p,miR-6887-5p,miR-7107-5p, A kit for detecting bladder cancer comprising at least one polynucleotide selected from miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide.

[0018] (2) Polynucleotide in which the above nucleic acid represents any one of (a) to (e) below:

[0019] (a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0020] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228,

[0021] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0022] (d) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0023] (e) a polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions,

[0024] A kit described in (1), which is a polynucleotide selected from the group consisting of

[0025] (3) The kit described in (1) or (2) further comprises at least one polynucleotide selected from other bladder cancer markers, miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p, miR-191-5p, miR-423-5p, miR-663a, miR-92a-2-5p, miR-92a-3p, miR-940, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide.

[0026] (4) Polynucleotide in which the above nucleic acid represents any one of (f) to (j) below:

[0027] (f) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,

[0028] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243,

[0029] (h) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0030] (i) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0031] (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions,

[0032] A kit described in (3), which is a polynucleotide selected from the group consisting of

[0033] (5) miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195, miR-3197, miR-320a, miR-320b, miR-328-5p miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298, miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459, miR-4462,miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p, miR-4687-5p miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771, miR-4783-3p miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p, miR-6515-5p, miR-663b miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p, miR-6743-5p,miR-6746-5p,miR-6749-5p,miR-6760-5p,miR-6762-5p,miR-6765-3p,miR-6765-5p,miR-6766-3p,miR-6766-5p,mimi6771-5p,mimi6774-5p,mimi6777-5p miR-6778-5p,miR-6780b-5p,miR-6781-5p,miR-6782-5p,miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p,miR-6794-5p,miR-6800-5p, miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p,miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p,miR-6840-3p,miR-6842-5p miR-6850-5p,miR-6861-5p,miR-6869-5p,miR-6870-5p,miR-6877-5p,miR-6879-5p,miR-6880-3p,miR-6880-5p,miR-6885-5p,miR-6887-5p,miR-7107-5p, A device for detecting bladder cancer comprising at least one polynucleotide selected from miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide.

[0034] (6) Polynucleotide in which the above nucleic acid represents any one of (a) to (e) below:

[0035] (a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0036] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228,

[0037] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0038] (d) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0039] (e) a polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions,

[0040] A device described in (5), which is a polynucleotide selected from the group consisting of

[0041] (7) The device described in (5) or (6) further comprises at least one polynucleotide selected from separate bladder cancer markers miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p, miR-191-5p, miR-423-5p, miR-663a, miR-92a-2-5p, miR-92a-3p, miR-940, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide.

[0042] (8) Polynucleotide in which the above nucleic acid represents any one of (f) to (j) below:

[0043] (f) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,

[0044] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243,

[0045] (h) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0046] (i) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0047] (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions,

[0048] A device described in (7), which is a polynucleotide selected from the group consisting of

[0049] (9) A device described in any one of (5) to (8) which is a device for measurement by hybridization technology.

[0050] (10) The device described in (9) which is a nucleic acid array technology, is a hybridization technology.

[0051] (11). miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195 miR-3197, miR-320a, miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298 miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455,miR-4459, miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771 miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p,miR-6742-5p,miR-6743-5p,miR-6746-5p,miR-6749-5p,miR-6760-5p,miR-6762-5p,miR-6765-3p,mimi6765-5p,mimi6766-3p,mimi6766-5p,mimi6771-5p miR-6774-5p,miR-6777-5p,miR-6778-5p,miR-6780b-5p,miR-6781-5p,miR-6782-5p,miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p, miR-6794-5p,miR-6800-5p,miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p,miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p, miR-6840-3p,miR-6842-5p,miR-6850-5p,miR-6861-5p,miR-6869-5p,miR-6870-5p,miR-6877-5p,miR-6879-5p,miR-6880-3p,mimi6880-5p,mimi-6885-5p A method for detecting bladder cancer, comprising measuring the expression level of at least one polynucleotide selected from miR-6887-5p, miR-7107-5p, miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, and miR-937-5p, and using the measured expression level to evaluate in vitro whether a subject has bladder cancer.

[0052] (12) A method of the method described in (11) comprising substituting the expression amount of at least one polynucleotide in the sample from the subject, which is capable of distinguishing the presence or absence of bladder cancer, into a discriminant formula that is prepared by using the gene expression amount of a sample from a subject known to have bladder cancer and the gene expression amount of a sample from a subject not known to have bladder cancer as a teacher sample, and which is capable of distinguishing the presence or absence of bladder cancer.

[0053] (13) A measurement of the expression amount of the polynucleotide is performed using the above polynucleotide or a nucleic acid capable of specifically binding to the complementary chain of the above polynucleotide, and the above nucleic acid is a polynucleotide that is represented in any one of (a) to (e) below:

[0054] (a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0055] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228,

[0056] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0057] (d) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0058] (e) a polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions,

[0059] A method described in (11) or (12) which is a polynucleotide selected from the group consisting of

[0060] (14) A method of any one of (11) to (13) further comprising measuring the expression amount of at least one polynucleotide selected from separate bladder cancer markers miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p, miR-191-5p, miR-423-5p, miR-663a, miR-92a-2-5p, miR-92a-3p, miR-940.

[0061] (15) A measurement of the expression amount of the polynucleotide is performed using the above polynucleotide or a nucleic acid capable of specifically binding to the complementary chain of the above polynucleotide, and the above nucleic acid is a polynucleotide that is represented in any one of (f) to (j) below:

[0062] (f) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,

[0063] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243,

[0064] (h) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0065] (i) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0066] (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions,

[0067] A method described in (14) which is a polynucleotide selected from the group consisting of

[0068] (16) A method of measuring the expression level of a target gene in a sample of a subject using a kit described in any one of (1) to (4) or a device described in any one of (5) to (10) that includes a nucleic acid capable of specifically binding to the polynucleotide or the complementary chain of the polynucleotide.

[0069] (17) A method described in any one of (11) to (16) in which the subject is a human.

[0070] (18) A method described in any one of (11) to (17) in which the above specimen is blood, serum or plasma.

[0071] Definition of Terms

[0072] Terms used in this specification have the following definitions.

[0073] Indications by abbreviations such as nucleotides, polynucleotides, DNA, RNA, etc., shall be in accordance with the “Guidelines for the Preparation of Specifications, etc. Including Base Sequences or Amino Acid Sequences” (compiled by the Patent Office of Japan) and convention in the technical field.

[0074] In this specification, the term "polynucleotide" is used for nucleic acids including RNA, DNA, and RNA / DNA (chimera). Furthermore, the DNA includes cDNA, genomic DNA, and synthetic DNA. Furthermore, the RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, "synthetic DNA" and "synthetic RNA" refer to DNA and RNA artificially produced, for example using an automated nucleic acid synthesizer, based on a predetermined base sequence (which may be either a natural sequence or a non-natural sequence). In this specification, "non-natural sequence" is intended to be used in a broad sense and includes sequences that differ from natural sequences, such as sequences containing one or more nucleotide substitutions, deletions, insertions, and / or additions (i.e., variant sequences), sequences containing one or more modifying nucleotides (i.e., modification sequences), etc. Additionally, in this specification, polynucleotides are used interchangeably with nucleic acids.

[0075] In this specification, "fragment" refers to a polynucleotide having a sequence of a continuous portion of the bases of a polynucleotide, and preferably has a length of 15 bases or more, preferably 17 bases or more, more preferably 19 bases or more.

[0076] In this specification, the term “gene” is used with the intent to include RNA and double-stranded DNA, as well as each single-stranded DNA such as the regular chain (or sense chain) or complementary chain (or antisense chain) constituting it. Furthermore, it is not particularly limited by its length.

[0077] Accordingly, in this specification, the term “gene” includes, unless specifically stated otherwise, double-stranded DNA including human genomic DNA, single-stranded DNA (main chain), single-stranded DNA having a sequence complementary to the main chain (complementary chain), cDNA, microRNA (miRNA), and fragments thereof, the human genome, and all transcription products thereof. Furthermore, the term “gene” includes not only “genes” represented by specific nucleotide sequences (or sequence numbers), but also “nucleic acids” encoding RNAs that have biological functions equivalent to the RNA encoded by these, such as homologues (i.e., homologs or osolologs), variants such as genetic polymorphisms, and derivatives. As for the “nucleic acid” encoding such homologues, variants, or derivatives, specifically, examples include a “nucleic acid” having a nucleotide sequence represented by any one of SEQ ID NOs 1 to 766 under stringent conditions described below, or a nucleotide sequence that hybridizes with a nucleotide sequence in which u is t. In addition, the “gene” may include, for example, an expression control region, a coding region, an exon, or an intron, without being distinguished by a functional region. Furthermore, the “gene” may be contained within a cell, may be released outside the cell and exist alone, or may be contained within a vesicle called an exosome.

[0078] In this specification, "exosome" refers to a vesicle enclosed in a lipid bilayer that is secreted from a cell. Exosomes originate from polypore endosomes and may contain biomaterials such as proteins or "genes" such as RNA and DNA when released into the extracellular environment. Exosomes are known to be contained in body fluids such as blood, serum, plasma, and lymph.

[0079] In this specification, "transcription product" refers to RNA synthesized using the DNA sequence of a gene as a template. RNA polymerase binds to a region called a promoter located upstream of the gene, and RNA is synthesized by attaching ribonucleotides to the 3' end to become complementary to the DNA base sequence. This RNA includes not only the gene itself but also the entire sequence from the transcription initiation point, including the expression control region, code region, exon, or intron, to the end of the poly-A sequence.

[0080] In addition, in this specification, "microRNA (miRNA)" is intended to be a non-coding RNA of 15 to 25 nucleotides that is transcribed as a hairpin-like RNA precursor, cleaved by a dsRNA cleavage enzyme having RNase III cleavage activity, introduced into a protein complex called RISC, and involved in the repression of mRNA translation, unless specifically stated otherwise. In addition, "miRNA" as used in this specification includes not only "miRNA" represented by a specific nucleotide sequence (or sequence number), but also "miRNA" that contains a precursor (pre-miRNA, pri-miRNA) of the "miRNA" and codes for a miRNA with biological function equivalent to the miRNA encoded by these, such as a homologue (i.e., homolog or osolog), a variant such as a genetic polymorphism, and a derivative. As for the “miRNA” encoding such a precursor, homologue, variant, or derivative, specifically, examples include a “miRNA” that can be identified by miRBase release 21 (http: / / www.mirbase.org / ) and has a nucleotide sequence that hybridizes with the complementary sequence of any one specific nucleotide sequence represented by any one of SEQ ID NOs 1 to 766 under the stringent conditions described below. Additionally, the “miRNA” used in this specification may be a gene product of a miR gene, and such gene product includes a mature miRNA (e.g., a non-coding RNA of 15 to 25 nucleotides or 19 to 25 nucleotides involved in the repression of translation of the mRNA as described above) or a miRNA precursor (e.g., a pre-miRNA or pri-miRNA as described above).

[0081] In this specification, the term “probe” includes a polynucleotide and / or a polynucleotide complementary thereto used to specifically detect RNA produced by gene expression or a polynucleotide derived therefrom.

[0082] In this specification, the term "primer" includes a sequence of polynucleotides and / or polynucleotides complementary thereto that specifically recognize and amplify RNA produced by gene expression or polynucleotides derived therefrom.

[0083] Here, a complementary polynucleotide (complementary chain, inverted chain) means a polynucleotide that is in a base-complementary relationship based on base pair relationships such as A:T(U) and G:C with respect to a full-length sequence of a polynucleotide or a partial sequence (here, for convenience, this is referred to as the main chain) defined by any one of SEQ ID NOs 1 to 766 or a sequence in which u is t in the said sequence. However, such a complementary chain is not limited to cases where it forms a completely complementary sequence with the base sequence of the main chain to be targeted, but may also have a complementary relationship to the extent that it can hybridize under stringent conditions with the main chain to be targeted.

[0084] In this specification, "stringent condition" refers to a condition in which a nucleic acid probe hybridizes to a target sequence to a greater degree of detectability than to other sequences (e.g., a value greater than the mean of background measurements + the standard error of background measurements × 2). Stringent condition is sequence-dependent and varies depending on the environment in which hybridization is performed. By controlling the stringency of hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. Specific examples of "stringent condition" are described below.

[0085] In this specification, "Tm value" means the temperature at which the double-stranded portion of the polynucleotide is denatured into a single strand, and the double strand and the single strand exist in a 1:1 ratio.

[0086] In this specification, the term "variant" refers to a natural variant resulting from polymorphism, mutation, etc., in the case of nucleic acids; a variant comprising a deletion, substitution, addition, or insertion of 1, 2, 3, or more (e.g., 1 to several) bases in a base sequence indicated by SEQ ID NO, a base sequence in which u is t, or a partial sequence thereof; a variant comprising a deletion, substitution, addition, or insertion of 1 or 2 or more bases in a base sequence of a premature miRNA of any one of SEQ ID NOs 1 to 243, a base sequence in which u is t, or a partial sequence thereof; a variant exhibiting at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% identity with each of the base sequences or their partial sequences; or a polynucleotide or oligonucleotide comprising the base sequence or its partial sequence and the definition above It refers to nucleic acids that hybridize under strict conditions.

[0087] In this specification, “a number” means about 10, 9, 8, 7, 6, 5, 4, 3 or 2 integers.

[0088] In this specification, variants can be produced using well-known techniques, such as site-specific mutagenesis and mutation introduction using PCR.

[0089] In this specification, “% identity” can be determined with or without introducing a gap by using a protein or gene screening system such as BLAST (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) or FASTA (http: / / www.genome.jp / tools / fasta / ) (Zheng Zhang et al., 2000, J.Comput.Biol., Vol. 7, pp. 203-214; Altschul, SF et al., 1990, Journal of Molecular Biology, Vol. 215, pp. 403-410; Pearson, WR et al., 1988, Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 2444-2448).

[0090] In this specification, the term “derivative” means a modified nucleic acid, non-limitingly a derivative labeled by a fluorescent dye, for example, a modified nucleotide (for example, a nucleotide containing a group such as a halogen, alkyl such as methyl, alkoxy such as methoxy, thio, carboxymethyl, etc., and a nucleotide that has undergone rearrangement of bases, saturation of double bonds, deamination, substitution of oxygen molecules with sulfur molecules, etc.), PNA (peptide nucleic acid; Nielsen, PE et al., 1991, Science, Vol. 254, pp. 1497-500), LNA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, pp. 5401-5404), etc.

[0091] In the present specification, the polynucleotide selected from the miRNA that is the bladder cancer marker or the “nucleic acid” capable of specifically binding to the complementary chain of the polynucleotide is a synthesized or prepared nucleic acid, specifically comprising a “nucleic acid probe” or a “primer,” and is used directly or indirectly to detect the presence or absence of bladder cancer in a subject, to diagnose the presence or absence of bladder cancer, the degree of disease, the presence or degree of improvement of bladder cancer, or sensitivity to treatment of bladder cancer, or to screen candidate substances useful for the prevention, improvement, or treatment of bladder cancer. These include a transcription product represented by any one of SEQ ID NOs 1 to 766 or a cDNA synthesized nucleic acid in vivo, particularly in bodily fluids such as blood or urine, in relation to bladder cancer disease, or nucleotides, oligonucleotides, and polynucleotides capable of specifically recognizing and binding to the complementary chains thereof. These nucleotides, oligonucleotides, and polynucleotides can be effectively used as probes for detecting the said gene expressed in vivo, in tissues or cells, etc., based on the above properties, and as primers for amplifying the said gene expressed in vivo.

[0092] The term “detection” used in this specification may be replaced with the terms inspection, measurement, detection, or judgment support. Additionally, the term “evaluation” in this specification is used to include supporting diagnosis or evaluation based on inspection results or measurement results.

[0093] As used in this specification, "subject" refers to mammals such as humans, primates including chimpanzees, pet animals such as dogs and cats, livestock animals such as cattle, horses, sheep, and goats, rodents such as mice and rats, and animals raised in zoos. A preferred subject is a human. Additionally, "healthy animal" also refers to such mammals and means an animal that is not suffering from the cancer to be detected. A preferred healthy animal is a human.

[0094] As used herein, "bladder cancer" refers to a malignant tumor occurring in the bladder, and includes urothelial carcinoma including the renal pelvis and ureter.

[0095] As used in this specification, “P” or “P-value” represents the probability that, in a statistical test, a statistic more extreme than the statistic actually calculated from the data is observed under the null hypothesis. Therefore, the smaller the “P” or “P-value,” the more significant the difference between the subjects of comparison can be considered to be.

[0096] In this specification, "sensitivity" refers to the value of (number of true positives) / (number of true positives + number of false negatives). High sensitivity enables the early detection of bladder cancer, leading to the complete resection of the cancerous area and a reduction in the recurrence rate.

[0097] In this specification, "specificity" means (number of true negatives) / (number of true negatives + number of false positives). High specificity prevents unnecessary additional testing caused by misdiagnosing healthy patients as bladder cancer patients, leading to a reduction in the burden on patients and a reduction in medical costs.

[0098] In this specification, “precision” means the value of (number of true positives + number of true negatives) / (total number of cases). Precision represents the ratio of correct identification results for all samples and serves as a primary indicator for evaluating detection performance.

[0099] In this specification, the term “specimen” subject to determination, detection, or diagnosis refers to tissues and biomaterials in which the expression of the gene of the present invention changes according to the occurrence of bladder cancer, the progression of bladder cancer, and the exertion of a therapeutic effect on bladder cancer. Specifically, it refers to bladder tissue, renal pelvis, ureter, lymph nodes and surrounding organs, organs suspected of metastasis, skin, and body fluids such as blood, urine, saliva, sweat, and tissue exudate, serum prepared from blood, plasma, and other feces, hair, etc. Furthermore, it refers to biological samples extracted from these, specifically genes such as RNA or miRNA.

[0100] The terms “hsa-miR-6087 gene” or “hsa-miR-6087” as used in this specification include the hsa-miR-6087 gene (miRBase Accession No. MIMAT0023712) described in SEQ ID NO. 1, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev., Vol. 21, 2049-2057. Additionally, “hsa-miR-6087” is known to have a hairpin-like structure as its precursor, “hsa-mir-6087” (miRBase Accession No. MI0020364, SEQ ID NO. 244).

[0101] The terms “hsa-miR-1185-1-3p gene” or “hsa-miR-1185-1-3p” as used herein include the hsa-miR-1185-1-3p gene (miRBase Accession No. MIMAT0022838) described in SEQ ID NO. 2 and other species homologs or osologs, etc. The gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res., Vol. 16, 1289-1298. Additionally, “hsa-miR-1185-1-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1185-1” (miRBase Accession No. MI0003844, SEQ ID NO. 245).

[0102] The terms “hsa-miR-1185-2-3p gene” or “hsa-miR-1185-2-3p” as used in this specification include the hsa-miR-1185-2-3p gene (miRBase Accession No. MIMAT0022713) described in SEQ ID NO. 3, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res., Vol. 16, 1289-1298. Additionally, “hsa-miR-1185-2-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1185-2” (miRBase Accession No. MI0003821, SEQ ID NO. 246).

[0103] The terms “hsa-miR-1193 gene” or “hsa-miR-1193” as used in this specification include the hsa-miR-1193 gene (miRBase Accession No. MIMAT0015049) described in SEQ ID No. 4, as well as other species homologs or osologs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-1193” is known to have a hairpin-like structure as a precursor to “hsa-miR-1193”, which is “hsa-mir-1193” (miRBase Accession No. MI0014205, SEQ ID No. 247).

[0104] The terms “hsa-miR-1199-5p gene” or “hsa-miR-1199-5p” as used in this specification include the hsa-miR-1199-5p gene (miRBase Accession No. MIMAT0031119) described in SEQ ID No. 5, or other biological species homologs or osologs, etc. The gene can be obtained by the method described in Salvi A et al., 2013, Int J Oncol., Vol. 42, 391-402. In addition, “hsa-miR-1199-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1199” (miRBase Accession No. MI0020340, SEQ ID No. 248).

[0105] The terms “hsa-miR-1225-5p gene” or “hsa-miR-1225-5p” as used herein include the hsa-miR-1225-5p gene (miRBase Accession No. MIMAT0005572) described in SEQ ID No. 6, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell., Vol. 28, 328-336. Additionally, “hsa-miR-1225-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1225” (miRBase Accession No. MI0006311, SEQ ID No. 249).

[0106] The terms “hsa-miR-1227-5p gene” or “hsa-miR-1227-5p” as used herein include the hsa-miR-1227-5p gene (miRBase Accession No. MIMAT0022941) described in SEQ ID No. 7, or other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell., Vol. 28, 328-336. Additionally, “hsa-miR-1227” (miRBase Accession No. MI0006316, SEQ ID No. 250), which has a hairpin-like structure, is known as a precursor of “hsa-miR-1227-5p”.

[0107] The terms “hsa-miR-1228-3p gene” or “hsa-miR-1228-3p” as used herein include the hsa-miR-1228-3p gene (miRBase Accession No. MIMAT0005583) described in SEQ ID No. 8, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell., Vol. 28, 328-336. Additionally, “hsa-miR-1228-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1228” (miRBase Accession No. MI0006318, SEQ ID No. 251).

[0108] The terms “hsa-miR-1228-5p gene” or “hsa-miR-1228-5p” as used herein include the hsa-miR-1228-5p gene (miRBase Accession No. MIMAT0005582) described in SEQ ID No. 9, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell., Vol. 28, 328-336. Additionally, “hsa-miR-1228-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1228” (miRBase Accession No. MI0006318, SEQ ID No. 252).

[0109] The terms “hsa-miR-1237-5p gene” or “hsa-miR-1237-5p” as used herein include the hsa-miR-1237-5p gene (miRBase Accession No. MIMAT0022946) described in SEQ ID NO. 10, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell., Vol. 28, 328-336. Additionally, “hsa-miR-1237-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1237” (miRBase Accession No. MI0006327, SEQ ID NO. 253).

[0110] The terms “hsa-miR-1238-5p gene” or “hsa-miR-1238-5p” as used herein include the hsa-miR-1238-5p gene (miRBase Accession No. MIMAT0022947) described in SEQ ID NO. 11, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell., Vol. 28, 328-336. Additionally, “hsa-miR-1238-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1238” (miRBase Accession No. MI0006328, SEQ ID NO. 254).

[0111] The terms “hsa-miR-1247-3p gene” or “hsa-miR-1247-3p” as used herein include the hsa-miR-1247-3p gene (miRBase Accession No. MIMAT0022721) described in SEQ ID NO. 12, and other species homologs or osologs. The gene can be obtained by the method described in Morin RD et al., 2008, Genome Res., Vol. 18, 610-621. Additionally, “hsa-miR-1247” (miRBase Accession No. MI0006382, SEQ ID NO. 255), which has a hairpin-like structure, is known as a precursor of “hsa-miR-1247-3p”.

[0112] The terms “hsa-miR-1268a gene” or “hsa-miR-1268a” as used in this specification include the hsa-miR-1268a gene (miRBase Accession No. MIMAT0005922) described in SEQ ID NO. 13, and other species homologs or oslogs. The gene can be obtained by the method described in Morin RD et al., 2008, Genome Res., Vol. 18, 610-621. Additionally, “hsa-miR-1268a” is known to have a hairpin-like structure as its precursor, “hsa-mir-1268a” (miRBase Accession No. MI0006405, SEQ ID NO. 256).

[0113] The terms “hsa-miR-1268b gene” or “hsa-miR-1268b” as used in this specification include the hsa-miR-1268b gene (miRBase Accession No. MIMAT0018925) described in SEQ ID NO. 14, or other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-1268b” is known to have a hairpin-like structure as its precursor, “hsa-mir-1268b” (miRBase Accession No. MI0016748, SEQ ID NO. 257).

[0114] The terms “hsa-miR-1273g-3p gene” or “hsa-miR-1273g-3p” as used herein include the hsa-miR-1273g-3p gene (miRBase Accession No. MIMAT0022742) described in SEQ ID NO. 15, as well as other species homologs or osologs. The gene can be obtained by the method described in Reshmi G et al., 2011, Genomics., Vol. 97, 333-340. Additionally, “hsa-miR-1273g-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1273g” (miRBase Accession No. MI0018003, SEQ ID NO. 258).

[0115] The terms “hsa-miR-128-2-5p gene” or “hsa-miR-128-2-5p” as used herein include the hsa-miR-128-2-5p gene (miRBase Accession No. MIMAT0031095) described in SEQ ID NO. 16, as well as other species homologs or osologs. The gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol., Vol. 12, 735-739. Additionally, “hsa-miR-128-2” (miRBase Accession No. MI0000727, SEQ ID NO. 259), which has a hairpin-like structure, is known as a precursor of “hsa-miR-128-2-5p”.

[0116] The terms “hsa-miR-1343-3p gene” or “hsa-miR-1343-3p” as used herein include the hsa-miR-1343-3p gene (miRBase Accession No. MIMAT0019776) described in SEQ ID No. 17, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-1343-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1343” (miRBase Accession No. MI0017320, SEQ ID No. 260).

[0117] The terms “hsa-miR-1343-5p gene” or “hsa-miR-1343-5p” as used herein include the hsa-miR-1343-5p gene (miRBase Accession No. MIMAT0027038) described in SEQ ID NO. 18, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-1343-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1343” (miRBase Accession No. MI0017320, SEQ ID NO. 261).

[0118] The terms “hsa-miR-1470 gene” or “hsa-miR-1470” as used in this specification include the hsa-miR-1470 gene (miRBase Accession No. MIMAT0007348) described in SEQ ID No. 19, as well as other species homologs or osologs. The gene can be obtained by the method described in Kawaji H et al., 2008, BMC Genomics., Vol. 9, 157. Additionally, “hsa-miR-1470” is known to have a hairpin-like structure as its precursor, “hsa-mir-1470” (miRBase Accession No. MI0007075, SEQ ID No. 262).

[0119] The terms “hsa-miR-17-3p gene” or “hsa-miR-17-3p” as used herein include the hsa-miR-17-3p gene (miRBase Accession No. MIMAT0000071) described in SEQ ID NO. 20, and other species homologs or oslogs. The gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science., Vol. 294, pp. 853-858. Additionally, “hsa-miR-17-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-17” (miRBase Accession No. MI0000071, SEQ ID NO. 263).

[0120] The terms “hsa-miR-187-5p gene” or “hsa-miR-187-5p” as used herein include the hsa-miR-187-5p gene (miRBase Accession No. MIMAT0004561) described in SEQ ID No. 21, as well as other species homologs or osologs. The gene can be obtained by the method described in Lim LP et al., 2003, Science., Vol. 299, 1540. Additionally, “hsa-miR-187-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-187” (miRBase Accession No. MI0000274, SEQ ID No. 264).

[0121] The terms “hsa-miR-1908-3p gene” or “hsa-miR-1908-3p” as used herein include the hsa-miR-1908-3p gene (miRBase Accession No. MIMAT0026916) described in SEQ ID No. 22, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Bar M et al., 2008, Stem Cells., Vol. 26, 2496-2505. Additionally, “hsa-miR-1908-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1908” (miRBase Accession No. MI0008329, SEQ ID No. 265).

[0122] The terms “hsa-miR-1908-5p gene” or “hsa-miR-1908-5p” as used herein include the hsa-miR-1908-5p gene (miRBase Accession No. MIMAT0007881) described in SEQ ID NO. 23, or other biological species homologs or osologs, etc. The gene can be obtained by the method described in Bar M et al., 2008, Stem Cells., Vol. 26, 2496-2505. Additionally, “hsa-miR-1908-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1908” (miRBase Accession No. MI0008329, SEQ ID NO. 266).

[0123] The terms “hsa-miR-1909-3p gene” or “hsa-miR-1909-3p” as used herein include the hsa-miR-1909-3p gene (miRBase Accession No. MIMAT0007883) described in SEQ ID No. 24, as well as other species homologs or osologs. The gene can be obtained by the method described in Bar M et al., 2008, Stem Cells., Vol. 26, 2496-2505. Additionally, “hsa-miR-1909-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1909” (miRBase Accession No. MI0008330, SEQ ID No. 267).

[0124] The terms “hsa-miR-1915-3p gene” or “hsa-miR-1915-3p” as used herein include the hsa-miR-1915-3p gene (miRBase Accession No. MIMAT0007892) described in SEQ ID NO. 25, or other species homologs or osologs, etc. The gene can be obtained by the method described in Bar M et al., 2008, Stem Cells., Vol. 26, 2496-2505. Additionally, “hsa-miR-1915-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1915” (miRBase Accession No. MI0008336, SEQ ID NO. 268).

[0125] The terms “hsa-miR-210-5p gene” or “hsa-miR-210-5p” as used herein include the hsa-miR-210-5p gene (miRBase Accession No. MIMAT0026475) described in SEQ ID No. 26, as well as other species homologs or oslogs. The gene can be obtained by the method described in Lim LP et al., 2003, Science., Vol. 299, 1540. Additionally, “hsa-miR-210-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-210” (miRBase Accession No. MI0000286, SEQ ID No. 269).

[0126] The terms “hsa-miR-24-3p gene” or “hsa-miR-24-3p” as used herein include the hsa-miR-24-3p gene (miRBase Accession No. MIMAT0000080) described in SEQ ID NO. 27 and other species homologs or osologs, etc. The gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science., Vol. 294, pp. 853-858. Additionally, “hsa-miR-24-3p” is known to have “hsa-mir-24-1” (miRBase Accession No. MI0000080, SEQ ID NO. 472) and “hsa-mir-24-2” (miRBase Accession No. MI0000081, SEQ ID NO. 484), which have a hairpin-like structure as precursors.

[0127] The terms “hsa-miR-2467-3p gene” or “hsa-miR-2467-3p” as used herein include the hsa-miR-2467-3p gene (miRBase Accession No. MIMAT0019953) described in SEQ ID No. 28, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-2467” (miRBase Accession No. MI0017432, SEQ ID No. 270), which has a hairpin-like structure, is known as a precursor of “hsa-miR-2467-3p”.

[0128] The terms “hsa-miR-2861 gene” or “hsa-miR-2861” as used in this specification include the hsa-miR-2861 gene (miRBase Accession No. MIMAT0013802) described in SEQ ID No. 29, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Li H et al., 2009, J Clin Invest., Vol. 119, 3666-3677. Additionally, “hsa-miR-2861” is known to have a hairpin-like structure as its precursor, “hsa-mir-2861” (miRBase Accession No. MI0013006, SEQ ID No. 271).

[0129] The terms “hsa-miR-296-3p gene” or “hsa-miR-296-3p” as used herein include the hsa-miR-296-3p gene (miRBase Accession No. MIMAT0004679) described in SEQ ID No. 30, and other species homologs or osologs. The gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell., Vol. 5, 351-358. Additionally, “hsa-miR-296-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-296” (miRBase Accession No. MI0000747, SEQ ID No. 272).

[0130] The terms “hsa-miR-29b-3p gene” or “hsa-miR-29b-3p” as used herein include the hsa-miR-29b-3p gene (miRBase Accession No. MIMAT0000100) described in SEQ ID NO. 31, and other species homologs or oslogs. The gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev., Vol. 16, 720-728. Additionally, “hsa-miR-29b-3p” is known to have “hsa-mir-29b-1” (miRBase Accession No. MI0000105, SEQ ID NO. 473) and “hsa-mir-29b-2” (miRBase Accession No. MI0000107, SEQ ID NO. 485), which have a hairpin-like structure as precursors.

[0131] The terms “hsa-miR-3131 gene” or “hsa-miR-3131” as used in this specification include the hsa-miR-3131 gene (miRBase Accession No. MIMAT0014996) described in SEQ ID NO. 32, as well as other species homologs or osologs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-3131” is known to have a hairpin-like structure as its precursor, “hsa-mir-3131” (miRBase Accession No. MI0014151, SEQ ID NO. 273).

[0132] The terms “hsa-miR-3154 gene” or “hsa-miR-3154” as used in this specification include the hsa-miR-3154 gene (miRBase Accession No. MIMAT0015028) described in SEQ ID NO. 33, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res., Vol. 16, 1289-1298. Additionally, “hsa-miR-3154” is known to have a hairpin-like structure as its precursor, “hsa-mir-3154” (miRBase Accession No. MI0014182, SEQ ID NO. 274).

[0133] The terms “hsa-miR-3158-5p gene” or “hsa-miR-3158-5p” as used herein include the hsa-miR-3158-5p gene (miRBase Accession No. MIMAT0019211) described in SEQ ID NO. 34, or other species homologs or oslogs. The gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One., Vol. 5, e9637. Additionally, “hsa-miR-3158-5p” is known to have “hsa-mir-3158-1” (miRBase Accession No. MI0014186, SEQ ID NO. 474), which has a hairpin-like structure as its precursor, and “hsa-mir-3158-2” (miRBase Accession No. MI0014187, SEQ ID NO. 486).

[0134] The terms “hsa-miR-3160-5p gene” or “hsa-miR-3160-5p” as used herein include the hsa-miR-3160-5p gene (miRBase Accession No. MIMAT0019212) described in SEQ ID NO. 35, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. In addition, “hsa-miR-3160-5p” is known to have “hsa-mir-3160-1” (miRBase Accession No. MI0014189, SEQ ID NO. 475) and “hsa-mir-3160-2” (miRBase Accession No. MI0014190, SEQ ID NO. 487), which have a hairpin-like structure as precursors.

[0135] The terms “hsa-miR-3162-5p gene” or “hsa-miR-3162-5p” as used herein include the hsa-miR-3162-5p gene (miRBase Accession No. MIMAT0015036) described in SEQ ID NO. 36, as well as other species homologs or osologs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-3162-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-3162” (miRBase Accession No. MI0014192, SEQ ID NO. 275).

[0136] The terms “hsa-miR-3178 gene” or “hsa-miR-3178” as used in this specification include the hsa-miR-3178 gene (miRBase Accession No. MIMAT0015055) described in SEQ ID No. 37, as well as other species homologs or osologs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-3178” is known to have a hairpin-like structure as its precursor, “hsa-mir-3178” (miRBase Accession No. MI0014212, SEQ ID No. 276).

[0137] The terms “hsa-miR-3180-3p gene” or “hsa-miR-3180-3p” as used herein include the hsa-miR-3180-3p gene (miRBase Accession No. MIMAT0015058) described in SEQ ID NO. 38, or other species homologs or oslogs. The gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One., Vol. 5, e9637. In addition, “hsa-miR-3180-3p” is known to have “hsa-mir-3180-1” (miRBase Accession No. MI0014214, SEQ No. 496), “hsa-mir-3180-2” (miRBase Accession No. MI0014215, SEQ No. 497), and “hsa-mir-3180-3” (miRBase Accession No. MI0014217, SEQ No. 498) as precursors having a hairpin-like structure.

[0138] The terms “hsa-miR-3184-5p gene” or “hsa-miR-3184-5p” as used herein include the hsa-miR-3184-5p gene (miRBase Accession No. MIMAT0015064) described in SEQ ID No. 39, as well as other species homologs or osologs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-3184” (miRBase Accession No. MI0014226, SEQ ID No. 277), which has a hairpin-like structure, is known as a precursor of “hsa-miR-3184-5p”.

[0139] The terms “hsa-miR-3185 gene” or “hsa-miR-3185” as used in this specification include the hsa-miR-3185 gene (miRBase Accession No. MIMAT0015065) described in SEQ ID NO. 40, and other biological species homologs or oslogs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-3185” is known as “hsa-mir-3185” (miRBase Accession No. MI0014227, SEQ ID NO. 278), which has a hairpin-like structure as its precursor.

[0140] The terms “hsa-miR-3194-3p gene” or “hsa-miR-3194-3p” as used herein include the hsa-miR-3194-3p gene (miRBase Accession No. MIMAT0019218) described in SEQ ID NO. 41, and other species homologs or oslogs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-3194” (miRBase Accession No. MI0014239, SEQ ID NO. 279), which has a hairpin-like structure, is known as a precursor of “hsa-miR-3194-3p”.

[0141] The terms “hsa-miR-3195 gene” or “hsa-miR-3195” as used in this specification include the hsa-miR-3195 gene (miRBase Accession No. MIMAT0015079) described in SEQ ID NO. 42, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. In addition, “hsa-miR-3195” is known as “hsa-mir-3195” (miRBase Accession No. MI0014240, SEQ ID NO. 280), which has a hairpin-like structure as its precursor.

[0142] The terms “hsa-miR-3197 gene” or “hsa-miR-3197” as used in this specification include the hsa-miR-3197 gene (miRBase Accession No. MIMAT0015082) described in SEQ ID NO. 43, as well as other species homologs or osologs. The gene can be obtained by the method described in Stark MS et al., 2010, PLoS One., Vol. 5, e9685. Additionally, “hsa-miR-3197” is known to have a hairpin-like structure as its precursor, “hsa-mir-3197” (miRBase Accession No. MI0014245, SEQ ID NO. 281).

[0143] The terms “hsa-miR-320a gene” or “hsa-miR-320a” as used herein include the hsa-miR-320a gene (miRBase Accession No. MIMAT0000510) described in SEQ ID NO. 44, as well as other species homologs or oslogs. The gene can be obtained by the method described in Michael MZ et al., 2003, Mol Cancer Res., Vol. 1, 882-891. Additionally, “hsa-miR-320a” is known to have a hairpin-like structure as its precursor, “hsa-mir-320a” (miRBase Accession No. MI0000542, SEQ ID NO. 282).

[0144] The terms “hsa-miR-320b gene” or “hsa-miR-320b” as used herein include the hsa-miR-320b gene (miRBase Accession No. MIMAT0005792) described in SEQ ID NO. 45, as well as other species homologs or oslogs. The gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res., Vol. 16, 1289-1298. Additionally, “hsa-miR-320b” is known to have “hsa-mir-320b-1” (miRBase Accession No. MI0003776, SEQ ID NO. 476) and “hsa-mir-320b-2” (miRBase Accession No. MI0003839, SEQ ID NO. 488), which have a hairpin-like structure as precursors.

[0145] The terms “hsa-miR-328-5p gene” or “hsa-miR-328-5p” as used herein include the hsa-miR-328-5p gene (miRBase Accession No. MIMAT0026486) described in SEQ ID NO. 46, as well as other species homologs or osologs. The gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci USA., Vol. 101, 360-365. Additionally, “hsa-miR-328-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-328” (miRBase Accession No. MI0000804, SEQ ID NO. 283).

[0146] The terms “hsa-miR-342-5p gene” or “hsa-miR-342-5p” as used herein include the hsa-miR-342-5p gene (miRBase Accession No. MIMAT0004694) described in SEQ ID No. 47, as well as other species homologs or osologs. The gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci USA., Vol. 101, 360-365. Additionally, “hsa-miR-342-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-342” (miRBase Accession No. MI0000805, SEQ ID No. 284).

[0147] The terms “hsa-miR-345-3p gene” or “hsa-miR-345-3p” as used herein include the hsa-miR-345-3p gene (miRBase Accession No. MIMAT0022698) described in SEQ ID No. 48, as well as other species homologs or osologs. The gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci USA., Vol. 101, 360-365. Additionally, “hsa-miR-345-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-345” (miRBase Accession No. MI0000825, SEQ ID No. 285).

[0148] The terms “hsa-miR-3616-3p gene” or “hsa-miR-3616-3p” as used herein include the hsa-miR-3616-3p gene (miRBase Accession No. MIMAT0017996) described in SEQ ID NO. 49, as well as other species homologs or osologs. The gene can be obtained by the method described in Witten D et al., 2010, BMC Biol., Vol. 8, 58. Additionally, “hsa-miR-3616-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-3616” (miRBase Accession No. MI0016006, SEQ ID NO. 286).

[0149] The terms “hsa-miR-3619-3p gene” or “hsa-miR-3619-3p” as used herein include the hsa-miR-3619-3p gene (miRBase Accession No. MIMAT0019219) described in SEQ ID No. 50, as well as other species homologs or osologs. The gene can be obtained by the method described in Witten D et al., 2010, BMC Biol., Vol. 8, 58. Additionally, “hsa-miR-3619-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-3619” (miRBase Accession No. MI0016009, SEQ ID No. 287).

[0150] The terms “hsa-miR-3620-5p gene” or “hsa-miR-3620-5p” as used herein include the hsa-miR-3620-5p gene (miRBase Accession No. MIMAT0022967) described in SEQ ID No. 51, as well as other species homologs or osologs. The gene can be obtained by the method described in Witten D et al., 2010, BMC Biol., Vol. 8, 58. Additionally, “hsa-miR-3620-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-3620” (miRBase Accession No. MI0016011, SEQ ID No. 288).

[0151] The terms “hsa-miR-3621 gene” or “hsa-miR-3621” as used in this specification include the hsa-miR-3621 gene (miRBase Accession No. MIMAT0018002) described in SEQ ID No. 52, as well as other species homologs or osologs. The gene can be obtained by the method described in Witten D et al., 2010, BMC Biol., Vol. 8, 58. Additionally, “hsa-miR-3621” is known to have a hairpin-like structure as its precursor, “hsa-mir-3621” (miRBase Accession No. MI0016012, SEQ ID No. 289).

[0152] The terms “hsa-miR-3622a-5p gene” or “hsa-miR-3622a-5p” as used herein include the hsa-miR-3622a-5p gene (miRBase Accession No. MIMAT0018003) described in SEQ ID No. 53, as well as other species homologs or osologs. The gene can be obtained by the method described in Witten D et al., 2010, BMC Biol., Vol. 8, 58. Additionally, “hsa-miR-3622a” (miRBase Accession No. MI0016013, SEQ ID No. 290), which has a hairpin-like structure, is known as a precursor of “hsa-miR-3622a-5p”.

[0153] The terms “hsa-miR-3648 gene” or “hsa-miR-3648” as used in this specification include the hsa-miR-3648 gene (miRBase Accession No. MIMAT0018068) described in SEQ ID NO. 54, as well as other species homologs or oslogs. The gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res., Vol. 38, 6234-6246. Additionally, “hsa-miR-3648” is known to have “hsa-mir-3648-1” (miRBase Accession No. MI0016048, SEQ ID NO. 477), which has a hairpin-like structure as its precursor, and “hsa-mir-3648-2” (miRBase Accession No. MI0031512, SEQ ID NO. 489).

[0154] The terms “hsa-miR-3652 gene” or “hsa-miR-3652” as used in this specification include the hsa-miR-3652 gene (miRBase Accession No. MIMAT0018072) described in SEQ ID No. 55, as well as other species homologs or osologs. The gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res., Vol. 38, 6234-6246. Additionally, “hsa-miR-3652” is known as “hsa-mir-3652” (miRBase Accession No. MI0016052, SEQ ID No. 291), which has a hairpin-like structure as its precursor.

[0155] The terms “hsa-miR-3656 gene” or “hsa-miR-3656” as used in this specification include the hsa-miR-3656 gene (miRBase Accession No. MIMAT0018076) described in SEQ ID No. 56, as well as other species homologs or osologs. The gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res., Vol. 38, 6234-6246. Additionally, “hsa-miR-3656” is known to have a hairpin-like structure as its precursor, “hsa-mir-3656” (miRBase Accession No. MI0016056, SEQ ID No. 292).

[0156] The terms “hsa-miR-3663-3p gene” or “hsa-miR-3663-3p” as used herein include the hsa-miR-3663-3p gene (miRBase Accession No. MIMAT0018085) described in SEQ ID No. 57, as well as other species homologs or osologs. The gene can be obtained by the method described in Liao JY et al., 2010, PLoS One., Vol. 5, e10563. Additionally, “hsa-miR-3663-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-3663” (miRBase Accession No. MI0016064, SEQ ID No. 293).

[0157] The terms “hsa-miR-3679-5p gene” or “hsa-miR-3679-5p” as used herein include the hsa-miR-3679-5p gene (miRBase Accession No. MIMAT0018104) described in SEQ ID No. 58, as well as other species homologs or osologs. The gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One., Vol. 5, e9637. Additionally, “hsa-miR-3679-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-3679” (miRBase Accession No. MI0016080, SEQ ID No. 294).

[0158] The terms “hsa-miR-371b-5p gene” or “hsa-miR-371b-5p” as used herein include the hsa-miR-371b-5p gene (miRBase Accession No. MIMAT0019892) described in SEQ ID No. 59, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-371b-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-371b” (miRBase Accession No. MI0017393, SEQ ID No. 295).

[0159] The terms “hsa-miR-373-5p gene” or “hsa-miR-373-5p” as used herein include the hsa-miR-373-5p gene (miRBase Accession No. MIMAT0000725) described in SEQ ID No. 60, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Suh MR et al., 2004, Dev Biol., Vol. 270, 488-498. Additionally, “hsa-miR-373-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-373” (miRBase Accession No. MI0000781, SEQ ID No. 296).

[0160] The terms “hsa-miR-3917 gene” or “hsa-miR-3917” as used in this specification include the hsa-miR-3917 gene (miRBase Accession No. MIMAT0018191) described in SEQ ID No. 61, as well as other species homologs or osologs. The gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One., Vol. 5, e9637. Additionally, “hsa-miR-3917” is known to have a hairpin-like structure as its precursor, “hsa-mir-3917” (miRBase Accession No. MI0016423, SEQ ID No. 297).

[0161] The terms “hsa-miR-3940-5p gene” or “hsa-miR-3940-5p” as used herein include the hsa-miR-3940-5p gene (miRBase Accession No. MIMAT0019229) described in SEQ ID No. 62, as well as other species homologs or osologs. The gene can be obtained by the method described in Liao JY et al., 2010, PLoS One., Vol. 5, e10563. Additionally, “hsa-miR-3940-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-3940” (miRBase Accession No. MI0016597, SEQ ID No. 298).

[0162] The terms “hsa-miR-3960 gene” or “hsa-miR-3960” as used in this specification include the hsa-miR-3960 gene (miRBase Accession No. MIMAT0019337) described in SEQ ID No. 63, as well as other species homologs or osologs. The gene can be obtained by the method described in Hu R et al., 2011, J Biol Chem., Vol. 286, 12328-12339. Additionally, “hsa-miR-3960” is known to have a hairpin-like structure as its precursor, “hsa-mir-3960” (miRBase Accession No. MI0016964, SEQ ID No. 299).

[0163] The terms “hsa-miR-4258 gene” or “hsa-miR-4258” as used in this specification include the hsa-miR-4258 gene (miRBase Accession No. MIMAT0016879) described in SEQ ID NO. 64, as well as other species homologs or osologs. The gene can be obtained by the method described in Goff LA et al., 2009, PLoS One., Vol. 4, e7192. Additionally, “hsa-miR-4258” is known as a precursor of which is “hsa-mir-4258” (miRBase Accession No. MI0015857, SEQ ID NO. 300), which has a hairpin-like structure.

[0164] The terms “hsa-miR-4259 gene” or “hsa-miR-4259” as used in this specification include the hsa-miR-4259 gene (miRBase Accession No. MIMAT0016880) described in SEQ ID NO. 65 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Goff LA et al., 2009, PLoS One., Vol. 4, e7192. In addition, “hsa-miR-4259” is known as “hsa-mir-4259” (miRBase Accession No. MI0015858, SEQ ID NO. 301), which has a hairpin-like structure as its precursor.

[0165] The terms “hsa-miR-4270 gene” or “hsa-miR-4270” as used in this specification include the hsa-miR-4270 gene (miRBase Accession No. MIMAT0016900) described in SEQ ID NO. 66, as well as other species homologs or osologs. The gene can be obtained by the method described in Goff LA et al., 2009, PLoS One., Vol. 4, e7192. Additionally, “hsa-miR-4270” is known to have a hairpin-like structure as its precursor, “hsa-mir-4270” (miRBase Accession No. MI0015878, SEQ ID NO. 302).

[0166] The terms “hsa-miR-4286 gene” or “hsa-miR-4286” as used in this specification include the hsa-miR-4286 gene (miRBase Accession No. MIMAT0016916) described in SEQ ID NO. 67 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Goff LA et al., 2009, PLoS One., Vol. 4, e7192. In addition, “hsa-miR-4286” is known as “hsa-mir-4286” (miRBase Accession No. MI0015894, SEQ ID NO. 303), which has a hairpin-like structure as its precursor.

[0167] The terms “hsa-miR-4298 gene” or “hsa-miR-4298” as used in this specification include the hsa-miR-4298 gene (miRBase Accession No. MIMAT0016852) described in SEQ ID No. 68, as well as other species homologs or osologs. The gene can be obtained by the method described in Goff LA et al., 2009, PLoS One., Vol. 4, e7192. Additionally, “hsa-miR-4298” is known to have a hairpin-like structure as its precursor, “hsa-mir-4298” (miRBase Accession No. MI0015830, SEQ ID No. 304).

[0168] The terms “hsa-miR-4322 gene” or “hsa-miR-4322” as used in this specification include the hsa-miR-4322 gene (miRBase Accession No. MIMAT0016873) described in SEQ ID No. 69, as well as other species homologs or osologs. The gene can be obtained by the method described in Goff LA et al., 2009, PLoS One., Vol. 4, e7192. Additionally, “hsa-miR-4322” is known to have a hairpin-like structure as its precursor, “hsa-mir-4322” (miRBase Accession No. MI0015851, SEQ ID No. 305).

[0169] The terms “hsa-miR-4327 gene” or “hsa-miR-4327” as used in this specification include the hsa-miR-4327 gene (miRBase Accession No. MIMAT0016889) described in SEQ ID No. 70, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Goff LA et al., 2009, PLoS One., Vol. 4, e7192. In addition, “hsa-miR-4327” is known as “hsa-mir-4327” (miRBase Accession No. MI0015867, SEQ ID No. 306), which has a hairpin-like structure as its precursor.

[0170] The terms “hsa-miR-4417 gene” or “hsa-miR-4417” as used in this specification include the hsa-miR-4417 gene (miRBase Accession No. MIMAT0018929) described in SEQ ID No. 71, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4417” is known to have a hairpin-like structure as its precursor, “hsa-mir-4417” (miRBase Accession No. MI0016753, SEQ ID No. 307).

[0171] The terms “hsa-miR-4419b gene” or “hsa-miR-4419b” as used in this specification include the hsa-miR-4419b gene (miRBase Accession No. MIMAT0019034) described in SEQ ID No. 72, and other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4419b” is known to have a hairpin-like structure as its precursor, “hsa-mir-4419b” (miRBase Accession No. MI0016861, SEQ ID No. 308).

[0172] The terms “hsa-miR-4429 gene” or “hsa-miR-4429” as used in this specification include the hsa-miR-4429 gene (miRBase Accession No. MIMAT0018944) described in SEQ ID No. 73, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4429” is known as “hsa-mir-4429” (miRBase Accession No. MI0016768, SEQ ID No. 309), which has a hairpin-like structure as its precursor.

[0173] The terms “hsa-miR-4430 gene” or “hsa-miR-4430” as used in this specification include the hsa-miR-4430 gene (miRBase Accession No. MIMAT0018945) described in SEQ ID No. 74, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4430” is known to have a hairpin-like structure as its precursor, “hsa-mir-4430” (miRBase Accession No. MI0016769, SEQ ID No. 310).

[0174] The terms “hsa-miR-4433a-3p gene” or “hsa-miR-4433a-3p” as used herein include the hsa-miR-4433a-3p gene (miRBase Accession No. MIMAT0018949) described in SEQ ID No. 75, as well as other species homologs or osologs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4433a” (miRBase Accession No. MI0016773, SEQ ID No. 311), which has a hairpin-like structure, is known as a precursor of “hsa-miR-4433a-3p”.

[0175] The terms “hsa-miR-4436b-5p gene” or “hsa-miR-4436b-5p” as used herein include the hsa-miR-4436b-5p gene (miRBase Accession No. MIMAT0019940) described in SEQ ID NO. 76, or other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. In addition, “hsa-miR-4436b-5p” is known to have “hsa-mir-4436b-1” (miRBase Accession No. MI0017425, SEQ No. 478) and “hsa-mir-4436b-2” (miRBase Accession No. MI0019110, SEQ No. 490) as precursors having a hairpin-like structure.

[0176] The terms “hsa-miR-4443 gene” or “hsa-miR-4443” as used in this specification include the hsa-miR-4443 gene (miRBase Accession No. MIMAT0018961) described in SEQ ID No. 77, as well as other species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4443” is known to have a hairpin-like structure as its precursor, “hsa-mir-4443” (miRBase Accession No. MI0016786, SEQ ID No. 312).

[0177] The terms “hsa-miR-4446-3p gene” or “hsa-miR-4446-3p” as used in this specification include the hsa-miR-4446-3p gene (miRBase Accession No. MIMAT0018965) described in SEQ ID No. 78, as well as other biological species homologs or osologs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4446-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4446” (miRBase Accession No. MI0016789, SEQ ID No. 313).

[0178] The terms “hsa-miR-4447 gene” or “hsa-miR-4447” as used in this specification include the hsa-miR-4447 gene (miRBase Accession No. MIMAT0018966) described in SEQ ID No. 79, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4447” is known to have a hairpin-like structure as its precursor, “hsa-mir-4447” (miRBase Accession No. MI0016790, SEQ ID No. 314).

[0179] The terms “hsa-miR-4448 gene” or “hsa-miR-4448” as used in this specification include the hsa-miR-4448 gene (miRBase Accession No. MIMAT0018967) described in SEQ ID No. 80, and other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4448” is known as “hsa-mir-4448” (miRBase Accession No. MI0016791, SEQ ID No. 315), which has a hairpin-like structure as its precursor.

[0180] The terms “hsa-miR-4449 gene” or “hsa-miR-4449” as used in this specification include the hsa-miR-4449 gene (miRBase Accession No. MIMAT0018968) described in SEQ ID No. 81, and other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4449” is known as “hsa-mir-4449” (miRBase Accession No. MI0016792, SEQ ID No. 316), which has a hairpin-like structure as its precursor.

[0181] The terms “hsa-miR-4454 gene” or “hsa-miR-4454” as used in this specification include the hsa-miR-4454 gene (miRBase Accession No. MIMAT0018976) described in SEQ ID No. 82, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4454” is known as “hsa-mir-4454” (miRBase Accession No. MI0016800, SEQ ID No. 317), which has a hairpin-like structure as its precursor.

[0182] The terms “hsa-miR-4455 gene” or “hsa-miR-4455” as used in this specification include the hsa-miR-4455 gene (miRBase Accession No. MIMAT0018977) described in SEQ ID No. 83, as well as other species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4455” is known to have a hairpin-like structure as its precursor, “hsa-mir-4455” (miRBase Accession No. MI0016801, SEQ ID No. 318).

[0183] The terms “hsa-miR-4459 gene” or “hsa-miR-4459” as used in this specification include the hsa-miR-4459 gene (miRBase Accession No. MIMAT0018981) described in SEQ ID No. 84, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4459” is known as “hsa-mir-4459” (miRBase Accession No. MI0016805, SEQ ID No. 319), which has a hairpin-like structure as its precursor.

[0184] The terms “hsa-miR-4462 gene” or “hsa-miR-4462” as used in this specification include the hsa-miR-4462 gene (miRBase Accession No. MIMAT0018986) described in SEQ ID No. 85, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4462” is known as a precursor of which is “hsa-mir-4462” (miRBase Accession No. MI0016810, SEQ ID No. 320), which has a hairpin-like structure.

[0185] The terms “hsa-miR-4466 gene” or “hsa-miR-4466” as used in this specification include the hsa-miR-4466 gene (miRBase Accession No. MIMAT0018993) described in SEQ ID No. 86, as well as other species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4466” is known to have a hairpin-like structure as its precursor, “hsa-mir-4466” (miRBase Accession No. MI0016817, SEQ ID No. 321).

[0186] The terms “hsa-miR-4467 gene” or “hsa-miR-4467” as used in this specification include the hsa-miR-4467 gene (miRBase Accession No. MIMAT0018994) described in SEQ ID No. 87, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4467” is known as a precursor of which is “hsa-mir-4467” (miRBase Accession No. MI0016818, SEQ ID No. 322), which has a hairpin-like structure.

[0187] The terms “hsa-miR-4480 gene” or “hsa-miR-4480” as used in this specification include the hsa-miR-4480 gene (miRBase Accession No. MIMAT0019014) described in SEQ ID No. 88, as well as other species homologs or osologs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4480” is known to have a hairpin-like structure as its precursor, “hsa-mir-4480” (miRBase Accession No. MI0016841, SEQ ID No. 323).

[0188] The terms “hsa-miR-4483 gene” or “hsa-miR-4483” as used in this specification include the hsa-miR-4483 gene (miRBase Accession No. MIMAT0019017) described in SEQ ID No. 89, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4483” is known to have a hairpin-like structure as its precursor, “hsa-mir-4483” (miRBase Accession No. MI0016844, SEQ ID No. 324).

[0189] The terms “hsa-miR-4484 gene” or “hsa-miR-4484” as used in this specification include the hsa-miR-4484 gene (miRBase Accession No. MIMAT0019018) described in SEQ ID No. 90, and other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4484” is known to have a hairpin-like structure as its precursor, “hsa-mir-4484” (miRBase Accession No. MI0016845, SEQ ID No. 325).

[0190] The terms “hsa-miR-4485-5p gene” or “hsa-miR-4485-5p” as used herein include the hsa-miR-4485-5p gene (miRBase Accession No. MIMAT0032116) described in SEQ ID No. 91, or other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4485-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4485” (miRBase Accession No. MI0016846, SEQ ID No. 326).

[0191] The terms “hsa-miR-4488 gene” or “hsa-miR-4488” as used in this specification include the hsa-miR-4488 gene (miRBase Accession No. MIMAT0019022) described in SEQ ID No. 92, as well as other species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4488” is known to have a hairpin-like structure as its precursor, “hsa-mir-4488” (miRBase Accession No. MI0016849, SEQ ID No. 327).

[0192] The terms “hsa-miR-4492 gene” or “hsa-miR-4492” as used in this specification include the hsa-miR-4492 gene (miRBase Accession No. MIMAT0019027) described in SEQ ID No. 93, as well as other species homologs or osologs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4492” is known to have a hairpin-like structure as its precursor, “hsa-mir-4492” (miRBase Accession No. MI0016854, SEQ ID No. 328).

[0193] The terms “hsa-miR-4505 gene” or “hsa-miR-4505” as used in this specification include the hsa-miR-4505 gene (miRBase Accession No. MIMAT0019041) described in SEQ ID No. 94, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4505” is known to have a hairpin-like structure as its precursor, “hsa-mir-4505” (miRBase Accession No. MI0016868, SEQ ID No. 329).

[0194] The terms “hsa-miR-4515 gene” or “hsa-miR-4515” as used in this specification include the hsa-miR-4515 gene (miRBase Accession No. MIMAT0019052) described in SEQ ID No. 95, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4515” is known to have a hairpin-like structure as its precursor, “hsa-mir-4515” (miRBase Accession No. MI0016881, SEQ ID No. 330).

[0195] The terms “hsa-miR-4525 gene” or “hsa-miR-4525” as used in this specification include the hsa-miR-4525 gene (miRBase Accession No. MIMAT0019064) described in SEQ ID No. 96, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4525” is known to have a hairpin-like structure as its precursor, “hsa-mir-4525” (miRBase Accession No. MI0016892, SEQ ID No. 331).

[0196] The terms “hsa-miR-4534 gene” or “hsa-miR-4534” as used in this specification include the hsa-miR-4534 gene (miRBase Accession No. MIMAT0019073) described in SEQ ID No. 97, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4534” is known to have a hairpin-like structure as its precursor, “hsa-mir-4534” (miRBase Accession No. MI0016901, SEQ ID No. 332).

[0197] The terms “hsa-miR-4535 gene” or “hsa-miR-4535” as used in this specification include the hsa-miR-4535 gene (miRBase Accession No. MIMAT0019075) described in SEQ ID No. 98, as well as other biological species homologs or osologs. The gene can be obtained by the method described in Jima DD et al., 2010, Blood., Vol. 116, e118-e127. Additionally, “hsa-miR-4535” is known to have a hairpin-like structure as its precursor, “hsa-mir-4535” (miRBase Accession No. MI0016903, SEQ ID No. 333).

[0198] The terms “hsa-miR-4633-3p gene” or “hsa-miR-4633-3p” as used herein include the hsa-miR-4633-3p gene (miRBase Accession No. MIMAT0019690) described in SEQ ID No. 99, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4633-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4633” (miRBase Accession No. MI0017260, SEQ ID No. 334).

[0199] The terms “hsa-miR-4634 gene” or “hsa-miR-4634” as used in this specification include the hsa-miR-4634 gene (miRBase Accession No. MIMAT0019691) described in SEQ ID NO. 100, and other biological species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4634” is known as “hsa-mir-4634” (miRBase Accession No. MI0017261, SEQ ID NO. 335), which has a hairpin-like structure as its precursor.

[0200] The terms “hsa-miR-4640-5p gene” or “hsa-miR-4640-5p” as used herein include the hsa-miR-4640-5p gene (miRBase Accession No. MIMAT0019699) described in SEQ ID No. 101 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. In addition, “hsa-miR-4640-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4640” (miRBase Accession No. MI0017267, SEQ ID No. 336).

[0201] The terms “hsa-miR-4649-5p gene” or “hsa-miR-4649-5p” as used herein include the hsa-miR-4649-5p gene (miRBase Accession No. MIMAT0019711) described in SEQ ID NO. 102, or other species homologs or osologs, etc. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4649-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4649” (miRBase Accession No. MI0017276, SEQ ID NO. 337).

[0202] The terms “hsa-miR-4651 gene” or “hsa-miR-4651” as used in this specification include the hsa-miR-4651 gene (miRBase Accession No. MIMAT0019715) described in SEQ ID No. 103, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4651” is known to have a hairpin-like structure as its precursor, “hsa-mir-4651” (miRBase Accession No. MI0017279, SEQ ID No. 338).

[0203] The terms “hsa-miR-4652-5p gene” or “hsa-miR-4652-5p” as used herein include the hsa-miR-4652-5p gene (miRBase Accession No. MIMAT0019716) described in SEQ ID No. 104, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4652-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4652” (miRBase Accession No. MI0017280, SEQ ID No. 339).

[0204] The terms “hsa-miR-4655-5p gene” or “hsa-miR-4655-5p” as used herein include the hsa-miR-4655-5p gene (miRBase Accession No. MIMAT0019721) described in SEQ ID NO. 105 and other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4655-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4655” (miRBase Accession No. MI0017283, SEQ ID NO. 340).

[0205] The terms “hsa-miR-4656 gene” or “hsa-miR-4656” as used in this specification include the hsa-miR-4656 gene (miRBase Accession No. MIMAT0019723) described in SEQ ID No. 106, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4656” is known to have a hairpin-like structure as its precursor, “hsa-mir-4656” (miRBase Accession No. MI0017284, SEQ ID No. 341).

[0206] The terms “hsa-miR-4658 gene” or “hsa-miR-4658” as used in this specification include the hsa-miR-4658 gene (miRBase Accession No. MIMAT0019725) described in SEQ ID No. 107, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4658” is known to have a hairpin-like structure as its precursor, “hsa-mir-4658” (miRBase Accession No. MI0017286, SEQ ID No. 342).

[0207] The terms “hsa-miR-4663 gene” or “hsa-miR-4663” as used in this specification include the hsa-miR-4663 gene (miRBase Accession No. MIMAT0019735) described in SEQ ID No. 108, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4663” is known to have a hairpin-like structure as its precursor, “hsa-mir-4663” (miRBase Accession No. MI0017292, SEQ ID No. 343).

[0208] The terms “hsa-miR-4673 gene” or “hsa-miR-4673” as used in this specification include the hsa-miR-4673 gene (miRBase Accession No. MIMAT0019755) described in SEQ ID No. 109, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4673” is known to have a hairpin-like structure as its precursor, “hsa-mir-4673” (miRBase Accession No. MI0017304, SEQ ID No. 344).

[0209] The terms “hsa-miR-4675 gene” or “hsa-miR-4675” as used in this specification include the hsa-miR-4675 gene (miRBase Accession No. MIMAT0019757) described in SEQ ID No. 110, and other biological species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4675” is known as “hsa-mir-4675” (miRBase Accession No. MI0017306, SEQ ID No. 345), which has a hairpin-like structure as its precursor.

[0210] The terms “hsa-miR-4687-3p gene” or “hsa-miR-4687-3p” as used herein include the hsa-miR-4687-3p gene (miRBase Accession No. MIMAT0019775) described in SEQ ID No. 111 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. In addition, “hsa-miR-4687” (miRBase Accession No. MI0017319, SEQ ID No. 346), which has a hairpin-like structure as a precursor of “hsa-miR-4687-3p,” is known.

[0211] The terms “hsa-miR-4687-5p gene” or “hsa-miR-4687-5p” as used herein include the hsa-miR-4687-5p gene (miRBase Accession No. MIMAT0019774) described in SEQ ID No. 112, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4687” (miRBase Accession No. MI0017319, SEQ ID No. 347), which has a hairpin-like structure, is known as a precursor of “hsa-miR-4687-5p”.

[0212] The terms “hsa-miR-4690-5p gene” or “hsa-miR-4690-5p” as used herein include the hsa-miR-4690-5p gene (miRBase Accession No. MIMAT0019779) described in SEQ ID NO. 113, or other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4690-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4690” (miRBase Accession No. MI0017323, SEQ ID NO. 348).

[0213] The terms “hsa-miR-4695-5p gene” or “hsa-miR-4695-5p” as used herein include the hsa-miR-4695-5p gene (miRBase Accession No. MIMAT0019788) described in SEQ ID No. 114, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4695-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4695” (miRBase Accession No. MI0017328, SEQ ID No. 349).

[0214] The terms “hsa-miR-4697-5p gene” or “hsa-miR-4697-5p” as used herein include the hsa-miR-4697-5p gene (miRBase Accession No. MIMAT0019791) described in SEQ ID NO. 115, or other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4697” (miRBase Accession No. MI0017330, SEQ ID NO. 350), which has a hairpin-like structure, is known as a precursor of “hsa-miR-4697-5p”.

[0215] The terms “hsa-miR-4706 gene” or “hsa-miR-4706” as used in this specification include the hsa-miR-4706 gene (miRBase Accession No. MIMAT0019806) described in SEQ ID No. 116, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4706” is known to have a hairpin-like structure as its precursor, “hsa-mir-4706” (miRBase Accession No. MI0017339, SEQ ID No. 351).

[0216] The terms “hsa-miR-4707-3p gene” or “hsa-miR-4707-3p” as used herein include the hsa-miR-4707-3p gene (miRBase Accession No. MIMAT0019808) described in SEQ ID No. 117 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. In addition, “hsa-miR-4707-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4707” (miRBase Accession No. MI0017340, SEQ ID No. 352).

[0217] The terms “hsa-miR-4707-5p gene” or “hsa-miR-4707-5p” as used herein include the hsa-miR-4707-5p gene (miRBase Accession No. MIMAT0019807) described in SEQ ID No. 118, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4707” (miRBase Accession No. MI0017340, SEQ ID No. 353), which has a hairpin-like structure, is known as a precursor of “hsa-miR-4707-5p”.

[0218] The terms “hsa-miR-4708-3p gene” or “hsa-miR-4708-3p” as used herein include the hsa-miR-4708-3p gene (miRBase Accession No. MIMAT0019810) described in SEQ ID No. 119, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4708” (miRBase Accession No. MI0017341, SEQ ID No. 354), which has a hairpin-like structure, is known as a precursor of “hsa-miR-4708-3p”.

[0219] The terms “hsa-miR-4710 gene” or “hsa-miR-4710” as used in this specification include the hsa-miR-4710 gene (miRBase Accession No. MIMAT0019815) described in SEQ ID No. 120, and other biological species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4710” is known as “hsa-mir-4710” (miRBase Accession No. MI0017344, SEQ ID No. 355), which has a hairpin-like structure as its precursor.

[0220] The terms “hsa-miR-4718 gene” or “hsa-miR-4718” as used in this specification include the hsa-miR-4718 gene (miRBase Accession No. MIMAT0019831) described in SEQ ID NO. 121, or other biological species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4718” is known as “hsa-mir-4718” (miRBase Accession No. MI0017353, SEQ ID NO. 356), which has a hairpin-like structure as its precursor.

[0221] The terms “hsa-miR-4722-5p gene” or “hsa-miR-4722-5p” as used herein include the hsa-miR-4722-5p gene (miRBase Accession No. MIMAT0019836) described in SEQ ID No. 122, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4722-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4722” (miRBase Accession No. MI0017357, SEQ ID No. 357).

[0222] The terms “hsa-miR-4725-3p gene” or “hsa-miR-4725-3p” as used herein include the hsa-miR-4725-3p gene (miRBase Accession No. MIMAT0019844) described in SEQ ID No. 123, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4725-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4725” (miRBase Accession No. MI0017362, SEQ ID No. 358).

[0223] The terms “hsa-miR-4726-5p gene” or “hsa-miR-4726-5p” as used herein include the hsa-miR-4726-5p gene (miRBase Accession No. MIMAT0019845) described in SEQ ID No. 124, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4726-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4726” (miRBase Accession No. MI0017363, SEQ ID No. 359).

[0224] The terms “hsa-miR-4727-3p gene” or “hsa-miR-4727-3p” as used herein include the hsa-miR-4727-3p gene (miRBase Accession No. MIMAT0019848) described in SEQ ID No. 125, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4727-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4727” (miRBase Accession No. MI0017364, SEQ ID No. 360).

[0225] The terms “hsa-miR-4728-5p gene” or “hsa-miR-4728-5p” as used herein include the hsa-miR-4728-5p gene (miRBase Accession No. MIMAT0019849) described in SEQ ID No. 126, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4728-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4728” (miRBase Accession No. MI0017365, SEQ ID No. 361).

[0226] The terms “hsa-miR-4731-5p gene” or “hsa-miR-4731-5p” as used herein include the hsa-miR-4731-5p gene (miRBase Accession No. MIMAT0019853) described in SEQ ID No. 127, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4731-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4731” (miRBase Accession No. MI0017368, SEQ ID No. 362).

[0227] The terms “hsa-miR-4736 gene” or “hsa-miR-4736” as used in this specification include the hsa-miR-4736 gene (miRBase Accession No. MIMAT0019862) described in SEQ ID No. 128, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4736” is known as a precursor of which is “hsa-mir-4736” (miRBase Accession No. MI0017373, SEQ ID No. 363), which has a hairpin-like structure.

[0228] The terms “hsa-miR-4739 gene” or “hsa-miR-4739” as used in this specification include the hsa-miR-4739 gene (miRBase Accession No. MIMAT0019868) described in SEQ ID No. 129, and other biological species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4739” is known as “hsa-mir-4739” (miRBase Accession No. MI0017377, SEQ ID No. 364), which has a hairpin-like structure as its precursor.

[0229] The terms “hsa-miR-4740-5p gene” or “hsa-miR-4740-5p” as used herein include the hsa-miR-4740-5p gene (miRBase Accession No. MIMAT0019869) described in SEQ ID No. 130, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. In addition, “hsa-miR-4740-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4740” (miRBase Accession No. MI0017378, SEQ ID No. 365).

[0230] The terms “hsa-miR-4741 gene” or “hsa-miR-4741” as used in this specification include the hsa-miR-4741 gene (miRBase Accession No. MIMAT0019871) described in SEQ ID No. 131, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. In addition, “hsa-miR-4741” is known as “hsa-mir-4741” (miRBase Accession No. MI0017379, SEQ ID No. 366), which has a hairpin-like structure as its precursor.

[0231] The terms “hsa-miR-4750-5p gene” or “hsa-miR-4750-5p” as used herein include the hsa-miR-4750-5p gene (miRBase Accession No. MIMAT0019887) described in SEQ ID No. 132, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4750-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4750” (miRBase Accession No. MI0017389, SEQ ID No. 367).

[0232] The terms “hsa-miR-4755-3p gene” or “hsa-miR-4755-3p” as used herein include the hsa-miR-4755-3p gene (miRBase Accession No. MIMAT0019896) described in SEQ ID No. 133, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4755-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4755” (miRBase Accession No. MI0017395, SEQ ID No. 368).

[0233] The terms “hsa-miR-4763-3p gene” or “hsa-miR-4763-3p” as used herein include the hsa-miR-4763-3p gene (miRBase Accession No. MIMAT0019913) described in SEQ ID No. 134, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4763-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4763” (miRBase Accession No. MI0017404, SEQ ID No. 369).

[0234] The terms “hsa-miR-4771 gene” or “hsa-miR-4771” as used in this specification include the hsa-miR-4771 gene (miRBase Accession No. MIMAT0019925) described in SEQ ID NO. 135, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4771” is known to have “hsa-mir-4771-1” (miRBase Accession No. MI0017412, SEQ ID NO. 479) and “hsa-mir-4771-2” (miRBase Accession No. MI0017413, SEQ ID NO. 491) as precursors having a hairpin-like structure.

[0235] The terms “hsa-miR-4783-3p gene” or “hsa-miR-4783-3p” as used herein include the hsa-miR-4783-3p gene (miRBase Accession No. MIMAT0019947) described in SEQ ID No. 136, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4783-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4783” (miRBase Accession No. MI0017428, SEQ ID No. 370).

[0236] The terms “hsa-miR-4783-5p gene” or “hsa-miR-4783-5p” as used herein include the hsa-miR-4783-5p gene (miRBase Accession No. MIMAT0019946) described in SEQ ID No. 137, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4783-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4783” (miRBase Accession No. MI0017428, SEQ ID No. 371).

[0237] The terms “hsa-miR-4787-3p gene” or “hsa-miR-4787-3p” as used herein include the hsa-miR-4787-3p gene (miRBase Accession No. MIMAT0019957) described in SEQ ID No. 138, as well as other species homologs or osologs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4787-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-4787” (miRBase Accession No. MI0017434, SEQ ID No. 372).

[0238] The terms “hsa-miR-4792 gene” or “hsa-miR-4792” as used in this specification include the hsa-miR-4792 gene (miRBase Accession No. MIMAT0019964) described in SEQ ID No. 139, as well as other species homologs or oslogs. The gene can be obtained by the method described in Persson H et al., 2011, Cancer Res., Vol. 71, 78-86. Additionally, “hsa-miR-4792” is known as a precursor of which is “hsa-mir-4792” (miRBase Accession No. MI0017439, SEQ ID No. 373), which has a hairpin-like structure.

[0239] The terms “hsa-miR-498 gene” or “hsa-miR-498” as used in this specification include the hsa-miR-498 gene (miRBase Accession No. MIMAT0002824) described in SEQ ID No. 140, as well as other species homologs or osologs. The gene can be obtained by the method described in Bentwich I et al., 2005, Nat Genet., Vol. 37, 766-770. Additionally, “hsa-miR-498” is known to have a hairpin-like structure as its precursor, “hsa-mir-498” (miRBase Accession No. MI0003142, SEQ ID No. 374).

[0240] The terms “hsa-miR-5008-5p gene” or “hsa-miR-5008-5p” as used herein include the hsa-miR-5008-5p gene (miRBase Accession No. MIMAT0021039) described in SEQ ID No. 141, or other biological species homologs or osologs, etc. The gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol., Vol. 8, 378-383. Additionally, “hsa-miR-5008” (miRBase Accession No. MI0017876, SEQ ID No. 375), which has a hairpin-like structure, is known as a precursor of “hsa-miR-5008-5p”.

[0241] The terms “hsa-miR-5010-5p gene” or “hsa-miR-5010-5p” as used herein include the hsa-miR-5010-5p gene (miRBase Accession No. MIMAT0021043) described in SEQ ID No. 142, as well as other species homologs or osologs. The gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol., Vol. 8, 378-383. Additionally, “hsa-miR-5010-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-5010” (miRBase Accession No. MI0017878, SEQ ID No. 376).

[0242] The terms “hsa-miR-504-3p gene” or “hsa-miR-504-3p” as used herein include the hsa-miR-504-3p gene (miRBase Accession No. MIMAT0026612) described in SEQ ID No. 143, and other species homologs or osologs, etc. The gene can be obtained by the method described in Bentwich I et al., 2005, Nat Genet., Vol. 37, 766-770. Additionally, “hsa-miR-504-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-504” (miRBase Accession No. MI0003189, SEQ ID No. 377).

[0243] The terms “hsa-miR-5195-3p gene” or “hsa-miR-5195-3p” as used herein include the hsa-miR-5195-3p gene (miRBase Accession No. MIMAT0021127) described in SEQ ID No. 144, as well as other species homologs or osologs. The gene can be obtained by the method described in Schotte D et al., 2011, Leukemia., Vol. 25, 1389-1399. Additionally, “hsa-miR-5195-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-5195” (miRBase Accession No. MI0018174, SEQ ID No. 378).

[0244] The terms “hsa-miR-550a-5p gene” or “hsa-miR-550a-5p” as used herein include the hsa-miR-550a-5p gene (miRBase Accession No. MIMAT0004800) described in SEQ ID NO. 145, or other biological species homologs or oslogs, etc. The gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA., Vol. 103, 3687-3692. In addition, “hsa-miR-550a-5p” is known to have “hsa-mir-550a-1” (miRBase Accession No. MI0003600, SEQ No. 480) and “hsa-mir-550a-2” (miRBase Accession No. MI0003601, SEQ No. 492) as precursors having a hairpin-like structure.

[0245] The terms “hsa-miR-5572 gene” or “hsa-miR-5572” as used in this specification include the hsa-miR-5572 gene (miRBase Accession No. MIMAT0022260) described in SEQ ID No. 146, as well as other biological species homologs or osologs, etc. The gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis., Vol. 18, 127-131. Additionally, “hsa-miR-5572” is known as “hsa-mir-5572” (miRBase Accession No. MI0019117, SEQ ID No. 379), which has a hairpin-like structure as its precursor.

[0246] The terms “hsa-miR-5739 gene” or “hsa-miR-5739” as used in this specification include the hsa-miR-5739 gene (miRBase Accession No. MIMAT0023116) described in SEQ ID No. 147, as well as other biological species homologs or osologs. The gene can be obtained by the method described in Yoo JK et al., 2011, Biochem Biophys Res Commun., Vol. 415, 258-262. Additionally, “hsa-miR-5739” is known as “hsa-mir-5739” (miRBase Accession No. MI0019412, SEQ ID No. 380), which has a hairpin-like structure as its precursor.

[0247] The terms “hsa-miR-6075 gene” or “hsa-miR-6075” as used in this specification include the hsa-miR-6075 gene (miRBase Accession No. MIMAT0023700) described in SEQ ID No. 148, as well as other species homologs or osologs. The gene can be obtained by the method described in Voellenkle C et al., 2012, RNA., Vol. 18, 472-484. Additionally, “hsa-miR-6075” is known to have a hairpin-like structure as its precursor, “hsa-mir-6075” (miRBase Accession No. MI0020352, SEQ ID No. 381).

[0248] The terms “hsa-miR-6076 gene” or “hsa-miR-6076” as used herein include the hsa-miR-6076 gene (miRBase Accession No. MIMAT0023701) described in SEQ ID No. 149, as well as other species homologs or osologs. The gene can be obtained by the method described in Voellenkle C et al., 2012, RNA., Vol. 18, 472-484. Additionally, “hsa-miR-6076” is known to have a hairpin-like structure as its precursor, “hsa-mir-6076” (miRBase Accession No. MI0020353, SEQ ID No. 382).

[0249] The terms “hsa-miR-6088 gene” or “hsa-miR-6088” as used in this specification include the hsa-miR-6088 gene (miRBase Accession No. MIMAT0023713) described in SEQ ID NO. 150, and other biological species homologs or oslogs. The gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev., Vol. 21, 2049-2057. Additionally, “hsa-miR-6088” is known to have a hairpin-like structure as its precursor, “hsa-mir-6088” (miRBase Accession No. MI0020365, SEQ ID NO. 383).

[0250] The terms “hsa-miR-6124 gene” or “hsa-miR-6124” as used in this specification include the hsa-miR-6124 gene (miRBase Accession No. MIMAT0024597) described in SEQ ID NO. 151, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Smith JL et al., 2012, J Virol., Vol. 86, 5278-5287. Additionally, “hsa-miR-6124” is known as “hsa-mir-6124” (miRBase Accession No. MI0021258, SEQ ID NO. 384), which has a hairpin-like structure as its precursor.

[0251] The terms “hsa-miR-6131 gene” or “hsa-miR-6131” as used in this specification include the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO. 152, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol., Vol. 4, 552-564. In addition, “hsa-miR-6131” is known as “hsa-mir-6131” (miRBase Accession No. MI0021276, SEQ ID NO. 385), which has a hairpin-like structure as its precursor.

[0252] The terms “hsa-miR-6132 gene” or “hsa-miR-6132” as used in this specification include the hsa-miR-6132 gene (miRBase Accession No. MIMAT0024616) described in SEQ ID NO. 153, as well as other species homologs or osologs. The gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol., Vol. 4, 552-564. Additionally, “hsa-miR-6132” is known to have a hairpin-like structure as its precursor, “hsa-mir-6132” (miRBase Accession No. MI0021277, SEQ ID NO. 386).

[0253] The terms “hsa-miR-614 gene” or “hsa-miR-614” as used in this specification include the hsa-miR-614 gene (miRBase Accession No. MIMAT0003282) described in SEQ ID NO. 154, as well as other biological species homologs or oslogs. The gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA., Vol. 103, 3687-3692. Additionally, “hsa-miR-614” is known to have a hairpin-like structure as its precursor, “hsa-mir-614” (miRBase Accession No. MI0003627, SEQ ID NO. 387).

[0254] The terms “hsa-miR-615-5p gene” or “hsa-miR-615-5p” as used herein include the hsa-miR-615-5p gene (miRBase Accession No. MIMAT0004804) described in SEQ ID No. 155, as well as other species homologs or oslogs. The gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA., Vol. 103, 3687-3692. Additionally, “hsa-miR-615-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-615” (miRBase Accession No. MI0003628, SEQ ID No. 388).

[0255] The terms “hsa-miR-619-5p gene” or “hsa-miR-619-5p” as used herein include the hsa-miR-619-5p gene (miRBase Accession No. MIMAT0026622) described in SEQ ID No. 156, as well as other species homologs or osologs. The gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA., Vol. 103, 3687-3692. Additionally, “hsa-miR-619-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-619” (miRBase Accession No. MI0003633, SEQ ID No. 389).

[0256] The terms “hsa-miR-642b-3p gene” or “hsa-miR-642b-3p” as used herein include the hsa-miR-642b-3p gene (miRBase Accession No. MIMAT0018444) described in SEQ ID No. 157 and other species homologs or osologs, etc. The gene can be obtained by the method described in Witten D et al., 2010, BMC Biol., Vol. 8, 58. In addition, “hsa-miR-642b-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-642b” (miRBase Accession No. MI0016685, SEQ ID No. 390).

[0257] The terms “hsa-miR-6510-5p gene” or “hsa-miR-6510-5p” as used herein include the hsa-miR-6510-5p gene (miRBase Accession No. MIMAT0025476) described in SEQ ID No. 158, as well as other species homologs or osologs. The gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet., Vol. 20, 4025-4040. Additionally, “hsa-miR-6510-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6510” (miRBase Accession No. MI0022222, SEQ ID No. 391).

[0258] The terms “hsa-miR-6511a-5p gene” or “hsa-miR-6511a-5p” as used herein include the hsa-miR-6511a-5p gene (miRBase Accession No. MIMAT0025478) described in SEQ ID NO. 159, or other species homologs or osologs, etc. The gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet., Vol. 20, 4025-4040. In addition, “hsa-miR-6511a-5p” is known to have “hsa-mir-6511a-1” (miRBase Accession No. MI0022223, SEQ No. 499), “hsa-mir-6511a-2” (miRBase Accession No. MI0023564, SEQ No. 501), “hsa-mir-6511a-3” (miRBase Accession No. MI0023565, SEQ No. 503), and “hsa-mir-6511a-4” (miRBase Accession No. MI0023566, SEQ No. 505) as precursors having a hairpin-like structure.

[0259] The terms “hsa-miR-6515-3p gene” or “hsa-miR-6515-3p” as used herein include the hsa-miR-6515-3p gene (miRBase Accession No. MIMAT0025487) described in SEQ ID NO. 160, and other species homologs or osologs. The gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet., Vol. 20, 4025-4040. Additionally, “hsa-miR-6515-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6515” (miRBase Accession No. MI0022227, SEQ ID NO. 392).

[0260] The terms “hsa-miR-6515-5p gene” or “hsa-miR-6515-5p” as used herein include the hsa-miR-6515-5p gene (miRBase Accession No. MIMAT0025486) described in SEQ ID NO. 161 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet., Vol. 20, 4025-4040. Additionally, “hsa-miR-6515-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6515” (miRBase Accession No. MI0022227, SEQ ID NO. 393).

[0261] The terms “hsa-miR-663b gene” or “hsa-miR-663b” as used herein include the hsa-miR-663b gene (miRBase Accession No. MIMAT0005867) described in SEQ ID NO. 162, as well as other species homologs or osologs. The gene can be obtained by the method described in Takada S et al., 2008, Leukemia., Vol. 22, 1274-1278. Additionally, “hsa-miR-663b” is known to have a hairpin-like structure as its precursor, “hsa-mir-663b” (miRBase Accession No. MI0006336, SEQ ID NO. 394).

[0262] The terms “hsa-miR-6716-5p gene” or “hsa-miR-6716-5p” as used herein include the hsa-miR-6716-5p gene (miRBase Accession No. MIMAT0025844) described in SEQ ID NO. 163, as well as other species homologs or osologs. The gene can be obtained by the method described in Li Y et al., 2012, Gene., Vol. 497, pp. 330-335. Additionally, “hsa-miR-6716-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6716” (miRBase Accession No. MI0022550, SEQ ID NO. 395).

[0263] The terms “hsa-miR-6717-5p gene” or “hsa-miR-6717-5p” as used herein include the hsa-miR-6717-5p gene (miRBase Accession No. MIMAT0025846) described in SEQ ID NO. 164 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Li Y et al., 2012, Gene., Vol. 497, 330-335. Additionally, “hsa-miR-6717-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6717” (miRBase Accession No. MI0022551, SEQ ID NO. 396).

[0264] The terms “hsa-miR-6722-3p gene” or “hsa-miR-6722-3p” as used herein include the hsa-miR-6722-3p gene (miRBase Accession No. MIMAT0025854) described in SEQ ID NO. 165 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Li Y et al., 2012, Gene., Vol. 497, pp. 330-335. Additionally, “hsa-miR-6722-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6722” (miRBase Accession No. MI0022557, SEQ ID NO. 397).

[0265] The terms “hsa-miR-6724-5p gene” or “hsa-miR-6724-5p” as used herein include the hsa-miR-6724-5p gene (miRBase Accession No. MIMAT0025856) described in SEQ ID NO. 166, or other biological species homologs or oslogs, etc. The gene can be obtained by the method described in Li Y et al., 2012, Gene., Vol. 497, 330-335. In addition, “hsa-miR-6724-5p” is known to have “hsa-mir-6724-1” (miRBase Accession No. MI0022559, SEQ No. 500), “hsa-mir-6724-2” (miRBase Accession No. MI0031516, SEQ No. 502), “hsa-mir-6724-3” (miRBase Accession No. MI0031517, SEQ No. 504), and “hsa-mir-6724-4” (miRBase Accession No. MI0031518, SEQ No. 506) as precursors having a hairpin-like structure.

[0266] The terms “hsa-miR-6726-5p gene” or “hsa-miR-6726-5p” as used herein include the hsa-miR-6726-5p gene (miRBase Accession No. MIMAT0027353) described in SEQ ID NO. 167 and other species homologs or osologs, etc. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6726-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6726” (miRBase Accession No. MI0022571, SEQ ID NO. 398).

[0267] The terms “hsa-miR-6737-5p gene” or “hsa-miR-6737-5p” as used herein include the hsa-miR-6737-5p gene (miRBase Accession No. MIMAT0027375) described in SEQ ID NO. 168, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6737-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6737” (miRBase Accession No. MI0022582, SEQ ID NO. 399).

[0268] The terms “hsa-miR-6741-5p gene” or “hsa-miR-6741-5p” as used herein include the hsa-miR-6741-5p gene (miRBase Accession No. MIMAT0027383) described in SEQ ID NO. 169, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6741-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6741” (miRBase Accession No. MI0022586, SEQ ID NO. 400).

[0269] The terms “hsa-miR-6742-5p gene” or “hsa-miR-6742-5p” as used herein include the hsa-miR-6742-5p gene (miRBase Accession No. MIMAT0027385) described in SEQ ID No. 170, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6742-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6742” (miRBase Accession No. MI0022587, SEQ ID No. 401).

[0270] The terms “hsa-miR-6743-5p gene” or “hsa-miR-6743-5p” as used herein include the hsa-miR-6743-5p gene (miRBase Accession No. MIMAT0027387) described in SEQ ID No. 171, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6743-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6743” (miRBase Accession No. MI0022588, SEQ ID No. 402).

[0271] The terms “hsa-miR-6746-5p gene” or “hsa-miR-6746-5p” as used herein include the hsa-miR-6746-5p gene (miRBase Accession No. MIMAT0027392) described in SEQ ID No. 172, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6746-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6746” (miRBase Accession No. MI0022591, SEQ ID No. 403).

[0272] The terms “hsa-miR-6749-5p gene” or “hsa-miR-6749-5p” as used herein include the hsa-miR-6749-5p gene (miRBase Accession No. MIMAT0027398) described in SEQ ID No. 173, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6749-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6749” (miRBase Accession No. MI0022594, SEQ ID No. 404).

[0273] The terms “hsa-miR-6760-5p gene” or “hsa-miR-6760-5p” as used herein include the hsa-miR-6760-5p gene (miRBase Accession No. MIMAT0027420) described in SEQ ID No. 174, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6760-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6760” (miRBase Accession No. MI0022605, SEQ ID No. 405).

[0274] The terms “hsa-miR-6762-5p gene” or “hsa-miR-6762-5p” as used herein include the hsa-miR-6762-5p gene (miRBase Accession No. MIMAT0027424) described in SEQ ID No. 175, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6762-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6762” (miRBase Accession No. MI0022607, SEQ ID No. 406).

[0275] The terms “hsa-miR-6765-3p gene” or “hsa-miR-6765-3p” as used herein include the hsa-miR-6765-3p gene (miRBase Accession No. MIMAT0027431) described in SEQ ID No. 176, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6765-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6765” (miRBase Accession No. MI0022610, SEQ ID No. 407).

[0276] The terms “hsa-miR-6765-5p gene” or “hsa-miR-6765-5p” as used herein include the hsa-miR-6765-5p gene (miRBase Accession No. MIMAT0027430) described in SEQ ID No. 177 and other species homologs or osologs, etc. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6765-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6765” (miRBase Accession No. MI0022610, SEQ ID No. 408).

[0277] The terms “hsa-miR-6766-3p gene” or “hsa-miR-6766-3p” as used herein include the hsa-miR-6766-3p gene (miRBase Accession No. MIMAT0027433) described in SEQ ID No. 178, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6766-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6766” (miRBase Accession No. MI0022611, SEQ ID No. 409).

[0278] The terms “hsa-miR-6766-5p gene” or “hsa-miR-6766-5p” as used herein include the hsa-miR-6766-5p gene (miRBase Accession No. MIMAT0027432) described in SEQ ID No. 179, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6766-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6766” (miRBase Accession No. MI0022611, SEQ ID No. 410).

[0279] The terms “hsa-miR-6771-5p gene” or “hsa-miR-6771-5p” as used herein include the hsa-miR-6771-5p gene (miRBase Accession No. MIMAT0027442) described in SEQ ID No. 180, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6771-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6771” (miRBase Accession No. MI0022616, SEQ ID No. 411).

[0280] The terms “hsa-miR-6774-5p gene” or “hsa-miR-6774-5p” as used herein include the hsa-miR-6774-5p gene (miRBase Accession No. MIMAT0027448) described in SEQ ID No. 181, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6774-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6774” (miRBase Accession No. MI0022619, SEQ ID No. 412).

[0281] The terms “hsa-miR-6777-5p gene” or “hsa-miR-6777-5p” as used herein include the hsa-miR-6777-5p gene (miRBase Accession No. MIMAT0027454) described in SEQ ID No. 182, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6777-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6777” (miRBase Accession No. MI0022622, SEQ ID No. 413).

[0282] The terms “hsa-miR-6778-5p gene” or “hsa-miR-6778-5p” as used herein include the hsa-miR-6778-5p gene (miRBase Accession No. MIMAT0027456) described in SEQ ID No. 183, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6778-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6778” (miRBase Accession No. MI0022623, SEQ ID No. 414).

[0283] The terms “hsa-miR-6780b-5p gene” or “hsa-miR-6780b-5p” as used herein include the hsa-miR-6780b-5p gene (miRBase Accession No. MIMAT0027572) described in SEQ ID No. 184, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6780b-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6780b” (miRBase Accession No. MI0022681, SEQ ID No. 415).

[0284] The terms “hsa-miR-6781-5p gene” or “hsa-miR-6781-5p” as used herein include the hsa-miR-6781-5p gene (miRBase Accession No. MIMAT0027462) described in SEQ ID No. 185, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6781” (miRBase Accession No. MI0022626, SEQ ID No. 416), which has a hairpin-like structure, is known as a precursor of “hsa-miR-6781-5p”.

[0285] The terms “hsa-miR-6782-5p gene” or “hsa-miR-6782-5p” as used herein include the hsa-miR-6782-5p gene (miRBase Accession No. MIMAT0027464) described in SEQ ID No. 186, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6782-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6782” (miRBase Accession No. MI0022627, SEQ ID No. 417).

[0286] The terms “hsa-miR-6784-5p gene” or “hsa-miR-6784-5p” as used herein include the hsa-miR-6784-5p gene (miRBase Accession No. MIMAT0027468) described in SEQ ID No. 187, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6784” (miRBase Accession No. MI0022629, SEQ ID No. 418), which has a hairpin-like structure, is known as a precursor of “hsa-miR-6784-5p”.

[0287] The terms “hsa-miR-6785-5p gene” or “hsa-miR-6785-5p” as used herein include the hsa-miR-6785-5p gene (miRBase Accession No. MIMAT0027470) described in SEQ ID No. 188, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6785-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6785” (miRBase Accession No. MI0022630, SEQ ID No. 419).

[0288] The terms “hsa-miR-6787-5p gene” or “hsa-miR-6787-5p” as used herein include the hsa-miR-6787-5p gene (miRBase Accession No. MIMAT0027474) described in SEQ ID No. 189, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6787” (miRBase Accession No. MI0022632, SEQ ID No. 420), which has a hairpin-like structure, is known as a precursor of “hsa-miR-6787-5p”.

[0289] The terms “hsa-miR-6789-5p gene” or “hsa-miR-6789-5p” as used herein include the hsa-miR-6789-5p gene (miRBase Accession No. MIMAT0027478) described in SEQ ID No. 190, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6789-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6789” (miRBase Accession No. MI0022634, SEQ ID No. 421).

[0290] The terms “hsa-miR-6791-5p gene” or “hsa-miR-6791-5p” as used herein include the hsa-miR-6791-5p gene (miRBase Accession No. MIMAT0027482) described in SEQ ID No. 191, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6791” (miRBase Accession No. MI0022636, SEQ ID No. 422), which has a hairpin-like structure, is known as a precursor of “hsa-miR-6791-5p”.

[0291] The terms “hsa-miR-6794-5p gene” or “hsa-miR-6794-5p” as used herein include the hsa-miR-6794-5p gene (miRBase Accession No. MIMAT0027488) described in SEQ ID No. 192, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6794” (miRBase Accession No. MI0022639, SEQ ID No. 423), which has a hairpin-like structure, is known as a precursor of “hsa-miR-6794-5p”.

[0292] The terms “hsa-miR-6800-5p gene” or “hsa-miR-6800-5p” as used herein include the hsa-miR-6800-5p gene (miRBase Accession No. MIMAT0027500) described in SEQ ID No. 193, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6800-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6800” (miRBase Accession No. MI0022645, SEQ ID No. 424).

[0293] The terms “hsa-miR-6802-5p gene” or “hsa-miR-6802-5p” as used herein include the hsa-miR-6802-5p gene (miRBase Accession No. MIMAT0027504) described in SEQ ID No. 194, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6802-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6802” (miRBase Accession No. MI0022647, SEQ ID No. 425).

[0294] The terms “hsa-miR-6803-5p gene” or “hsa-miR-6803-5p” as used herein include the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID No. 195, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6803-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6803” (miRBase Accession No. MI0022648, SEQ ID No. 426).

[0295] The terms “hsa-miR-6812-5p gene” or “hsa-miR-6812-5p” as used herein include the hsa-miR-6812-5p gene (miRBase Accession No. MIMAT0027524) described in SEQ ID No. 196, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6812-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6812” (miRBase Accession No. MI0022657, SEQ ID No. 427).

[0296] The terms “hsa-miR-6816-5p gene” or “hsa-miR-6816-5p” as used herein include the hsa-miR-6816-5p gene (miRBase Accession No. MIMAT0027532) described in SEQ ID No. 197, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6816-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6816” (miRBase Accession No. MI0022661, SEQ ID No. 428).

[0297] The terms “hsa-miR-6819-5p gene” or “hsa-miR-6819-5p” as used herein include the hsa-miR-6819-5p gene (miRBase Accession No. MIMAT0027538) described in SEQ ID No. 198, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6819-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6819” (miRBase Accession No. MI0022664, SEQ ID No. 429).

[0298] The terms “hsa-miR-6821-5p gene” or “hsa-miR-6821-5p” as used herein include the hsa-miR-6821-5p gene (miRBase Accession No. MIMAT0027542) described in SEQ ID No. 199, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6821” (miRBase Accession No. MI0022666, SEQ ID No. 430), which has a hairpin-like structure, is known as a precursor of “hsa-miR-6821-5p”.

[0299] The terms “hsa-miR-6826-5p gene” or “hsa-miR-6826-5p” as used herein include the hsa-miR-6826-5p gene (miRBase Accession No. MIMAT0027552) described in SEQ ID No. 200, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6826-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6826” (miRBase Accession No. MI0022671, SEQ ID No. 431).

[0300] The terms “hsa-miR-6831-5p gene” or “hsa-miR-6831-5p” as used herein include the hsa-miR-6831-5p gene (miRBase Accession No. MIMAT0027562) described in SEQ ID No. 201, or other species homologs or osologs, etc. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6831” (miRBase Accession No. MI0022676, SEQ ID No. 432), which has a hairpin-like structure as a precursor to “hsa-miR-6831-5p,” is known.

[0301] The terms “hsa-miR-6836-3p gene” or “hsa-miR-6836-3p” as used herein include the hsa-miR-6836-3p gene (miRBase Accession No. MIMAT0027575) described in SEQ ID No. 202, and other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6836-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6836” (miRBase Accession No. MI0022682, SEQ ID No. 433).

[0302] The terms “hsa-miR-6840-3p gene” or “hsa-miR-6840-3p” as used herein include the hsa-miR-6840-3p gene (miRBase Accession No. MIMAT0027583) described in SEQ ID No. 203, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6840-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6840” (miRBase Accession No. MI0022686, SEQ ID No. 434).

[0303] The terms “hsa-miR-6842-5p gene” or “hsa-miR-6842-5p” as used herein include the hsa-miR-6842-5p gene (miRBase Accession No. MIMAT0027586) described in SEQ ID No. 204, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6842-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6842” (miRBase Accession No. MI0022688, SEQ ID No. 435).

[0304] The terms “hsa-miR-6850-5p gene” or “hsa-miR-6850-5p” as used herein include the hsa-miR-6850-5p gene (miRBase Accession No. MIMAT0027600) described in SEQ ID No. 205, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6850-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6850” (miRBase Accession No. MI0022696, SEQ ID No. 436).

[0305] The terms “hsa-miR-6861-5p gene” or “hsa-miR-6861-5p” as used herein include the hsa-miR-6861-5p gene (miRBase Accession No. MIMAT0027623) described in SEQ ID No. 206, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6861-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6861” (miRBase Accession No. MI0022708, SEQ ID No. 437).

[0306] The terms “hsa-miR-6869-5p gene” or “hsa-miR-6869-5p” as used herein include the hsa-miR-6869-5p gene (miRBase Accession No. MIMAT0027638) described in SEQ ID No. 207, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6869-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6869” (miRBase Accession No. MI0022716, SEQ ID No. 438).

[0307] The terms “hsa-miR-6870-5p gene” or “hsa-miR-6870-5p” as used herein include the hsa-miR-6870-5p gene (miRBase Accession No. MIMAT0027640) described in SEQ ID No. 208, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6870-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6870” (miRBase Accession No. MI0022717, SEQ ID No. 439).

[0308] The terms “hsa-miR-6877-5p gene” or “hsa-miR-6877-5p” as used herein include the hsa-miR-6877-5p gene (miRBase Accession No. MIMAT0027654) described in SEQ ID No. 209, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6877-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6877” (miRBase Accession No. MI0022724, SEQ ID No. 440).

[0309] The terms “hsa-miR-6879-5p gene” or “hsa-miR-6879-5p” as used herein include the hsa-miR-6879-5p gene (miRBase Accession No. MIMAT0027658) described in SEQ ID No. 210, or other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6879-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6879” (miRBase Accession No. MI0022726, SEQ ID No. 441).

[0310] The terms “hsa-miR-6880-3p gene” or “hsa-miR-6880-3p” as used herein include the hsa-miR-6880-3p gene (miRBase Accession No. MIMAT0027661) described in SEQ ID No. 211, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6880-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6880” (miRBase Accession No. MI0022727, SEQ ID No. 442).

[0311] The terms “hsa-miR-6880-5p gene” or “hsa-miR-6880-5p” as used herein include the hsa-miR-6880-5p gene (miRBase Accession No. MIMAT0027660) described in SEQ ID No. 212, and other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6880-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6880” (miRBase Accession No. MI0022727, SEQ ID No. 443).

[0312] The terms “hsa-miR-6885-5p gene” or “hsa-miR-6885-5p” as used herein include the hsa-miR-6885-5p gene (miRBase Accession No. MIMAT0027670) described in SEQ ID NO. 213, or other species homologs or osologs, etc. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6885-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-6885” (miRBase Accession No. MI0022732, SEQ ID NO. 444).

[0313] The terms “hsa-miR-6887-5p gene” or “hsa-miR-6887-5p” as used herein include the hsa-miR-6887-5p gene (miRBase Accession No. MIMAT0027674) described in SEQ ID No. 214, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-6887” (miRBase Accession No. MI0022734, SEQ ID No. 445), which has a hairpin-like structure, is known as a precursor of “hsa-miR-6887-5p”.

[0314] The terms “hsa-miR-7107-5p gene” or “hsa-miR-7107-5p” as used herein include the hsa-miR-7107-5p gene (miRBase Accession No. MIMAT0028111) described in SEQ ID No. 215, or other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-7107” (miRBase Accession No. MI0022958, SEQ ID No. 446), which has a hairpin-like structure, is known as a precursor of “hsa-miR-7107-5p”.

[0315] The terms “hsa-miR-7108-3p gene” or “hsa-miR-7108-3p” as used herein include the hsa-miR-7108-3p gene (miRBase Accession No. MIMAT0028114) described in SEQ ID No. 216, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-7108” (miRBase Accession No. MI0022959, SEQ ID No. 447), which has a hairpin-like structure, is known as a precursor of “hsa-miR-7108-3p”.

[0316] The terms “hsa-miR-7109-5p gene” or “hsa-miR-7109-5p” as used herein include the hsa-miR-7109-5p gene (miRBase Accession No. MIMAT0028115) described in SEQ ID No. 217, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-7109-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-7109” (miRBase Accession No. MI0022960, SEQ ID No. 448).

[0317] The terms “hsa-miR-711 gene” or “hsa-miR-711” as used in this specification include the hsa-miR-711 gene (miRBase Accession No. MIMAT0012734) described in SEQ ID No. 218, as well as other species homologs or osologs. The gene can be obtained by the method described in Artzi S et al., 2008, BMC Bioinformatics., Vol. 9, 39. Additionally, “hsa-miR-711” is known to have a hairpin-like structure as its precursor, “hsa-mir-711” (miRBase Accession No. MI0012488, SEQ ID No. 449).

[0318] The terms “hsa-miR-7113-3p gene” or “hsa-miR-7113-3p” as used herein include the hsa-miR-7113-3p gene (miRBase Accession No. MIMAT0028124) described in SEQ ID No. 219, as well as other species homologs or osologs. The gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., Vol. 22, 1634-1645. Additionally, “hsa-miR-7113-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-7113” (miRBase Accession No. MI0022964, SEQ ID No. 450).

[0319] The terms “hsa-miR-7150 gene” or “hsa-miR-7150” as used in this specification include the hsa-miR-7150 gene (miRBase Accession No. MIMAT0028211) described in SEQ ID No. 220, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Oulas A et al., 2009, Nucleic Acids Res., Vol. 37, 3276-3287. Additionally, “hsa-miR-7150” is known as “hsa-mir-7150” (miRBase Accession No. MI0023610, SEQ ID No. 451), which has a hairpin-like structure as its precursor.

[0320] The terms “hsa-miR-744-5p gene” or “hsa-miR-744-5p” as used herein include the hsa-miR-744-5p gene (miRBase Accession No. MIMAT0004945) described in SEQ ID No. 221, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res., Vol. 16, 1289-1298. Additionally, “hsa-miR-744-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-744” (miRBase Accession No. MI0005559, SEQ ID No. 452).

[0321] The terms “hsa-miR-7975 gene” or “hsa-miR-7975” as used in this specification include the hsa-miR-7975 gene (miRBase Accession No. MIMAT0031178) described in SEQ ID No. 222, and other biological species homologs or oslogs. The gene can be obtained by the method described in Velthut-Meikas A et al., 2013, Mol Endocrinol., Vol. 27, 1128-1141. Additionally, “hsa-miR-7975” is known as “hsa-mir-7975” (miRBase Accession No. MI0025751, SEQ ID No. 453), which has a hairpin-like structure as its precursor.

[0322] The terms “hsa-miR-7977 gene” or “hsa-miR-7977” as used in this specification include the hsa-miR-7977 gene (miRBase Accession No. MIMAT0031180) described in SEQ ID No. 223, and other biological species homologs or oslogs. The gene can be obtained by the method described in Velthut-Meikas A et al., 2013, Mol Endocrinol., Vol. 27, 1128-1141. Additionally, “hsa-miR-7977” is known to have a hairpin-like structure as its precursor, “hsa-mir-7977” (miRBase Accession No. MI0025753, SEQ ID No. 454).

[0323] The terms “hsa-miR-8052 gene” or “hsa-miR-8052” as used in this specification include the hsa-miR-8052 gene (miRBase Accession No. MIMAT0030979) described in SEQ ID No. 224, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Wang HJ et al., 2013, Shock., Vol. 39, 480-487. Additionally, “hsa-miR-8052” is known as “hsa-mir-8052” (miRBase Accession No. MI0025888, SEQ ID No. 455), which has a hairpin-like structure as its precursor.

[0324] The terms “hsa-miR-8069 gene” or “hsa-miR-8069” as used herein include the hsa-miR-8069 gene (miRBase Accession No. MIMAT0030996) described in SEQ ID NO. 225 and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Wang HJ et al., 2013, Shock., Vol. 39, 480-487. Additionally, “hsa-miR-8069” is known to have “hsa-mir-8069-1” (miRBase Accession No. MI0025905, SEQ ID NO. 481) and “hsa-mir-8069-2” (miRBase Accession No. MI0031519, SEQ ID NO. 493), which have a hairpin-like structure as precursors.

[0325] The terms “hsa-miR-8073 gene” or “hsa-miR-8073” as used herein include the hsa-miR-8073 gene (miRBase Accession No. MIMAT0031000) described in SEQ ID No. 226, as well as other species homologs or oslogs. The gene can be obtained by the method described in Wang HJ et al., 2013, Shock., Vol. 39, 480-487. Additionally, “hsa-miR-8073” is known to have a hairpin-like structure as its precursor, “hsa-mir-8073” (miRBase Accession No. MI0025909, SEQ ID No. 456).

[0326] The terms “hsa-miR-887-3p gene” or “hsa-miR-887-3p” as used herein include the hsa-miR-887-3p gene (miRBase Accession No. MIMAT0004951) described in SEQ ID No. 227, as well as other species homologs or osologs. The gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res., Vol. 16, 1289-1298. Additionally, “hsa-miR-887” (miRBase Accession No. MI0005562, SEQ ID No. 457), which has a hairpin-like structure, is known as a precursor of “hsa-miR-887-3p”.

[0327] The terms “hsa-miR-937-5p gene” or “hsa-miR-937-5p” as used in this specification include the hsa-miR-937-5p gene (miRBase Accession No. MIMAT0022938) described in SEQ ID No. 228, as well as other species homologs or oslogs. The gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res., Vol. 67, 6031-6043. Additionally, “hsa-miR-937-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-937” (miRBase Accession No. MI0005759, SEQ ID No. 458).

[0328] The terms “hsa-miR-1202 gene” or “hsa-miR-1202” as used herein include the hsa-miR-1202 gene (miRBase Accession No. MIMAT0005865) described in SEQ ID No. 229, as well as other species homologs or osologs. The gene can be obtained by the method described in Marton S et al., 2008, Leukemia., Vol. 22, 330-338. Additionally, “hsa-miR-1202” is known to have a hairpin-like structure as its precursor, “hsa-mir-1202” (miRBase Accession No. MI0006334, SEQ ID No. 459).

[0329] The terms “hsa-miR-1207-5p gene” or “hsa-miR-1207-5p” as used herein include the hsa-miR-1207-5p gene (miRBase Accession No. MIMAT0005871) described in SEQ ID No. 230, and other biological species homologs or oslogs. The gene can be obtained by the method described in Huppi K et al., 2008, Mol Cancer Res., Vol. 6, 212-221. Additionally, “hsa-miR-1207” (miRBase Accession No. MI0006340, SEQ ID No. 460), which has a hairpin-like structure, is known as a precursor of “hsa-miR-1207-5p”.

[0330] The terms “hsa-miR-1246 gene” or “hsa-miR-1246” as used in this specification include the hsa-miR-1246 gene (miRBase Accession No. MIMAT0005898) described in SEQ ID No. 231, as well as other species homologs or osologs. The gene can be obtained by the method described in Morin RD et al., 2008, Genome Res., Vol. 18, 610-621. Additionally, “hsa-miR-1246” is known to have a hairpin-like structure as its precursor, “hsa-mir-1246” (miRBase Accession No. MI0006381, SEQ ID No. 461).

[0331] The terms “hsa-miR-1254 gene” or “hsa-miR-1254” as used in this specification include the hsa-miR-1254 gene (miRBase Accession No. MIMAT0005905) described in SEQ ID NO. 232, as well as other species homologs or osologs. The gene can be obtained by the method described in Morin RD et al., 2008, Genome Res., Vol. 18, 610-621. Additionally, “hsa-miR-1254” is known to have “hsa-mir-1254-1” (miRBase Accession No. MI0006388, SEQ ID NO. 482) and “hsa-mir-1254-2” (miRBase Accession No. MI0016747, SEQ ID NO. 494), which have a hairpin-like structure as precursors.

[0332] The terms “hsa-miR-135a-3p gene” or “hsa-miR-135a-3p” as used herein include the hsa-miR-135a-3p gene (miRBase Accession No. MIMAT0004595) described in SEQ ID No. 233, as well as other species homologs or osologs. The gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol., Vol. 12, 735-739. Additionally, “hsa-miR-135a-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-135a-1” (miRBase Accession No. MI0000452, SEQ ID No. 462).

[0333] The terms “hsa-miR-1469 gene” or “hsa-miR-1469” as used in this specification include the hsa-miR-1469 gene (miRBase Accession No. MIMAT0007347) described in SEQ ID No. 234, as well as other biological species homologs or osologs. The gene can be obtained by the method described in Kawaji H et al., 2008, BMC Genomics., Vol. 9, 157. Additionally, “hsa-miR-1469” is known to have a hairpin-like structure as its precursor, “hsa-mir-1469” (miRBase Accession No. MI0007074, SEQ ID No. 463).

[0334] The terms “hsa-miR-149-3p gene” or “hsa-miR-149-3p” as used herein include the hsa-miR-149-3p gene (miRBase Accession No. MIMAT0004609) described in SEQ ID No. 235, as well as other species homologs or osologs. The gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol., Vol. 12, 735-739. Additionally, “hsa-miR-149-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-149” (miRBase Accession No. MI0000478, SEQ ID No. 464).

[0335] The terms “hsa-miR-150-3p gene” or “hsa-miR-150-3p” as used herein include the hsa-miR-150-3p gene (miRBase Accession No. MIMAT0004610) described in SEQ ID No. 236, as well as other species homologs or oslogs. The gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol., Vol. 12, 735-739. Additionally, “hsa-miR-150-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-150” (miRBase Accession No. MI0000479, SEQ ID No. 465).

[0336] The terms “hsa-miR-1914-3p gene” or “hsa-miR-1914-3p” as used herein include the hsa-miR-1914-3p gene (miRBase Accession No. MIMAT0007890) described in SEQ ID No. 237, as well as other species homologs or osologs. The gene can be obtained by the method described in Bar M et al., 2008, Stem Cells., Vol. 26, 2496-2505. Additionally, “hsa-miR-1914-3p” is known to have a hairpin-like structure as its precursor, “hsa-mir-1914” (miRBase Accession No. MI0008335, SEQ ID No. 466).

[0337] The terms “hsa-miR-191-5p gene” or “hsa-miR-191-5p” as used herein include the hsa-miR-191-5p gene (miRBase Accession No. MIMAT0000440) described in SEQ ID No. 238, as well as other species homologs or osologs. The gene can be obtained by the method described in Lagos-Quintana M et al., 2003, RNA., Vol. 9, 175-179. Additionally, “hsa-miR-191-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-191” (miRBase Accession No. MI0000465, SEQ ID No. 467).

[0338] The terms “hsa-miR-423-5p gene” or “hsa-miR-423-5p” as used herein include the hsa-miR-423-5p gene (miRBase Accession No. MIMAT0004748) described in SEQ ID No. 239, as well as other biological species homologs or osologs. The gene can be obtained by the method described in Kasashima K et al., 2004, Biochem Biophys Res Commun., Vol. 322, 403-410. Additionally, “hsa-miR-423-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-423” (miRBase Accession No. MI0001445, SEQ ID No. 468).

[0339] The terms “hsa-miR-663a gene” or “hsa-miR-663a” as used in this specification include the hsa-miR-663a gene (miRBase Accession No. MIMAT0003326) described in SEQ ID No. 240, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA., Vol. 103, 3687-3692. Additionally, “hsa-miR-663a” is known to have a hairpin-like structure as its precursor, “hsa-mir-663a” (miRBase Accession No. MI0003672, SEQ ID No. 469).

[0340] The terms “hsa-miR-92a-2-5p gene” or “hsa-miR-92a-2-5p” as used herein include the hsa-miR-92a-2-5p gene (miRBase Accession No. MIMAT0004508) described in SEQ ID No. 241, and other biological species homologs or osologs, etc. The gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev., Vol. 16, 720-728. Additionally, “hsa-miR-92a-2-5p” is known to have a hairpin-like structure as its precursor, “hsa-mir-92a-2” (miRBase Accession No. MI0000094, SEQ ID No. 470).

[0341] The terms “hsa-miR-92a-3p gene” or “hsa-miR-92a-3p” as used in this specification include the hsa-miR-92a-3p gene (miRBase Accession No. MIMAT0000092) described in SEQ ID NO. 242, and other biological species homologs or oslogs. The gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev., Vol. 16, 720-728. Additionally, “hsa-miR-92a-3p” is known to have “hsa-mir-92a-1” (miRBase Accession No. MI0000093, SEQ ID NO. 483) and “hsa-mir-92a-2” (miRBase Accession No. MI0000094, SEQ ID NO. 495), which have a hairpin-like structure as precursors.

[0342] The terms “hsa-miR-940 gene” or “hsa-miR-940” as used in this specification include the hsa-miR-940 gene described in SEQ ID NO. 243 (miRBase Accession No. MIMAT0004983) and other biological species homologs or oslogs. The gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res., Vol. 67, 6031-6043. Additionally, “hsa-miR-940” is known to have a hairpin-like structure as its precursor, “hsa-mir-940” (miRBase Accession No. MI0005762, SEQ ID NO. 471).

[0343] In addition, when mature miRNAs are cut from RNA precursors that have a hairpin-like structure as mature miRNAs, there are cases where the sequence is cut with one to several bases shorter or longer at the beginning or end, or where base substitutions occur, resulting in variants, which are referred to as isomiRs (Morin RD. et al., 2008, Genome Res., Vol. 18, pp. 610-621). In miRBase Release 21, in addition to the base sequence represented by any one of SEQ ID NOs 1 to 243, variants and fragments of the base sequence represented by any one of SEQ ID NOs 507 to 766, which are called numerous isomiRs, are also presented. These variants can also be obtained as miRNAs of the base sequence represented by any one of SEQ ID NOs 1 to 243.That is, the sequence numbers 1, 2, 3, 8, 9, 10, 12, 13, 14, 15, 16, 17, 20, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 42, 43, 44, 45, 46, 47, 48, 49, 51, 54, 55, 56, 58, 61, 62, 63, 67, 68, 69, 71, 72, 73, 74, 75, 77, 78, 80, 81, 82, 84, 86, 87 of the present invention 89, 90, 91, 92, 93, 94, 95, 96, 101, 103, 105, 109, 111, 113, 114, 116, 117, 118, 119, 123, 124, 126, 127, 129, 131, 132, 133, 134, 135, 136, 139, 142, 143, 146, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 161, 162, 163, 164, 166, 218, Among variants of polynucleotides consisting of base sequences represented as 221, 227, 228, 231, 232, 233, 235, 236, 237, 238, 239, 240, 241, 242, 243 or base sequences in which u is t, for example, the longest variants registered in miRBase Release 21 are polynucleotides represented by SEQ ID NOs 507 to 632.In addition, SEQ ID NOs 1, 2, 3, 4, 8, 9, 10, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 51, 53, 54, 55, 56, 58, 61, 62, 63, 67, 68, 71, 72, 73, 74, 75, 77, 78, 80, 81 of the present invention 82, 84, 86, 90, 91, 92, 93, 95, 96, 101, 105, 107, 109, 111, 112, 113, 114, 116, 117, 118, 119, 120, 122, 123, 124, 125, 126, 127, 129, 131, 132, 133, 134, 135, 136, 138, 139, 142, 143, 145, 146, 150, 151, 152, 154, 155, 156, 157, 158, 159, 161, Among variants of polynucleotides consisting of nucleotide sequences represented by 162, 163, 164, 166, 218, 221, 222, 227, 228, 229, 231, 232, 233, and 235, or nucleotide sequences in which u is t in the said nucleotide sequences, for example, the shortest variants registered in miRBase Release 21, such as polynucleotides with sequences represented by SEQ ID NOs 633 to 766. In addition, in addition to these variants and fragments, polynucleotides that are multiple isomiRs of SEQ ID NOs 1 to 243 registered in miRBase may be cited. Furthermore, as examples of polynucleotides containing nucleotide sequences represented by any one of SEQ ID NOs 1 to 243, polynucleotides represented by any one of SEQ ID NOs 507 to 766, which are precursors, may be cited.

[0344] The names of the genes represented by sequence numbers 1 to 766 and the miRBase Accession No. (registration number) are listed in Table 1.

[0345] In this specification, "specifically bindable" means that the nucleic acid probe or primer used in the present invention binds to a specific target nucleic acid and cannot substantially bind to other nucleic acids.

[0346] [Table 1]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353]

[0354]

[0355]

[0356]

[0357]

[0358]

[0359]

[0360]

[0361]

[0362] This specification includes the disclosure of Japanese Patent Application No. 2018-084416, which forms the basis of the priority of this application. Effects of the invention

[0363] The present invention makes it possible to detect bladder cancer easily and with high precision. For example, by using the measured expression levels of one to several miRNAs in the patient's blood, serum, and / or plasma, which can be collected minimally invasively, it is possible to easily detect whether the patient has bladder cancer. Brief explanation of the drawing

[0364] Figure 1 shows the relationship between the nucleotide sequences of hsa-miR-1228-5p, represented by sequence number 9, and hsa-miR-1228-3p, represented by sequence number 8, which are generated from hsa-mir-1228, represented by sequence number 251, which is a precursor. Figure 2 shows the discrimination score plots of the learning sample group (A) and the verification sample group (B) by one miRNA discrimination expression. Figure 3 shows a plot of discrimination scores by disease type for a group of verified samples by one miRNA discrimination expression. AB in Fig. 4a shows the discrimination score plots of the verification sample group by stage (A) and wall delivery (B) based on one discriminant of miRNA. CD in Fig. 4b shows the discrimination score plots of the verified sample group for histological atypicality (C) and initial / recurrent (D) by one miRNA discriminant. Figure 5 shows the discrimination score plots of the learning sample group (A) and the verification sample group (B) based on three miRNA discrimination expressions. Figure 6 shows the discrimination score plot by disease type of the verified sample group by three miRNA discriminants. AB in Fig. 7a shows the discrimination score plots of the verification sample group by stage (A) and wall delivery (B) according to three miRNA discrimination formulas. CD in Fig. 7b shows the discriminant score plots of the verified sample group for histological atypicality (C) and initial / recurrent (D) by three miRNA discriminant formulas. Figure 8 shows the discrimination score plots of the learning sample group (A) and the verification sample group (B) based on four miRNA discrimination expressions. Figure 9 shows the discrimination score plot by disease type of the verified sample group by four miRNA discriminant expressions. AB in Fig. 10a shows the discrimination score plots of the verification sample group by stage (A) and wall delivery (B) according to four miRNA discrimination formulas. CD in Fig. 10b shows the discriminant score plots of the verified sample group by histological atypicality (C) and initial / recurrent (D) according to four miRNA discriminant formulas. Figure 11 shows the discrimination score plots of the learning sample group (A) and the verification sample group (B) based on five miRNA discrimination expressions. Figure 12 shows the discrimination score plot by disease type of the verified sample group by five miRNA discriminant expressions. AB in Fig. 13a shows the discrimination score plots of the verification sample group by stage (A) and wall delivery (B) according to five miRNA discrimination formulas. CD in Fig. 13b shows the discriminant score plots of the verified sample group for histological atypicality (C) and initial / recurrent (D) by five miRNA discriminant formulas. Figure 14 shows a plot of the discrimination scores by disease type for the verified sample group based on three miRNA discriminant expressions. AB in Fig. 15a shows the discrimination score plots of the verification sample group by stage (A) and wall delivery (B) according to three miRNA discrimination expressions. CD in Fig. 15b shows the discriminant score plot of the verified sample group by histological atypicality (C) and initial / recurrent (D) according to three miRNA discriminant formulas. Figure 16 shows a plot of the discrimination scores by disease type for the verified sample group based on 10 miRNA discriminant expressions. AB in Fig. 17a shows the discrimination score plots of the verification sample group by stage (A) and wall delivery (B) according to 10 miRNA discrimination expressions. CD in Fig. 17b shows the discrimination score plots of the verified sample group by histological atypicality (C) and initial / recurrent (D) according to 10 miRNA discriminants. Figure 18 shows a plot of the discrimination scores by disease type for the verified sample group by 104 miRNA discrimination expressions. AB in Fig. 19a shows the discrimination score plots of the validation sample group by stage (A) and wall delivery (B) according to 104 miRNA discrimination expressions. CD in Fig. 19b shows the discriminant score plots of the verified sample group for histological atypicality (C) and initial / recurrent (D) by 104 miRNA discriminants. Figure 20 shows the ROC curves of the learning sample group (A) and the verification sample group (C) for one miRNA, and the ROC curves of the learning sample group (B) and the verification sample group (D) for a combination of seven miRNAs. Figure 21 shows a plot of differential scores by disease type for combinations of 7 miRNAs. Specific details for implementing the invention

[0365] The present invention will be described in more detail below.

[0366] 1. Target nucleic acids of bladder cancer

[0367] The major target nucleic acids as bladder cancer markers for detecting the presence and / or absence of bladder cancer or bladder cancer cells using the nucleic acid probe or primer for bladder cancer detection of the above definition of the present invention include miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470,miR-17-3p,miR-187-5p,miR-1908-3p,miR-1908-5p,miR-1909-3p,miR-1915-3p,miR-210-5p,miR-24-3p,miR-2467-3p,miR-2861,miR-296-3p,miR-29b-3p miR-3131,miR-3154,miR-3158-5p,miR-3160-5p,miR-3162-5p,miR-3178,miR-3180-3p,miR-3184-5p,miR-3185,miR-3194-3p,miR-3195,miR-3197, miR-320a,miR-320b,miR-328-5p,miR-342-5p,miR-345-3p,miR-3616-3p,miR-3619-3p,miR-3620-5p,miR-3621,miR-3622a-5p,miR-3648,miR-3652,miR-3656 miR-3663-3p,miR-3679-5p,miR-371b-5p,miR-373-5p,miR-3917,miR-3940-5p,miR-3960,miR-4258,miR-4259,miR-4270,miR-4286,miR-4298,miR-4322 MiR-4327,miR-4417,miR-4419b,miR-4429,miR-4430,miR-4433a-3p,miR-4436b-5p,miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459, miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p, miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739 miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771, miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p, miR-6515-5p, miR-663b, miR-6716-5p,miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p, miR-6743-5p, miR-6746-5p, miR-6749-5p, miR-6760-5p, miR-6762-5p, miR-6765-3p, miR-6765-5p, miR-6766-3p, miR-6766-5p, miR-6771-5p, miR-6774-5p, miR-6777-5p, miR-6778-5p, miR-6780b-5p, miR-6781-5p miR-6782-5p, miR-6784-5p, miR-6785-5p, miR-6787-5p, miR-6789-5p, miR-6791-5p, miR-6794-5p, miR-6800-5p, miR-6802-5p, miR-6803-5p, miR-6812-5p, miR-6816-5p, miR-6819-5p, miR-6821-5p, miR-6826-5p, miR-6831-5p, miR-6836-3p, miR-6840-3p, miR-6842-5p, miR-6850-5p, miR-6861-5p, miR-6869-5p miR-6870-5p, miR-6877-5p, miR-6879-5p, miR-6880-3p, miR-6880-5p, miR-6885-5p, miR-6887-5p, miR-7107-5p, miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p로 이루어진 군으로부터 선택되는 적어도 1개의 miRNA가 포함된다. 또한 이들 miRNA와 조합시킬 수 있는 다른 방광암 마커, 즉, miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p,At least one miRNA selected from the group consisting of miR-191-5p, miR-423-5p, miR-663a, miR-92a-2-5p, miR-92a-3p, and miR-940 may also preferably be used as a target nucleic acid.

[0368] 상기 miRNA에는, 예를 들면, 서열번호 1∼243 중 어느 하나로 나타내어지는 염기서열을 포함하는 인간 유전자(즉, 각각, miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131 miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195, miR-3197, miR-320a, miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298, miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447miR-4448, miR-4449, miR-4454, miR-4455, miR-4459, miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658 miR-4663, miR-4673, miR-4675, miR-4687-3p, miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741 miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771, miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p miR-6510-5p, miR-6511a-5p, miR-6515-3p, miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p,miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p, miR-6743-5p, miR-6746-5p, miR-6749-5p, miR-6760-5p, miR-6762-5p, miR-6765-3p, miR-6765-5p, miR-6766-3p, miR-6766-5p, miR-6771-5p, miR-6774-5p, miR-6777-5p, miR-6778-5p, miR-6780b-5p, miR-6781-5p, miR-6782-5p, miR-6784-5p, miR-6785-5p miR-6787-5p, miR-6789-5p, miR-6791-5p, miR-6794-5p, miR-6800-5p, miR-6802-5p, miR-6803-5p, miR-6812-5p, miR-6816-5p, miR-6819-5p, miR-6821-5p, miR-6826-5p, miR-6831-5p, miR-6836-3p, miR-6840-3p, miR-6842-5p, miR-6850-5p, miR-6861-5p, miR-6869-5p, miR-6870-5p, miR-6877-5p, miR-6879-5p miR-6880-3p, miR-6880-5p, miR-6885-5p, miR-6887-5p, miR-7107-5p, miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p miR-150-3p, miR-1914-3p, miR-191-5p, miR-423-5p, miR-663a, miR-92a-2-5p, miR-92a-3p, miR-940), 그 동족체, 그 전사 산물, 및 그 변이체 또는 유도체가 포함된다. 여기에서,Genes, homologues, transcript products, variants, and derivatives are as defined above.

[0369] A preferred target nucleic acid is a human gene comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 243, its transcription product, more preferably said transcription product, namely miRNA, its precursor RNA, pri-miRNA or pre-miRNA.

[0370] The primary target genes are the hsa-miR-6087 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0371] The second target gene is the hsa-miR-1185-1-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0372] The third target gene is the hsa-miR-1185-2-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0373] The fourth target gene is the hsa-miR-1193 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0374] The fifth target gene is the hsa-miR-1199-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0375] The sixth target gene is the hsa-miR-1225-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0376] The seventh target gene is the hsa-miR-1227-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0377] The eighth target gene is the hsa-miR-1228-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0378] The ninth target gene is the hsa-miR-1228-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0379] The 10th target gene is the hsa-miR-1237-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0380] The eleventh target gene is the hsa-miR-1238-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0381] The 12th target gene is the hsa-miR-1247-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0382] The 13th target gene is the hsa-miR-1268a gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0383] The 14th target gene is the hsa-miR-1268b gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0384] The 15th target gene is the hsa-miR-1273g-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0385] The 16th target gene is the hsa-miR-128-2-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0386] The 17th target gene is the hsa-miR-1343-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0387] The 18th target gene is the hsa-miR-1343-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0388] The 19th target gene is the hsa-miR-1470 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0389] The 20th target gene is the hsa-miR-17-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0390] The 21st target gene is the hsa-miR-187-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0391] The 22nd target gene is the hsa-miR-1908-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0392] The 23rd target gene is the hsa-miR-1908-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0393] The 24th target gene is the hsa-miR-1909-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0394] The 25th target gene is the hsa-miR-1915-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0395] The 26th target gene is the hsa-miR-210-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0396] The 27th target gene is the hsa-miR-24-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0397] The 28th target gene is the hsa-miR-2467-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0398] The 29th target gene is the hsa-miR-2861 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0399] The 30th target gene is the hsa-miR-296-3p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0400] The 31st target gene is the hsa-miR-29b-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0401] The 32nd target gene is the hsa-miR-3131 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0402] The 33rd target gene is the hsa-miR-3154 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0403] The 34th target gene is the hsa-miR-3158-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0404] The 35th target gene is the hsa-miR-3160-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0405] The 36th target gene is the hsa-miR-3162-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0406] The 37th target gene is the hsa-miR-3178 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0407] The 38th target gene is the hsa-miR-3180-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0408] The 39th target gene is the hsa-miR-3184-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0409] The 40th target gene is the hsa-miR-3185 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0410] The 41st target gene is the hsa-miR-3194-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0411] The 42nd target gene is the hsa-miR-3195 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0412] The 43rd target gene is the hsa-miR-3197 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0413] The 44th target gene is the hsa-miR-320a gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0414] The 45th target gene is the hsa-miR-320b gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0415] The 46th target gene is the hsa-miR-328-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0416] The 47th target gene is the hsa-miR-342-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0417] The 48th target gene is the hsa-miR-345-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0418] The 49th target gene is the hsa-miR-3616-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0419] The 50th target gene is the hsa-miR-3619-3p gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0420] The 51st target gene is the hsa-miR-3620-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0421] The 52nd target gene is the hsa-miR-3621 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0422] The 53rd target gene is the hsa-miR-3622a-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0423] The 54th target gene is the hsa-miR-3648 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0424] The 55th target gene is the hsa-miR-3652 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0425] The 56th target gene is the hsa-miR-3656 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0426] The 57th target gene is the hsa-miR-3663-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0427] The 58th target gene is the hsa-miR-3679-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0428] The 59th target gene is the hsa-miR-371b-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0429] The 60th target gene is the hsa-miR-373-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0430] The 61st target gene is the hsa-miR-3917 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0431] The 62nd target gene is the hsa-miR-3940-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0432] The 63rd target gene is the hsa-miR-3960 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0433] The 64th target gene is the hsa-miR-4258 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0434] The 65th target gene is the hsa-miR-4259 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0435] The 66th target gene is the hsa-miR-4270 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0436] The 67th target gene is the hsa-miR-4286 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0437] The 68th target gene is the hsa-miR-4298 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0438] The 69th target gene is the hsa-miR-4322 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0439] The 70th target gene is the hsa-miR-4327 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0440] The 71st target gene is the hsa-miR-4417 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0441] The 72nd target gene is the hsa-miR-4419b gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0442] The 73rd target gene is the hsa-miR-4429 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0443] The 74th target gene is the hsa-miR-4430 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0444] The 75th target gene is the hsa-miR-4433a-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0445] The 76th target gene is the hsa-miR-4436b-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0446] The 77th target gene is the hsa-miR-4443 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0447] The 78th target gene is the hsa-miR-4446-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0448] The 79th target gene is the hsa-miR-4447 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0449] The 80th target gene is the hsa-miR-4448 gene, its homologues, its transcript products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0450] The 81st target gene is the hsa-miR-4449 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0451] The 82nd target gene is the hsa-miR-4454 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0452] The 83rd target gene is the hsa-miR-4455 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0453] The 84th target gene is the hsa-miR-4459 gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0454] The 85th target gene is the hsa-miR-4462 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0455] The 86th target gene is the hsa-miR-4466 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0456] The 87th target gene is the hsa-miR-4467 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0457] The target genes of 88 are the hsa-miR-4480 genes, their homologues, their transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0458] The 89th target gene is the hsa-miR-4483 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0459] The 90th target gene is the hsa-miR-4484 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0460] The target genes of the 91st study are the hsa-miR-4485-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0461] The 92nd target gene is the hsa-miR-4488 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0462] The 93rd target gene is the hsa-miR-4492 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0463] The 94th target gene is the hsa-miR-4505 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0464] The 95th target gene is the hsa-miR-4515 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0465] The 96th target gene is the hsa-miR-4525 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0466] The target genes of No. 97 are the hsa-miR-4534 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0467] The 98th target gene is the hsa-miR-4535 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0468] The 99th target gene is the hsa-miR-4633-3p gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0469] The 100th target gene is the hsa-miR-4634 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0470] The target genes of the 101st study are the hsa-miR-4640-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0471] The 102nd target gene is the hsa-miR-4649-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0472] The 103rd target gene is the hsa-miR-4651 gene, its homologues, its transcription products, or its variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0473] The 104th target gene is the hsa-miR-4652-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0474] The 105th target gene is the hsa-miR-4655-5p gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0475] The target genes of No. 106 are the hsa-miR-4656 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0476] The target genes of No. 107 are the hsa-miR-4658 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0477] The target genes of the 108th study are the hsa-miR-4663 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0478] The target genes of No. 109 are the hsa-miR-4673 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0479] The target genes of the 110th are the hsa-miR-4675 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0480] The target genes of No. 111 are the hsa-miR-4687-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0481] The target genes of No. 112 are the hsa-miR-4687-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0482] The target genes of No. 113 are the hsa-miR-4690-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0483] The target genes of No. 114 are the hsa-miR-4695-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0484] The target genes of No. 115 are the hsa-miR-4697-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0485] The target genes of No. 116 are the hsa-miR-4706 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0486] The target genes of No. 117 are the hsa-miR-4707-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0487] The target genes of No. 118 are the hsa-miR-4707-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0488] The target genes of No. 119 are the hsa-miR-4708-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0489] The 120th target gene is the hsa-miR-4710 gene, its homologues, its transcription products, or its variants or derivatives. To date, there are no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0490] The target genes of No. 121 are the hsa-miR-4718 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0491] The target genes of No. 122 are the hsa-miR-4722-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0492] The target genes of No. 123 are the hsa-miR-4725-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0493] The target genes of No. 124 are the hsa-miR-4726-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0494] The target genes of No. 125 are the hsa-miR-4727-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0495] The target genes of No. 126 are the hsa-miR-4728-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0496] The target genes of No. 127 are the hsa-miR-4731-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0497] The target genes of No. 128 are the hsa-miR-4736 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0498] The target genes of No. 129 are the hsa-miR-4739 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0499] The target genes of No. 130 are the hsa-miR-4740-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0500] The target genes of No. 131 are the hsa-miR-4741 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0501] The target genes of No. 132 are the hsa-miR-4750-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0502] The target genes of No. 133 are the hsa-miR-4755-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0503] The target genes of No. 134 are the hsa-miR-4763-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0504] The target genes of No. 135 are the hsa-miR-4771 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0505] The target genes of No. 136 are the hsa-miR-4783-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0506] The target genes of No. 137 are the hsa-miR-4783-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0507] The target genes of No. 138 are the hsa-miR-4787-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0508] The target genes of No. 139 are the hsa-miR-4792 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0509] The target genes of the 140th study are the hsa-miR-498 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0510] The target genes of No. 141 are the hsa-miR-5008-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0511] The target genes of No. 142 are the hsa-miR-5010-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0512] The target genes of No. 143 are the hsa-miR-504-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0513] The target genes of No. 144 are the hsa-miR-5195-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0514] The target genes of No. 145 are the hsa-miR-550a-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0515] The target genes of No. 146 are the hsa-miR-5572 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0516] The target genes of No. 147 are the hsa-miR-5739 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0517] The target genes of No. 148 are the hsa-miR-6075 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0518] The target genes of No. 149 are the hsa-miR-6076 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0519] The 150th target gene is the hsa-miR-6088 gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0520] The target genes of No. 151 are the hsa-miR-6124 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0521] The target genes of No. 152 are the hsa-miR-6131 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0522] The target genes of No. 153 are the hsa-miR-6132 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0523] The target genes of No. 154 are the hsa-miR-614 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0524] The target genes of 155 are the hsa-miR-615-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0525] The target genes of No. 156 are the hsa-miR-619-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0526] The target genes of No. 157 are the hsa-miR-642b-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0527] The target genes of No. 158 are the hsa-miR-6510-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0528] The target genes of No. 159 are the hsa-miR-6511a-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0529] The target genes of No. 160 are the hsa-miR-6515-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0530] The target genes of No. 161 are the hsa-miR-6515-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0531] The target genes of No. 162 are the hsa-miR-663b gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0532] The target genes of No. 163 are the hsa-miR-6716-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0533] The target genes of No. 164 are the hsa-miR-6717-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0534] The target genes of No. 165 are the hsa-miR-6722-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0535] The target genes of No. 166 are the hsa-miR-6724-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0536] The target genes of No. 167 are the hsa-miR-6726-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0537] The target genes of No. 168 are the hsa-miR-6737-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0538] The target genes of No. 169 are the hsa-miR-6741-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0539] The target genes of No. 170 are the hsa-miR-6742-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0540] The target genes of No. 171 are the hsa-miR-6743-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript product can serve as a marker for bladder cancer.

[0541] The target genes of No. 172 are the hsa-miR-6746-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0542] The target genes of No. 173 are the hsa-miR-6749-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0543] The target genes of No. 174 are the hsa-miR-6760-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0544] The target genes of No. 175 are the hsa-miR-6762-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0545] The target genes of No. 176 are the hsa-miR-6765-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0546] The target genes of No. 177 are the hsa-miR-6765-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0547] The target genes of No. 178 are the hsa-miR-6766-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0548] The target genes of No. 179 are the hsa-miR-6766-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0549] The target genes of the 180th are the hsa-miR-6771-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0550] The target genes of No. 181 are the hsa-miR-6774-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0551] The target genes of No. 182 are the hsa-miR-6777-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0552] The target genes of No. 183 are the hsa-miR-6778-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0553] The target genes of No. 184 are the hsa-miR-6780b-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0554] The target genes of No. 185 are the hsa-miR-6781-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0555] The target genes of No. 186 are the hsa-miR-6782-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0556] The target genes of No. 187 are the hsa-miR-6784-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0557] The target genes of No. 188 are the hsa-miR-6785-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0558] The target genes of No. 189 are the hsa-miR-6787-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0559] The target genes of No. 190 are the hsa-miR-6789-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0560] The target genes of No. 191 are the hsa-miR-6791-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0561] The target genes of No. 192 are the hsa-miR-6794-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0562] The target genes of No. 193 are the hsa-miR-6800-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0563] The target genes of No. 194 are the hsa-miR-6802-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0564] The target genes of No. 195 are the hsa-miR-6803-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0565] The target genes of No. 196 are the hsa-miR-6812-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0566] The target genes of No. 197 are the hsa-miR-6816-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0567] The target genes of No. 198 are the hsa-miR-6819-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0568] The target genes of No. 199 are the hsa-miR-6821-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0569] The 200th target gene is the hsa-miR-6826-5p gene, its homologues, its transcript products, or its variants or derivatives. To date, there are no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0570] The target genes of No. 201 are the hsa-miR-6831-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0571] The target genes of 202 are the hsa-miR-6836-3p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript product can serve as a marker for bladder cancer.

[0572] The target genes of 203 are the hsa-miR-6840-3p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript product can serve as a marker for bladder cancer.

[0573] The target genes of No. 204 are the hsa-miR-6842-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0574] The target genes of 205 are the hsa-miR-6850-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0575] The target genes of 206 are the hsa-miR-6861-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript product can serve as a marker for bladder cancer.

[0576] The target genes of No. 207 are the hsa-miR-6869-5p gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcript products can serve as markers for bladder cancer.

[0577] The target genes of No. 208 are the hsa-miR-6870-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0578] The target genes of No. 209 are the hsa-miR-6877-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0579] The target genes of No. 210 are the hsa-miR-6879-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0580] The target genes of 211 are the hsa-miR-6880-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there are no known reports that changes in the expression of genes or their transcription products can serve as markers for bladder cancer.

[0581] The target genes of No. 212 are the hsa-miR-6880-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0582] The target genes of No. 213 are the hsa-miR-6885-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0583] The target genes of No. 214 are the hsa-miR-6887-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0584] The target genes of No. 215 are the hsa-miR-7107-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0585] The target genes of No. 216 are the hsa-miR-7108-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0586] The target genes of No. 217 are the hsa-miR-7109-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0587] The target genes of No. 218 are the hsa-miR-711 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0588] The target genes of No. 219 are the hsa-miR-7113-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0589] The target genes of 220 are the hsa-miR-7150 genes, their homologues, their transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of genes or their transcript products can serve as markers for bladder cancer.

[0590] The target genes of No. 221 are the hsa-miR-744-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0591] The target genes of 222 are the hsa-miR-7975 gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0592] The target genes of No. 223 are the hsa-miR-7977 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0593] The target genes of No. 224 are the hsa-miR-8052 gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0594] The target genes of No. 225 are the hsa-miR-8069 gene, its homologues, its transcript products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcript products can serve as markers for bladder cancer.

[0595] The target genes of No. 226 are the hsa-miR-8073 gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0596] The target genes of No. 227 are the hsa-miR-887-3p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of the gene or its transcription products can serve as markers for bladder cancer.

[0597] The target genes of No. 228 are the hsa-miR-937-5p gene, its homologues, its transcription products, or their variants or derivatives. To date, there have been no known reports that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer.

[0598] The target genes of No. 229 are the miR-1202 gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0599] The target genes of No. 230 are the miR-1207-5p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0600] The target genes of No. 231 are the miR-1246 gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 2).

[0601] The target genes of No. 232 are the miR-1254 gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 2).

[0602] The target genes of No. 233 are the miR-135a-3p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0603] The target gene of No. 234 is the miR-1469 gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0604] The target genes of No. 235 are the miR-149-3p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0605] The target genes of No. 236 are the miR-150-3p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0606] The target genes of No. 237 are the miR-1914-3p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0607] The target genes of No. 238 are the miR-191-5p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Non-patent Literature 2).

[0608] The target genes of No. 239 are the miR-423-5p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Non-patent Literature 3).

[0609] The target genes of No. 240 are the miR-663a gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0610] The target genes of No. 241 are the miR-92a-2-5p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 1).

[0611] The target genes of No. 242 are the miR-92a-3p gene, its homologues, its transcription products, or their variants or derivatives. It has been reported that changes in the expression of a gene or its transcription products can serve as markers for bladder cancer (Patent Document 2).

[0612] The target genes of No. 243 are miR-940 genes, their homologues, their transcription products, or their variants or derivatives. It has been reported that changes in the expression of genes or their transcription products can serve as markers for bladder cancer (Non-patent Literature 2).

[0613] In one embodiment, the present invention relates to a marker for detecting or diagnosing bladder cancer, comprising at least one of the target nucleic acids.

[0614] In one form, the present invention relates to the use of at least one of the target nucleic acids for detecting bladder cancer or diagnosing bladder cancer.

[0615] 2. Nucleic acid probes or primers for bladder cancer detection

[0616] In the present invention, a nucleic acid probe or primer usable for detecting or diagnosing bladder cancer is a human-derived miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470 as a target nucleic acid for bladder cancer. miR-17-3p,miR-187-5p,miR-1908-3p,miR-1908-5p,miR-1909-3p,miR-1915-3p,miR-210-5p,miR-24-3p,miR-2467-3p,miR-2861,miR-296-3p,miR-29b-3p,miR-3131 miR-3154,miR-3158-5p,miR-3160-5p,miR-3162-5p,miR-3178,miR-3180-3p,miR-3184-5p,miR-3185,miR-3194-3p,miR-3195,miR-3197,miR-320a, miR-320b,miR-328-5p,miR-342-5p,miR-345-3p,miR-3616-3p,miR-3619-3p,miR-3620-5p,miR-3621,miR-3622a-5p,miR-3648,miR-3652,miR-3656,miR-3663-3p, miR-3679-5p,miR-371b-5p,miR-373-5p,miR-3917,miR-3940-5p,miR-3960,miR-4258,miR-4259,miR-4270,miR-4286,miR-4298,miR-4322,miR-4327, MiR-4417,miR-4419b,miR-4429,miR-4430,miR-4433a-3p,miR-4436b-5p,miR-4443,miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459, miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p, miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771, miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p, miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p,miR-6722-3p,miR-6724-5p,mimir-6726-5p,mir-6737-5p,mir-6741-5p,mir-6742-5p,mir-6743-5p,mir-6746-5p,mir-6749-5p,mir-6760-5p,mir-6762-5p miR-6765-3p,miR-6765-5p,mimir-6766-3p,mir-6766-5p,mir-6771-5p,mir-6774-5p,mir-6777-5p,mir-6778-5p,mir-6780b-5p,mir-6781-5p,mir-6782-5p, miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p,miR-6794-5p,miR-6800-5p,miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p,miR-6840-3p,miR-6842-5p,miR-6850-5p,mimi6861-5p,mimi6869-5p,mimi6870-5p It makes it possible to qualitatively and / or quantitatively measure the presence, expression amount, or presence of miR-6877-5p, miR-6879-5p, miR-6880-3p, miR-6880-5p, miR-6885-5p, miR-6887-5p, miR-7107-5p, miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, or combinations thereof, their homologues, their transcription products, or their variants or derivatives.

[0617] In subjects with bladder cancer, compared to healthy individuals, patients with benign diseases, and subjects with cancer other than bladder cancer, the expression levels of the above-mentioned target nucleic acids may increase or decrease depending on the type of target nucleic acid (hereinafter referred to as "increase / decrease"). Therefore, the kit or device of the present invention can be effectively used to detect bladder cancer by measuring the expression levels of the above-mentioned target nucleic acids in body fluids derived from subjects suspected of having bladder cancer (e.g., humans) and in body fluids derived from healthy individuals, patients with benign diseases, and patients with cancer other than bladder cancer, and comparing them.

[0618] The nucleic acid probe or primer usable in the present invention is a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 1 to 228, a nucleic acid probe capable of specifically binding to the complementary chain of said polynucleotide, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 1 to 228.

[0619] The nucleic acid probe or primer usable in the present invention may also include a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 229 to 243, a nucleic acid probe capable of specifically binding to the complementary chain of said polynucleotide, or a primer for amplifying a polynucleotide consisting of a nucleotide sequence represented by at least one of SEQ ID NOs 229 to 243.

[0620] In a preferred embodiment of the method of the present invention, the nucleic acid probe or primer comprises a combination of one or more polynucleotides selected from a polynucleotide group comprising a base sequence represented by any one of SEQ ID NOs 1 to 766 or a base sequence in which u is t in said base sequence, and a polynucleotide group complementary thereof, a polynucleotide group that hybridizes with DNA formed by a base sequence complementary to said base sequence under stringent conditions (described later), and a polynucleotide group complementary thereof, and a polynucleotide group comprising 15 or more, preferably 17 or more, consecutive bases in the base sequence of said polynucleotide group. These polynucleotides can be used as nucleic acid probes and primers for detecting the bladder cancer marker, which is the target nucleic acid.

[0621] More specifically, examples of nucleic acid probes or primers usable in the present invention are one or more polynucleotides selected from the group consisting of any one of the following polynucleotides (a) to (e).

[0622] (a) A polynucleotide, a variant thereof, or a derivative thereof comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence in which u is t in said nucleotide sequence, the fragment comprising 15 or more consecutive nucleotides,

[0623] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228,

[0624] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0625] (d) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and,

[0626] (e) A polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions.

[0627] The nucleic acid probe or primer available in the present invention may also include, in addition to at least one polynucleotide selected from any one of the above polynucleotides (a) to (e), a polynucleotide shown in any one of (f) to (j) below.

[0628] (f) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,

[0629] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243,

[0630] (h) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0631] (i) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and,

[0632] (j) A polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions.

[0633] The polynucleotides or fragments used in the present invention may all be DNA or RNA.

[0634] The polynucleotide usable in the present invention can be produced using general techniques such as DNA recombination technology, PCR method, or a method using an automated DNA / RNA synthesizer.

[0635] DNA recombination technology and PCR methods may be used, for example, those described in Ausubel et al., Current Protocols in Molecular Biology, John Willey & Sons, US (1993); Sambrook et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory Press, US (1989), etc.

[0636] 서열번호 1∼243로 나타내어지는 인간 유래의 miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195 miR-3197, miR-320a, miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298 miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455,miR-4459, miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771 miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p,miR-6742-5p, miR-6743-5p, miR-6746-5p, miR-6749-5p, miR-6760-5p, miR-6762-5p, miR-6765-3p, miR-6765-5p, miR-6766-3p, miR-6766-5p, miR-6771-5p, miR-6774-5p, miR-6777-5p, miR-6778-5p, miR-6780b-5p, miR-6781-5p, miR-6782-5p, miR-6784-5p, miR-6785-5p, miR-6787-5p, miR-6789-5p, miR-6791-5p miR-6794-5p, miR-6800-5p, miR-6802-5p, miR-6803-5p, miR-6812-5p, miR-6816-5p, miR-6819-5p, miR-6821-5p, miR-6826-5p, miR-6831-5p, miR-6836-3p, miR-6840-3p, miR-6842-5p, miR-6850-5p, miR-6861-5p, miR-6869-5p, miR-6870-5p, miR-6877-5p, miR-6879-5p, miR-6880-3p, miR-6880-5p, miR-6885-5p miR-6887-5p, miR-7107-5p, miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p, miR-191-5p, miR-423-5p miR-663a, miR-92a-2-5p, miR-92a-3p, miR-940은 공지이며, 상술과 같이 그 취득 방법도 알려져 있다. 이 때문에,By cloning this gene, a polynucleotide usable as a nucleic acid probe or primer in the present invention can be produced.

[0637] Such nucleic acid probes or primers can be chemically synthesized using an automated DNA synthesis device. The phosphoamidite method is generally used for this synthesis, and this method can automatically synthesize single-stranded DNA of up to about 100 bases. Automated DNA synthesis devices are commercially available from, for example, Polygen, ABI, and Applied BioSystems.

[0638] Alternatively, the polynucleotide of the present invention may be produced by cDNA cloning. For example, the microRNA Cloning Kit Wako may be used as the cDNA cloning technology.

[0639] Here, the sequences of the nucleic acid probe and primer for detecting a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs 1 to 243 do not exist in vivo as miRNA or its precursor. For example, the nucleotide sequences represented by SEQ ID NOs 9 and 8 are generated from the precursor represented by SEQ ID NOs 251, but this precursor has a hairpin-like structure as shown in FIG. 1, and the nucleotide sequences represented by SEQ ID NOs 9 and 8 have mismatched sequences. For this reason, a nucleotide sequence that is completely complementary to the nucleotide sequence represented by SEQ ID NOs 9 or 8 is not naturally generated in vivo. For this reason, the nucleic acid probe and primer for detecting a nucleotide sequence represented by any one of SEQ ID NOs 1 to 243 may have artificial nucleotide sequences that do not exist in vivo.

[0640] 3. Kit or device for detecting bladder cancer

[0641] The present invention also provides a kit or device for detecting bladder cancer comprising one or more polynucleotides (which may include variants, fragments, or derivatives) that can be used as nucleic acid probes or primers in the present invention for measuring target nucleic acids that are bladder cancer markers.

[0642] The target nucleic acid that is a bladder cancer marker in the present invention is preferably selected from the following group A.

[0643] Army A:

[0644] miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195, miR-3197, miR-320a, miR-320b, miR-328-5p, miR-342-5p, miR-345-3p miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298, miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430 miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459, miR-4462, miR-4466,miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p, miR-4687-5p, miR-4690-5p miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771, miR-4783-3p, miR-4783-5p miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p, miR-6515-5p, miR-663b, miR-6716-5p miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p, miR-6743-5p,miR-6746-5p, miR-6749-5p, miR-6760-5p, miR-6762-5p, miR-6765-3p, miR-6765-5p, miR-6766-3p, miR-6766-5p, miR-6771-5p, miR-6774-5p, miR-6777-5p, miR-6778-5p, miR-6780b-5p, miR-6781-5p, miR-6782-5p, miR-6784-5p, miR-6785-5p, miR-6787-5p, miR-6789-5p, miR-6791-5p, miR-6794-5p, miR-6800-5p miR-6802-5p, miR-6803-5p, miR-6812-5p, miR-6816-5p, miR-6819-5p, miR-6821-5p, miR-6826-5p, miR-6831-5p, miR-6836-3p, miR-6840-3p, miR-6842-5p, miR-6850-5p, miR-6861-5p, miR-6869-5p, miR-6870-5p, miR-6877-5p, miR-6879-5p, miR-6880-3p, miR-6880-5p, miR-6885-5p, miR-6887-5p, miR-7107-5p miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p.

[0645] 바람직하게는 이하의 군 B로부터 선택된다.

[0646] 군 B:

[0647] miR-1202,miR-1207-5p,miR-1246,miR-1254,miR-135a-3p,miR-1469,miR-149-3p,miR-150-3p,miR-1914-3p,miR-191-5p,miR-423-5p,miR-663a,miR-92a-2-5p, miR-92a-3p,miR-940.

[0648] The kit or device of the present invention comprises a nucleic acid capable of specifically binding to the target nucleic acid, which is the bladder cancer marker, preferably one or more polynucleotides selected from the polynucleotides described in 2 or a variant thereof.

[0649] Specifically, the kit or device of the present invention may include at least one polynucleotide comprising (or consisting of) a base sequence represented by any one of SEQ ID NOs 1 to 228 or a base sequence in which u is t in said base sequence, a polynucleotide comprising (or consisting of) a complementary sequence said, a polynucleotide hybridizing with said polynucleotide under stringent conditions, or a variant or fragment comprising 15 or more consecutive bases of said polynucleotide sequence.

[0650] The kit or device of the present invention may also include one or more of a polynucleotide comprising (or consisting of) a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence, a polynucleotide comprising (or consisting of) a complementary sequence said, a polynucleotide hybridizing with said polynucleotide under stringent conditions, or a variant or fragment comprising 15 or more consecutive bases of said polynucleotide sequence.

[0651] A fragment that may be included in the kit or device of the present invention is, for example, one or more, preferably two or more, polynucleotides selected from the group consisting of (1) and (2) below: (1) a polynucleotide comprising 15 or more consecutive bases in a base sequence in which u is t in any one of SEQ ID NOs 1 to 228 or in a sequence complementary thereof.

[0652] (2) A polynucleotide comprising 15 or more consecutive bases in a base sequence in which u is t in any one of sequence numbers 229 to 243 or in a complementary sequence.

[0653] In a preferred embodiment, the polynucleotide is a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 1 to 228 or a base sequence in which u is t, a polynucleotide comprising a sequence complementary thereto, a polynucleotide hybridized under stringent conditions with the polynucleotides, or a variant comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive bases of the same.

[0654] In addition, in a preferred embodiment, the polynucleotide is a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t, a polynucleotide comprising a sequence complementary thereto, a polynucleotide hybridized under stringent conditions with the polynucleotides, or a variant comprising 15 or more, preferably 17 or more, more preferably 19 or more consecutive bases of the same.

[0655] In a preferred embodiment, the fragment may be a polynucleotide comprising 15 or more, preferably 17 or more, and more preferably 19 or more consecutive bases.

[0656] In the present invention, the size of the polynucleotide fragment is a number of bases in the base sequence of each polynucleotide, for example, less than the total number of bases in the sequence from 15, less than the total number of bases in the sequence from 17, less than the total number of bases in the sequence from 19, etc.

[0657] The polynucleotide as a target nucleic acid in the kit or device of the present invention may specifically be a combination of one polynucleotide or two, three, four, five, six, seven, eight, nine, ten, or more, consisting of the base sequences represented by SEQ ID NOs 1 to 243 shown in Table 1, but these are merely examples, and all other various possible combinations are included in the present invention.

[0658] For example, in the present invention, as a combination of target nucleic acids in a kit or device for determining whether a bladder cancer patient is a healthy patient, a patient with benign osteosoft edema and benign breast disease, or a patient with cancer other than bladder cancer, a combination of two or more polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs shown in Table 1 may be used. Specifically, it is preferable to combine any two or more of the polynucleotides consisting of nucleotide sequences represented by SEQ ID NOs 1 to 243. Among these, it is preferable to select at least one polynucleotide consisting of nucleotide sequences represented by SEQ ID NOs 1 to 228, which were newly discovered. Among these, a combination including at least one polynucleotide selected from the group consisting of polynucleotides listed in any one of Tables 20 to 22, and more preferably from the group consisting of polynucleotides listed in Table 23, is more preferable.

[0659] Below, 253 examples are provided, without limitation, of polynucleotides comprising the nucleotide sequence represented by SEQ ID NO. 1 (miR-6087) or its complementary sequence, or combinations comprising the same, as shown in the following examples in Tables 7-No. 1–11, Tables 13–16, and Tables 26-No. 2–9 (256 discriminant formulas are provided in the said tables).

[0660] In addition to the polynucleotide of the present invention described above (which may include variants, fragments, or derivatives), the kit or device of the present invention may also include known polynucleotides or polynucleotides to be discovered in the future that enable bladder cancer detection.

[0661] In addition to the polynucleotide of the present invention described above, the kit or device of the present invention may also include antibodies for measuring known markers for bladder cancer screening, such as the NMP22 test for detecting the nuclear matrix protein NuMA and the BTAtrak test for detecting specific basement membrane fragment complexes.

[0662] The polynucleotide included in the kit of the present invention, and its variants or fragments, may be packaged in different containers individually or optionally in combination.

[0663] The kit of the present invention may include a kit for extracting nucleic acids (e.g., total RNA) from body fluids, cells, or tissues, a fluorescent material for labeling, an enzyme and culture medium for nucleic acid amplification, an instruction manual, etc.

[0664] The device of the present invention is a device for measuring cancer markers in which a nucleic acid, such as a polynucleotide, a variant thereof, a derivative thereof, or a fragment thereof, as described above in the present invention, is bound or attached to a solid, for example. Examples of materials for the solid are plastic, paper, glass, silicon, etc., and plastic is a preferred material for the solid due to ease of processing. The shape of the solid is arbitrary and may be, for example, square, circular, a narrow and long rectangle, a film type, etc. The device of the present invention includes, for example, a device for measurement using hybridization technology, and specifically, examples include a blotting device, a nucleic acid array (e.g., a microarray, a DNA chip, an RNA chip, etc.).

[0665] Nucleic acid array technology is a technology that fabricates an array, such as a chip, by binding or attaching the nucleic acids one by one using methods such as a high-density dispenser called a spotter or arrayer, which are surface treatments such as L-lysine coating or the introduction of functional groups such as amino groups or carboxyl groups as needed, a method of spotting nucleic acids on a solid surface using a high-density dispenser called a spotter or arrayer, a method of spraying nucleic acids onto a solid surface using an inkjet that sprays minute droplets from a nozzle by means of a piezoelectric element, or a method of performing sequential nucleotide synthesis on a solid surface, and uses this array to measure target nucleic acids using hybridization.

[0666] The kit or device of the present invention comprises at least one, preferably at least two, more preferably at least three, most preferably at least five, or all of the polynucleotides of miRNAs that are bladder cancer markers of group A, or a nucleic acid capable of specifically binding to each of the complementary chains of said polynucleotides. The kit or device of the present invention may also, in some cases, comprise at least one, preferably at least two, more preferably at least three, most preferably at least five, or all of the polynucleotides of miRNAs that are bladder cancer markers of group B, or a nucleic acid capable of specifically binding to each of the complementary chains of said polynucleotides.

[0667] The kit or device of the present invention can be used for the detection of bladder cancer of 4 below.

[0668] 4. Methods for detecting bladder cancer

[0669] 본 발명은 또한, 검체 중의 miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195, miR-3197, miR-320a miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298, miR-4322, miR-4327 miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459,miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771 miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p,miR-6743-5p,miR-6746-5p,mimir-6749-5p,mir-6760-5p,mir-6762-5p,mir-6765-3p,mir-6765-5p,mir-6766-3p,mir-6766-5p,mir-6771-5p,mir-6774-5p miR-6777-5p,miR-6778-5p,miR-6780b-5p,miR-6781-5p,miR-6782-5p,miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p,miR-6794-5p miR-6800-5p,miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p,miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p,miR-6840-3p, miR-6842-5p,miR-6850-5p,miR-6861-5p,miR-6869-5p,miR-6870-5p,miR-6877-5p,miR-6879-5p,miR-6880-3p,miR-6880-5p,miR-6885-5p,miR-6887-5p Expression levels of bladder cancer-derived genes represented as miR-7107-5p, miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, and in some cases miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p, miR-191-5p, One or more expression levels (e.g., expression profiles) of bladder cancer-derived genes represented by miR-423-5p, miR-663a, miR-92a-2-5p, miR-92a-3p, and miR-940 were measured in vitro, andThe present invention relates to a method for detecting bladder cancer, comprising evaluating in vitro whether a subject has bladder cancer using the above-mentioned expression level (and optionally a control expression level of a healthy person measured in the same way). In the present method, for example, regarding specimens such as blood, serum, and plasma collected from a subject suspected of having bladder cancer and a subject not having bladder cancer, the expression level of the gene in the specimen and the control expression level of the subject not having bladder cancer are used (for example, by comparing the two expression levels), and if there is a difference in the expression level of the target nucleic acid in the specimen, the subject may be evaluated as having bladder cancer.

[0670] The above method of the present invention enables early diagnosis of bladder cancer with low invasiveness, high sensitivity and specificity, thereby leading to early treatment and improvement of prognosis, and also enables monitoring of disease symptoms or monitoring of the effectiveness of surgical, radiotherapeutic, and chemotherapy treatments.

[0671] As a method for extracting genes derived from bladder cancer from specimens such as blood, serum, and plasma according to the present invention, it is particularly preferable to prepare by adding the RNA extraction reagent in the 3D-Gene (registered trademark) RNA extraction reagent from liquid sample kit (Toray Kabushiki Kaisha), but the general acidic phenol method (Acid Guanidinium-Phenol-Chloroform (AGPC) method) may be used, or Trizol (registered trademark) (Life Technologies Co., Ltd.) may be used, or the preparation may be made by adding an RNA extraction reagent containing acidic phenol such as Trizol (Life Technologies Co., Ltd.) or Isogen (Nippon Gene Co., Ltd.). In addition, kits such as the miRNeasy (registered trademark) Mini Kit (Qiagen Co., Ltd.) may be used, but are not limited to these methods.

[0672] The present invention also provides for the in vitro detection of expression products of miRNA genes derived from bladder cancer in specimens derived from subjects.

[0673] The method of carrying out the method of the present invention is not limited, but may be carried out, for example, using the kit or device of the present invention described in 3 above (which includes the nucleic acid usable in the present invention). In this method, the kit or device is used to include the polynucleotide usable in the present invention as described above, in all possible combinations.

[0674] In the detection or (genetic) diagnosis of bladder cancer according to the present invention, the polynucleotide included in the kit or device of the present invention may be used as a probe or primer. When used as a primer, the TaqMan (registered trademark) MicroRNA Assays of Life Technologies, the miScript PCR System of Qiagen, etc., may be used, but are not limited to these methods.

[0675] In the method of the present invention, the measurement of gene expression levels may be performed according to a standard method in a known method for specifically detecting a specific gene, such as the Northern blotting method, the Southern blotting method, hybridization techniques such as in situ hybridization, Northern hybridization, and Southern hybridization, quantitative amplification techniques such as quantitative RT-PCR, and methods using a next-generation sequencer. As a sample to be measured, body fluids such as blood, serum, plasma, and urine of a subject are collected depending on the type of detection method used. Alternatively, total RNA prepared by the above method may be used from such body fluids, or various polynucleotides containing cDNA prepared based on the RNA may be used.

[0676] The method of the present invention is useful for diagnosing bladder cancer or detecting the presence or absence of the disease. Specifically, the detection of bladder cancer according to the present invention can be performed by using specimens such as blood, serum, plasma, and urine from a subject suspected of having bladder cancer, and detecting the expression level of a gene detected by a nucleic acid probe or primer included in the kit or device of the present invention in vitro. If the expression level of a polynucleotide consisting of at least one base sequence represented by SEQ ID NOs 1 to 228 and, in some cases, one or more base sequences represented by SEQ ID NOs 229 to 243 in specimens such as blood, serum, plasma, and urine of a subject suspected of having bladder cancer is statistically significantly higher compared to the expression level of such polynucleotides in specimens such as blood, serum, plasma, and urine of a subject not having bladder cancer, the subject may be evaluated as having bladder cancer.

[0677] In the method of the present invention, the method for detecting whether a sample derived from a subject does not contain bladder cancer or contains bladder cancer comprises collecting a body fluid such as blood, serum, plasma, or urine of a subject, and measuring the expression level of a target gene (or target nucleic acid) contained therein using a single or multiple polynucleotides selected from the polynucleotide group of the present invention (including variants, fragments, or derivatives) to evaluate the presence or absence of bladder cancer or to detect bladder cancer. In addition, the bladder cancer detection method of the present invention may be used to evaluate or diagnose whether there is improvement in the disease or the degree of improvement when a known or developing bladder cancer-related therapeutic agent (non-limiting examples include gemcitabine, platinum-based agents (cisplatin / carboplatin), paclitaxel, methotrexate, vinblastine, adriamycin, cisplatin, taxane-based agents (docetaxel), isofamide, other platinum-based agents (nedaplatin), combination drugs thereof, etc.) is administered to a patient with bladder cancer for the purpose of treating or improving the disease.

[0678] The method of the present invention is, for example, steps (a), (b) and (c) below:

[0679] (a) A step of contacting a sample derived from a subject with a polynucleotide of the kit or device of the present invention in a test tube,

[0680] (b) a step of measuring the expression level of a target nucleic acid in a sample using the polynucleotide as a nucleic acid probe or primer,

[0681] (c) A step of evaluating the presence or absence of bladder cancer (cells) in the subject based on the results of (b),

[0682] It may include.

[0683] 일실시형태에 있어서, 본 발명은 miR-6087, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195, miR-3197, miR-320a miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298, miR-4322, miR-4327 miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459,miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771 miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p,miR-6743-5p,miR-6746-5p,mimir-6749-5p,mir-6760-5p,mir-6762-5p,mir-6765-3p,mir-6765-5p,mir-6766-3p,mir-6766-5p,mir-6771-5p,mir-6774-5p miR-6777-5p,miR-6778-5p,miR-6780b-5p,miR-6781-5p,miR-6782-5p,miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p,miR-6794-5p miR-6800-5p,miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p,miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p,miR-6840-3p, miR-6842-5p,miR-6850-5p,miR-6861-5p,miR-6869-5p,miR-6870-5p,miR-6877-5p,miR-6879-5p,miR-6880-3p,miR-6880-5p,miR-6885-5p,miR-6887-5p A method for detecting bladder cancer is provided, comprising measuring the expression level of a target nucleic acid in a sample of a subject using at least one, preferably at least two, polynucleotides selected from miR-7107-5p, miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotides, and evaluating in vitro whether the subject has bladder cancer using said measured expression level and a control expression level of a subject not having bladder cancer, which is likewise measured.

[0684] In this specification, "evaluate" refers to an evaluation based on the results of an in vitro test, rather than a judgment by a physician.

[0685] As described above, specifically in the method of the present invention, miR-6087 is hsa-miR-6087, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-1193 is hsa-miR-1193, miR-1199-5p is hsa-miR-1199-5p, miR-1225-5p is hsa-miR-1225-5p, miR-1227-5p is hsa-miR-1227-5p, miR-1228-3p is hsa-miR-1228-3p, and miR-1228-5p is hsa-miR-1228-5p, and miR-1237-5p is hsa-miR-1237-5p, miR-1238-5p is hsa-miR-1238-5p, miR-1247-3p is hsa-miR-1247-3p, miR-1268a is hsa-miR-1268a, miR-1268b is hsa-miR-1268b, miR-1273g-3p is hsa-miR-1273g-3p, miR-128-2-5p is hsa-miR-128-2-5p, miR-1343-3p is hsa-miR-1343-3p, miR-1343-5p is hsa-miR-1343-5p, and miR-1470 is hsa-miR-1470, miR-17-3p is hsa-miR-17-3p, miR-187-5p is hsa-miR-187-5p, miR-1908-3p is hsa-miR-1908-3p, miR-1908-5p is hsa-miR-1908-5p, miR-1909-3p is hsa-miR-1909-3p, miR-1915-3p is hsa-miR-1915-3p, miR-210-5p is hsa-miR-210-5p, miR-24-3p is hsa-miR-24-3p, miR-2467-3p is hsa-miR-2467-3p, miR-2861 is hsa-miR-2861, miR-296-3p is hsa-miR-296-3p, miR-29b-3p is hsa-miR-29b-3p, andmiR-3131 is hsa-miR-3131, miR-3154 is hsa-miR-3154, miR-3158-5p is hsa-miR-3158-5p, miR-3160-5p is hsa-miR-3160-5p, miR-3162-5p is hsa-miR-3162-5p, miR-3178 is hsa-miR-3178, miR-3180-3p is hsa-miR-3180-3p, miR-3184-5p is hsa-miR-3184-5p, miR-3185 is hsa-miR-3185, miR-3194-3p is hsa-miR-3194-3p, and miR-3195 is hsa-miR-3195, miR-3197 is hsa-miR-3197, miR-320a is hsa-miR-320a, miR-320b is hsa-miR-320b, miR-328-5p is hsa-miR-328-5p, miR-342-5p is hsa-miR-342-5p, miR-345-3p is hsa-miR-345-3p, miR-3616-3p is hsa-miR-3616-3p, miR-3619-3p is hsa-miR-3619-3p, miR-3620-5p is hsa-miR-3620-5p, miR-3621 is hsa-miR-3621, miR-3622a-5p is hsa-miR-3622a-5p, miR-3648 is hsa-miR-3648, miR-3652 is hsa-miR-3652, miR-3656 is hsa-miR-3656, miR-3663-3p is hsa-miR-3663-3p, miR-3679-5p is hsa-miR-3679-5p, miR-371b-5p is hsa-miR-371b-5p, miR-373-5p is hsa-miR-373-5p, miR-3917 is hsa-miR-3917, miR-3940-5p is hsa-miR-3940-5p, and miR-3960 is hsa-miR-3960, miR-4258 is hsa-miR-4258, miR-4259 is hsa-miR-4259, andmiR-4270 is hsa-miR-4270, miR-4286 is hsa-miR-4286, miR-4298 is hsa-miR-4298, miR-4322 is hsa-miR-4322, miR-4327 is hsa-miR-4327, miR-4417 is hsa-miR-4417, miR-4419b is hsa-miR-4419b, miR-4429 is hsa-miR-4429, miR-4430 is hsa-miR-4430, miR-4433a-3p is hsa-miR-4433a-3p, miR-4436b-5p is hsa-miR-4436b-5p, and miR-4443 is hsa-miR-4443, miR-4446-3p is hsa-miR-4446-3p, miR-4447 is hsa-miR-4447, miR-4448 is hsa-miR-4448, miR-4449 is hsa-miR-4449, miR-4454 is hsa-miR-4454, miR-4455 is hsa-miR-4455, miR-4459 is hsa-miR-4459, miR-4462 is hsa-miR-4462, miR-4466 is hsa-miR-4466, miR-4467 is hsa-miR-4467, miR-4480 is hsa-miR-4480, miR-4483 is hsa-miR-4483, miR-4484 is hsa-miR-4484, miR-4485-5p is hsa-miR-4485-5p, miR-4488 is hsa-miR-4488, miR-4492 is hsa-miR-4492, miR-4505 is hsa-miR-4505, miR-4515 is hsa-miR-4515, miR-4525 is hsa-miR-4525, miR-4534 is hsa-miR-4534, miR-4535 is hsa-miR-4535, miR-4633-3p is hsa-miR-4633-3p, miR-4634 is hsa-miR-4634, miR-4640-5p is hsa-miR-4640-5p, andmiR-4649-5p is hsa-miR-4649-5p, miR-4651 is hsa-miR-4651, miR-4652-5p is hsa-miR-4652-5p, miR-4655-5p is hsa-miR-4655-5p, miR-4656 is hsa-miR-4656, miR-4658 is hsa-miR-4658, miR-4663 is hsa-miR-4663, miR-4673 is hsa-miR-4673, miR-4675 is hsa-miR-4675, miR-4687-3p is hsa-miR-4687-3p, miR-4687-5p is hsa-miR-4687-5p, miR-4690-5p is hsa-miR-4690-5p, miR-4695-5p is hsa-miR-4695-5p, miR-4697-5p is hsa-miR-4697-5p, miR-4706 is hsa-miR-4706, miR-4707-3p is hsa-miR-4707-3p, miR-4707-5p is hsa-miR-4707-5p, miR-4708-3p is hsa-miR-4708-3p, miR-4710 is hsa-miR-4710, miR-4718 is hsa-miR-4718, miR-4722-5p is hsa-miR-4722-5p, miR-4725-3p is hsa-miR-4725-3p, miR-4726-5p is hsa-miR-4726-5p, miR-4727-3p is hsa-miR-4727-3p, miR-4728-5p is hsa-miR-4728-5p, miR-4731-5p is hsa-miR-4731-5p, miR-4736 is hsa-miR-4736, miR-4739 is hsa-miR-4739, miR-4740-5p is hsa-miR-4740-5p, miR-4741 is hsa-miR-4741, miR-4750-5p is hsa-miR-4750-5p, miR-4755-3p is hsa-miR-4755-3p, miR-4763-3p is hsa-miR-4763-3p, and,miR-4771 is hsa-miR-4771, miR-4783-3p is hsa-miR-4783-3p, miR-4783-5p is hsa-miR-4783-5p, miR-4787-3p is hsa-miR-4787-3p, miR-4792 is hsa-miR-4792, miR-498 is hsa-miR-498, miR-5008-5p is hsa-miR-5008-5p, miR-5010-5p is hsa-miR-5010-5p, miR-504-3p is hsa-miR-504-3p, miR-5195-3p is hsa-miR-5195-3p, miR-550a-5p is hsa-miR-550a-5p, miR-5572 is hsa-miR-5572, miR-5739 is hsa-miR-5739, miR-6075 is hsa-miR-6075, miR-6076 is hsa-miR-6076, miR-6088 is hsa-miR-6088, miR-6124 is hsa-miR-6124, miR-6131 is hsa-miR-6131, miR-6132 is hsa-miR-6132, miR-614 is hsa-miR-614, miR-615-5p is hsa-miR-615-5p, miR-619-5p is hsa-miR-619-5p, miR-642b-3p is hsa-miR-642b-3p, miR-6510-5p is hsa-miR-6510-5p, miR-6511a-5p is hsa-miR-6511a-5p, miR-6515-3p is hsa-miR-6515-3p, miR-6515-5p is hsa-miR-6515-5p, miR-663b is hsa-miR-663b, miR-6716-5p is hsa-miR-6716-5p, miR-6717-5p is hsa-miR-6717-5p, miR-6722-3p is hsa-miR-6722-3p, miR-6724-5p is hsa-miR-6724-5p, miR-6726-5p is hsa-miR-6726-5p, and,miR-6737-5p is hsa-miR-6737-5p, miR-6741-5p is hsa-miR-6741-5p, miR-6742-5p is hsa-miR-6742-5p, miR-6743-5p is hsa-miR-6743-5p, miR-6746-5p is hsa-miR-6746-5p, miR-6749-5p is hsa-miR-6749-5p, miR-6760-5p is hsa-miR-6760-5p, miR-6762-5p is hsa-miR-6762-5p, miR-6765-3p is hsa-miR-6765-3p, and miR-6765-5p is hsa-miR-6765-5p, miR-6766-3p is hsa-miR-6766-3p, miR-6766-5p is hsa-miR-6766-5p, miR-6771-5p is hsa-miR-6771-5p, miR-6774-5p is hsa-miR-6774-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6778-5p is hsa-miR-6778-5p, miR-6780b-5p is hsa-miR-6780b-5p, miR-6781-5p is hsa-miR-6781-5p, miR-6782-5p is hsa-miR-6782-5p, miR-6784-5p is hsa-miR-6784-5p, miR-6785-5p is hsa-miR-6785-5p, miR-6787-5p is hsa-miR-6787-5p, miR-6789-5p is hsa-miR-6789-5p, miR-6791-5p is hsa-miR-6791-5p, miR-6794-5p is hsa-miR-6794-5p, miR-6800-5p is hsa-miR-6800-5p, miR-6802-5p is hsa-miR-6802-5p, miR-6803-5p is hsa-miR-6803-5p, miR-6812-5p is hsa-miR-6812-5p, miR-6816-5p is hsa-miR-6816-5p, miR-6819-5p is hsa-miR-6819-5p,miR-6821-5p is hsa-miR-6821-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6831-5p is hsa-miR-6831-5p, miR-6836-3p is hsa-miR-6836-3p, miR-6840-3p is hsa-miR-6840-3p, miR-6842-5p is hsa-miR-6842-5p, miR-6850-5p is hsa-miR-6850-5p, miR-6861-5p is hsa-miR-6861-5p, miR-6869-5p is hsa-miR-6869-5p, and miR-6870-5p is hsa-miR-6870-5p, miR-6877-5p is hsa-miR-6877-5p, miR-6879-5p is hsa-miR-6879-5p, miR-6880-3p is hsa-miR-6880-3p, miR-6880-5p is hsa-miR-6880-5p, miR-6885-5p is hsa-miR-6885-5p, miR-6887-5p is hsa-miR-6887-5p, miR-7107-5p is hsa-miR-7107-5p, miR-7108-3p is hsa-miR-7108-3p, miR-7109-5p is hsa-miR-7109-5p, miR-711 is hsa-miR-711, miR-7113-3p is hsa-miR-7113-3p, miR-7150 is hsa-miR-7150, miR-744-5p is hsa-miR-744-5p, miR-7975 is hsa-miR-7975, miR-7977 is hsa-miR-7977, miR-8052 is hsa-miR-8052, miR-8069 is hsa-miR-8069, miR-8073 is hsa-miR-8073, miR-887-3p is hsa-miR-887-3p, miR-937-5p is hsa-miR-937-5p is.

[0686] In addition, in one embodiment, the nucleic acid (specifically, a probe or a primer) in the method of the present invention is a polynucleotide shown in any one of (a) to (e) below:

[0687] (a) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0688] (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228,

[0689] (c) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0690] (d) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 1 to 228 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0691] (e) a polynucleotide that hybridizes with any one of the polynucleotides (a) to (d) under stringent conditions,

[0692] It is selected from a group consisting of.

[0693] In the method of the present invention, the expression amount of at least one polynucleotide selected from miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p, miR-191-5p, miR-423-5p, miR-663a, miR-92a-2-5p, miR-92a-3p, miR-940 can also be measured.

[0694] Specifically, miR-1202 is hsa-miR-1202, miR-1207-5p is hsa-miR-1207-5p, miR-1246 is hsa-miR-1246, miR-1254 is hsa-miR-1254, miR-135a-3p is hsa-miR-135a-3p, miR-1469 is hsa-miR-1469, miR-149-3p is hsa-miR-149-3p, miR-150-3p is hsa-miR-150-3p, miR-1914-3p is hsa-miR-1914-3p, miR-191-5p is hsa-miR-191-5p, and miR-423-5p is hsa-miR-423-5p, miR-663a is hsa-miR-663a, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-92a-3p is hsa-miR-92a-3p, and miR-940 is hsa-miR-940.

[0695] In addition, in one embodiment, the expression amount of the polynucleotide is measured using the polynucleotide or a nucleic acid capable of specifically binding to the complementary chain of the polynucleotide, and the nucleic acid is a polynucleotide shown in any one of (f) to (j) below:

[0696] (f) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence in which u is t in said nucleotide sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive nucleotides,

[0697] (g) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243,

[0698] (h) A polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive nucleotides,

[0699] (i) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs 229 to 243 or a nucleotide sequence complementary to a nucleotide sequence in which u is t, and

[0700] (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions,

[0701] It is selected from a group consisting of.

[0702] The specimen used in the method of the present invention may be a specimen prepared from the biological tissue of a subject (preferably, bladder tissue or renal pelvis or ureter tissue), body fluids such as blood, serum, plasma, and urine. Specifically, the specimen may be an RNA-containing specimen prepared from the tissue, a specimen containing polynucleotides further prepared therefrom, body fluids such as blood, serum, plasma, and urine, or a biological tissue obtained by collecting part or all of the subject's biological tissue using a biopsy or by surgical removal, and specimens for measurement may be prepared from these.

[0703] In this specification, the term "subjec...

Claims

Claim 1 A kit for detecting bladder cancer comprising a polynucleotide of miR-6087, a bladder cancer marker, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide. Claim 2 In claim 1, the nucleic acid is a polynucleotide represented by any one of the following (a) to (e): (a) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (b) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t; (c) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence complementary to the base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (d) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence complementary to the base sequence in which u is t; and (e) any one of the polynucleotides of (a) to (d) and A kit comprising a polynucleotide selected from the group consisting of polynucleotides that hybridize under stringent conditions. Claim 3 제 1 Page 1, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195 miR-3197, miR-320a, miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298 miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459,miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771 miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p,miR-6743-5p,miR-6746-5p,miR-6749-5p,miR-6760-5p,miR-6762-5p,miR-6765-3p,miR-6765-5p,miR-6766-3p,mimi6766-5p,mimi6771-5p,mimi6774-5p miR-6777-5p,miR-6778-5p,miR-6780b-5p,miR-6781-5p,miR-6782-5p,miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p,miR-6794-5p miR-6800-5p,miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p,miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p,miR-6840-3p, miR-6842-5p,miR-6850-5p,miR-6861-5p,miR-6869-5p,miR-6870-5p,miR-6877-5p,miR-6879-5p,miR-6880-3p,miR-6880-5p,miR-6885-5p,miR-6887-5p miR-7107-5p,miR-7108-3p,miR-7109-5p,miR-711,miR-7113-3p,miR-7150,miR-744-5p,miR-7975,miR-7977,miR-8052,miR-8069,miR-8073,miR-887-3p,miR-937-5p miR-1202,miR-1207-5p,miR-1246,miR-1254,miR-135a-3p,miR-1469,miR-149-3p,miR-150-3p,miR-1914-3p,miR-191-5p,miR-423-5p,miR-663a, A kit further comprising at least one polynucleotide selected from miR-92a-2-5p, miR-92a-3p, and miR-940, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide. Claim 4 In claim 3, the nucleic acid is a polynucleotide represented by any one of the following (a)' to (e)': (a)' a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (b)' a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t, said base sequence; (c)' a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence complementary to the base sequence in which u is t, said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (d)' a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t, said base sequence complementary A polynucleotide selected from the group consisting of a polynucleotide comprising a base sequence, and (e) a polynucleotide hybridized under stringent conditions with any one of (a)' to (d)', or a polynucleotide represented in any one of (f) to (j) below: (f) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (g) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence; (h) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or 15 or more The fragment containing a continuous base,A kit comprising a polynucleotide selected from the group consisting of (i) a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence complementary to a base sequence in which u is t, and (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions. Claim 5 A device for detecting bladder cancer comprising a polynucleotide of miR-6087, a bladder cancer marker, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide. Claim 6 In claim 5, the nucleic acid is a polynucleotide represented by any one of the following (a) to (e): (a) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (b) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t; (c) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence complementary to the base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (d) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence complementary to the base sequence in which u is t; and (e) any one of the polynucleotides of (a) to (d) and A device comprising a polynucleotide selected from the group consisting of polynucleotides that hybridize under stringent conditions. Claim 7 제 5 Pages, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185 miR-3194-3p, miR-3195, miR-3197, miR-320a, miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270 miR-4286, miR-4298, miR-4322, miR-4327, miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459,miR-4462, miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p miR-4687-5p, miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771 miR-4783-3p, miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p miR-6515-5p, miR-663b, miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p,miR-6743-5p,miR-6746-5p,miR-6749-5p,miR-6760-5p,miR-6762-5p,miR-6765-3p,miR-6765-5p,miR-6766-3p,mimi6766-5p,mimi6771-5p,mimi6774-5p miR-6777-5p,miR-6778-5p,miR-6780b-5p,miR-6781-5p,miR-6782-5p,miR-6784-5p,miR-6785-5p,miR-6787-5p,miR-6789-5p,miR-6791-5p,miR-6794-5p miR-6800-5p,miR-6802-5p,miR-6803-5p,miR-6812-5p,miR-6816-5p,miR-6819-5p,miR-6821-5p,miR-6826-5p,miR-6831-5p,miR-6836-3p,miR-6840-3p, miR-6842-5p,miR-6850-5p,miR-6861-5p,miR-6869-5p,miR-6870-5p,miR-6877-5p,miR-6879-5p,miR-6880-3p,miR-6880-5p,miR-6885-5p,miR-6887-5p miR-7107-5p,miR-7108-3p,miR-7109-5p,miR-711,miR-7113-3p,miR-7150,miR-744-5p,miR-7975,miR-7977,miR-8052,miR-8069,miR-8073,miR-887-3p,miR-937-5p miR-1202,miR-1207-5p,miR-1246,miR-1254,miR-135a-3p,miR-1469,miR-149-3p,miR-150-3p,miR-1914-3p,miR-191-5p,miR-423-5p,miR-663a, A device comprising at least one polynucleotide selected from miR-92a-2-5p, miR-92a-3p, and miR-940, or a nucleic acid capable of specifically binding to the complementary chain of said polynucleotide. Claim 8 In claim 7, the nucleic acid is a polynucleotide represented by any one of the following (a)' to (e)': (a)' a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (b)' a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t, said base sequence; (c)' a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence complementary to a base sequence in which u is t, said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (d)' a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t, said base sequence complementary A polynucleotide selected from the group consisting of a polynucleotide comprising a base sequence, and (e) a polynucleotide hybridized under stringent conditions with any one of (a)' to (d)', or a polynucleotide represented in any one of (f) to (j) below: (f) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (g) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence; (h) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or 15 or more The fragment containing a continuous base,A device comprising a polynucleotide selected from the group consisting of (i) a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence complementary to a base sequence in which u is t, and (j) a polynucleotide that hybridizes with any one of (f) to (i) under stringent conditions. Claim 9 A device according to any one of claims 5 to 8, wherein the device is a device for measurement by hybridization technology. Claim 10 In claim 9, the device wherein the hybridization technology is nucleic acid array technology. Claim 11 A method for providing information for the detection of bladder cancer, comprising measuring the expression level of a polynucleotide of miR-6087, a bladder cancer marker, in a sample of a subject, and comparing the expression level in the sample of the subject with a control expression level in a sample from a subject not affected by bladder cancer, which is measured in the same way. Claim 12 A method according to claim 11, comprising preparing a gene expression amount of a sample derived from a subject known to have bladder cancer and a gene expression amount of a sample derived from a subject not affected by bladder cancer as a teacher sample, and substituting the expression amount of the polynucleotide in the sample derived from the subject into a discriminant formula capable of distinguishing the presence or absence of bladder cancer, and evaluating the presence or absence of bladder cancer by the same. Claim 13 In claim 11, the expression amount of the polynucleotide is measured using the polynucleotide or a nucleic acid capable of specifically binding to the complementary chain of the polynucleotide, and the polynucleotide wherein the nucleic acid represents any one of the following (a) to (e): (a) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (b) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t in the base sequence; (c) a polynucleotide comprising the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment comprising 15 or more consecutive bases; (d) to the base sequence represented by SEQ ID NO. 1 or the base sequence in which u is t in the base sequence A method comprising a polynucleotide selected from the group consisting of a polynucleotide having a complementary base sequence, and (e) a polynucleotide that hybridizes with any one of (a) to (d) under stringent conditions. Claim 14 제 11 항에 있어서,다른 방광암 마커인, miR-1185-1-3p, miR-1185-2-3p, miR-1193, miR-1199-5p, miR-1225-5p, miR-1227-5p, miR-1228-3p, miR-1228-5p, miR-1237-5p, miR-1238-5p, miR-1247-3p, miR-1268a, miR-1268b, miR-1273g-3p, miR-128-2-5p, miR-1343-3p, miR-1343-5p, miR-1470, miR-17-3p, miR-187-5p, miR-1908-3p, miR-1908-5p, miR-1909-3p, miR-1915-3p, miR-210-5p, miR-24-3p, miR-2467-3p, miR-2861, miR-296-3p, miR-29b-3p, miR-3131, miR-3154, miR-3158-5p, miR-3160-5p, miR-3162-5p, miR-3178, miR-3180-3p, miR-3184-5p, miR-3185, miR-3194-3p, miR-3195, miR-3197, miR-320a miR-320b, miR-328-5p, miR-342-5p, miR-345-3p, miR-3616-3p, miR-3619-3p, miR-3620-5p, miR-3621, miR-3622a-5p, miR-3648, miR-3652, miR-3656, miR-3663-3p, miR-3679-5p, miR-371b-5p, miR-373-5p, miR-3917, miR-3940-5p, miR-3960, miR-4258, miR-4259, miR-4270, miR-4286, miR-4298, miR-4322, miR-4327 miR-4417, miR-4419b, miR-4429, miR-4430, miR-4433a-3p, miR-4436b-5p, miR-4443, miR-4446-3p, miR-4447, miR-4448, miR-4449, miR-4454, miR-4455, miR-4459, miR-4462,miR-4466, miR-4467, miR-4480, miR-4483, miR-4484, miR-4485-5p, miR-4488, miR-4492, miR-4505, miR-4515, miR-4525, miR-4534, miR-4535, miR-4633-3p, miR-4634, miR-4640-5p, miR-4649-5p, miR-4651, miR-4652-5p, miR-4655-5p, miR-4656, miR-4658, miR-4663, miR-4673, miR-4675, miR-4687-3p, miR-4687-5p miR-4690-5p, miR-4695-5p, miR-4697-5p, miR-4706, miR-4707-3p, miR-4707-5p, miR-4708-3p, miR-4710, miR-4718, miR-4722-5p, miR-4725-3p, miR-4726-5p, miR-4727-3p, miR-4728-5p, miR-4731-5p, miR-4736, miR-4739, miR-4740-5p, miR-4741, miR-4750-5p, miR-4755-3p, miR-4763-3p, miR-4771, miR-4783-3p miR-4783-5p, miR-4787-3p, miR-4792, miR-498, miR-5008-5p, miR-5010-5p, miR-504-3p, miR-5195-3p, miR-550a-5p, miR-5572, miR-5739, miR-6075, miR-6076, miR-6088, miR-6124, miR-6131, miR-6132, miR-614, miR-615-5p, miR-619-5p, miR-642b-3p, miR-6510-5p, miR-6511a-5p, miR-6515-3p, miR-6515-5p, miR-663b miR-6716-5p, miR-6717-5p, miR-6722-3p, miR-6724-5p, miR-6726-5p, miR-6737-5p, miR-6741-5p, miR-6742-5p, miR-6743-5p,miR-6746-5p, miR-6749-5p, miR-6760-5p, miR-6762-5p, miR-6765-3p, miR-6765-5p, miR-6766-3p, miR-6766-5p, miR-6771-5p, miR-6774-5p, miR-6777-5p, miR-6778-5p, miR-6780b-5p, miR-6781-5p, miR-6782-5p, miR-6784-5p, miR-6785-5p, miR-6787-5p, miR-6789-5p, miR-6791-5p, miR-6794-5p, miR-6800-5p miR-6802-5p, miR-6803-5p, miR-6812-5p, miR-6816-5p, miR-6819-5p, miR-6821-5p, miR-6826-5p, miR-6831-5p, miR-6836-3p, miR-6840-3p, miR-6842-5p, miR-6850-5p, miR-6861-5p, miR-6869-5p, miR-6870-5p, miR-6877-5p, miR-6879-5p, miR-6880-3p, miR-6880-5p, miR-6885-5p, miR-6887-5p, miR-7107-5p miR-7108-3p, miR-7109-5p, miR-711, miR-7113-3p, miR-7150, miR-744-5p, miR-7975, miR-7977, miR-8052, miR-8069, miR-8073, miR-887-3p, miR-937-5p, miR-1202, miR-1207-5p, miR-1246, miR-1254, miR-135a-3p, miR-1469, miR-149-3p, miR-150-3p, miR-1914-3p, miR-191-5p, miR-423-5p, miR-663a, miR-92a-2-5p MiR-92a-3p 것을 더 포함하는, 방법., Claim 15 In claim 14, the expression amount of the polynucleotide is measured using the polynucleotide or a nucleic acid capable of specifically binding to the complementary chain of the polynucleotide, and the nucleic acid is a polynucleotide represented in any one of (a)' to (e)' below: (a)' a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (b)' a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence in which u is t in said base sequence; (c)' a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs 2 to 228 or a base sequence complementary to said base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (d)' SEQ ID NO A polynucleotide selected from the group consisting of: (e) a polynucleotide comprising a base sequence represented by any one of 2 to 228 or a base sequence complementary to a base sequence in which u is t in said base sequence; and (a) a polynucleotide hybridized under stringent conditions with any one of (a)' to (d)'; or a polynucleotide represented by any one of (f) to (j) below: (f) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence, a variant thereof, a derivative thereof, or a fragment thereof comprising 15 or more consecutive bases; (g) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence in which u is t in said base sequence; (h) a base sequence represented by any one of SEQ ID NOs 229 to 243 or said base sequence A polynucleotide consisting of a base sequence complementary to a base sequence where u is t,A method comprising a polynucleotide selected from the group consisting of: the variant, the derivative, or the fragment comprising 15 or more consecutive bases; (i) a polynucleotide comprising a base sequence represented by any one of SEQ ID NOs 229 to 243 or a base sequence complementary to the base sequence in which u is t; and (j) a polynucleotide hybridized under stringent conditions with any one of the polynucleotides (f) to (i). Claim 16 A method for measuring the expression level of a target gene in a sample of a subject using a kit described in any one of claims 1 to 4 or a device described in any one of claims 5 to 8, wherein the kit comprises a polynucleotide or a nucleic acid capable of specifically binding to the complementary chain of the polynucleotide, in any one of claims 11 to 15. Claim 17 A method according to any one of claims 11 to 15, wherein the subject is a human. Claim 18 A method according to any one of claims 11 to 15, wherein the specimen is blood, serum, or plasma. Claim 19 In claim 16, the method in which the subject is a human. Claim 20 In claim 16, the method wherein the specimen is blood, serum, or plasma. Claim 21 delete

Images